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Abstract 
Tuberculosis (TB) is considered as an old infectious disease that leads to many 
fatalities in Man. Mycobacterium tuberculosis was discovered as the causative agent 
of tuberculosis by Robert Koch in 1882. Since then, scientists started the first move 
in order to develop such tools to prevent the disease. According to the WHO 2012 
TB report, about one-third of the population is infected with M.tuberculosis; TB 
causes nearly 1.8 million deaths every year. Perhaps most worrying, new strains of 
M.tuberculosis resistant to most or even all-standard anti-TB drugs are spreading 
throughout the world, making treatment more costly and often impossible. Therefore, 
we urgently need to discover new drugs to overcome TB. The genomic sequence of 
M.tuberculosis has been completed in 1998 and has helped to shed light on new 
pathways as drug targets [1].  
As part of a drug discovery programme, a structural genomics study of lipoproteins 
has been launched using the Mycobacterium smegmatis as a model organism for 
M.tuberculosis. A lipid-anchored protein is a class of protein that is produced in the 
cytoplasm as a pre-prolipoprotein and attached to the cell membrane following post-
translational modification (lipidation). Such proteins represent about 3% of bacterial 
genomes [1]. Furthermore, all bacteria apparently allocate particular proteins to the 
cell envelope by a process called post-translational lipid modification in order to 
produce membrane-anchored lipoproteins that are able to work in the aqueous 
environment at the membrane interface [2]. Therefore, this project aims to identify 
new targets suitable for drug discovery and shed light on their role in the cell. Eight 
targets were identified and put into a pipeline of cloning, over-expression, 
purification and crystallization for structure determination. Five target proteins of 
different putative functions were successfully purified with one (Msmeg_0515) 
annotated as an ABC sugar transporter protein, leading to structure determination. 
The structure of Msmeg_0515 (AgaE) has been determined to a high resolution of 
1.22 Å. Structure comparison of AgaE with other sugar binding proteins revealed 
that AgaE shares a similar fold with the maltose / maltodextrin binding protein 
(MalE) from E.coli. Previous bioinformatics studies on the sugar transporters of 
M.smegmatis and M.tuberculosis suggested that AgaE is an α-galactoside sugar 
binding protein [3], however, structural analysis of the binding site of AgaE protein 
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revealed that it’s more similar to malto-oligosaccharide binding proteins. Also, 
binding assay by Circular dichroism (CD) has revealed a significant affinity of AgaE 
for maltose, glycerol 3-phosphate and acarbose but not α-galactoside sugars. &
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Chapter 1 
Introduction 
Introduction of the pathogenic bacteria of Mycobacterium tuberculosis and an 
overview of the small-scale project of mycobacterial structural genomics. 
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1.1 Introduction 
1.1.1 Tuberculosis 
Tuberculosis (TB) is an infectious disease that is caused by the soil born pathogenic 
organism Mycobacterium tuberculosis. The disease infects both adults and children 
and mainly has an effect on the lung tissue and leads to Pulmonary TB [4, 5]. 
However, other parts of the body also can be infected, such as the skin, bones and 
intestine [4, 6]. Since the twenty-first century, TB has been considered as the second 
major global infectious disease after HIV. It is estimated that about one third of the 
world’s population is infected with TB, however, the vast majority of this population 
will not present the disease [4].  The latest World Health Organization (WHO) 
figures estimate that, in 2012, tuberculosis caused approximately 1.3 million deaths 
and there were ≈ 8.6 million new cases [4]. Although the introduction of antibacterial 
drug therapies have helped to decrease the rate of mortality by about 45% since 
1990, the mortality rate remains high, due to the emergence of drug resistant forms 
of the disease [4]. Despite this widespread use of antibacterial therapies, developing 
countries like Africa have had the highest rate of TB because of poverty and the lack 
of access to treatment (Figure 1.1). Also, immuno-compromised patients, such as 
those with HIV, are more likely to be infected with TB. [4]. Of the 8.6 million new 
cases of TB reported in 2012, 1.1 million were of HIV positive patients (75% of 
these cases were reported in Africa) and of the 1.3 million deaths of TB patients in 
the same year 0.3 million were also of HIV positive patients [4]. In fact, people with 
AIDS have a 50-fold increase in TB susceptibility over HIV negative patients [4].  
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Figure 1. 1 A map showing the highest rates of global TB infection. Areas are coloured as 
shown in the key, based on the estimated number of TB cases per 100,000-population/year. 
The highest numbers of cases were accounted in Swaziland and South Africa by about 1000 
per 100,000 people compared to 10 per 100,000 people in some area of America and other 
developed countries, such as Australia, Japan, New Zealand and Western Europe. The map 
has been adapted from the Global Tuberculosis Report 2013 [4].  
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1.1.2  Infection process of tuberculosis (TB) disease 
The main clinical symptoms that can be observed in a patient with TB are coughing 
with blood, sweating at night and loss in weight [7, 8]. The most common way of 
transfer of M.tuberculosis between people is by inhalation. TB transmission begins 
with a human source, most often a person with pulmonary TB. When an infected 
patient sneezes or coughs, aerosols are formed in the lungs and are expelled by 
coughing [9]. These aerosols contain thousands of micro-particles that carry the 
bacilli, and can be inhaled by others [9]. The disease affects the lungs in 
approximately two thirds of cases, but almost all other organs can be the site of TB 
infection. Although approximately one third of the world population is infected by 
M.tuberculosis, the infection is contained by the immune system in about 90 % of 
these cases [4, 9]. The TB bacilli can lie dormant for years, being protected by a 
thick waxy coat [8]. If the immune system is weakened, for instance by an HIV 
infection or treatment with immunosuppressive agents, the chance of developing 
active TB become much higher [9]. 
The process of TB infection in the lung starts by the inhalation of the droplets 
carrying M.tuberculosis bacillus. The bacterium is then ingested by phagocytosis by 
alveolar macrophages of the lung and dendritic cells (DCs) of the tissue [10]. DCs 
normally have some effect against a pathogen as a killing agent; however, 
M.tuberculosis can also disturb the normal killing effect of dendritic cells, to allow 
growth of the infecting agent [11]. The immune system of the body responds against 
the bacteria and starts to fight the bacteria by forming fibrosis and scar tissue around 
the bacteria. If the immune system failed to control the growth of TB bacteria, the 
bacteria will then be active again and infect other parts of the body [12] (Figure 1.2).  
Active M.tuberculosis starts to spread through out the body by developing pro-
inflammatory infected cytokines, which activate macrophages again. This in turn, 
will require the immune system to produce more DCs and other immune cells, such 
as blood neutrophils and monocytes, which will also be infected with disease [13]. 
Thus, the bacterium can be transferred into other parts of the body through both 
infected dendritics cells that have the ability for migration and also through the blood 
stream to the area, such as neighboring lymph nodes.  The lymph node specific T-
cells will be activated and the activity of the natural killer (NK) cells will be induced 
by the release of interleukin 12 (IL-12) and interleukin18 (IL-18) of the newly 
infected cell cytokines, which in turn will produce gamma interferon (IFN-γ) that 
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helps to make TNF-α and microbiocide substances that are released by macrophage 
activation [14, 15].  
In the last stage of the disease where granuloma are formed (the pathological feature 
of the disease), infected tissue starts to be destroyed due to the development of 
necrosis and macrophage differentiation action [7]. In the stage of advanced TB, the 
granuloma structure bursts, due to the presence of more infected immune cells, and 
in turn, the bacilli start to leak out to the air passages allowing the spread of TB [16, 
17] (Figure 1.2).  
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Figure 1.2 The process of human host TB and the development of granuloma transfer. 
The first stage occurs when the bacterium has been engulfed by phagocytosis by the lung 
alveolar macrophages. The immune system responds to the infection and leads to the 
development of a granuloma and transfer of the bacterium into other parts of the body 
through the blood vessels. The granuloma can lie dormant in the macrophages, however, in 
the case of advanced tuberculosis; the immune system fails to control the disease, the 
granuloma rupture allowing the TB bacteria to spread. This figure has been adapted from 
Russell, 2007 [16]. 
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1.1.3 Treatment and diagnosis of TB 
Since the discovery of M.tuberculosis there have been many studies towards finding 
a proper treatment. For example, in 1943-1947 Selman Waksman, a scientist in 
America discovered the first antibiotic, streptomycin, that is active against the 
disease [18]. Streptomycin was generated from the Actinobacteria Streptomyces 
griseus, however, M.tuberculosis has become resistant to this antibiotic and other 
drugs have been developed, such as para-aminosalicylic acids (PAS) in 1948 and 
isoniazid (INH) which was developed in 1952 [18]. However, these drugs had to be 
given together to overcome drug resistance in M.tuberculosis and have to be 
administrated for a period of two years. Several years later different drugs have 
appeared for instance, ethambutol (EMB), that took the place of PAS in 1960, mainly 
because it had to be taken for only 18 months [18]. Later, rifampicin (RIF) and 
pyrazinamide (PZA) were produced in 1970, which decreased the course of 
therapeutics even more, to just 6 months [18]. All of these developed drugs are 
known as first line agents (Figure 1.3). However, the emergence of new 
M.tuberculosis strains resistant to the first line drugs (usually isoniazid and 
rifampicin) (MDR-TB), resulted in these drugs being replaced by the second line 
agents, such as capreomycin, amikacin and canamycin, which are less efficient, more 
expensive and have high pathogenicity [18]. For example, over 450,000 patients 
have been estimated to have developed resistance for MDR-TB in 2012, which 
resulted in 170,000 deaths [4]. Recently, strains of M.tuberculosis have arisen (XDR-
TB), that are also resistant to at least one of the second line antibiotics, such as 
capreomycin, amikacin and canamycin, which have presented even more problems 
for treatment. 
At present the TB disease is treated by the use of a group of drugs in combination. At 
first, antibiotics (rifampicin, isoniazid, pyrazinamide, and ethambutol) are normally 
used for approximately 2 months, based on the activity of TB, and two of them, 
rifampicin and isoniazid, are used for an additional four months [19]. In case of the 
emergence of multidrug resistant forms of TB, several choices of other drugs 
combination are used, including first and second line drugs and the treatment course 
lasts for 18 months. Treatment also might include surgery and other chemotherapy 
for cavitary TB cases [20, 21]. Therefore, new drugs are required against this 
persistent disease [7, 22]. 
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Two methods have been developed and have had a significant impact towards the 
diagnosis and treatment of the disease, which are chest X-rays and a sample test for a 
sputum spear under a microscope. However, the development of new drug resistant 
strains of M.tuberculosis have required the development of new methods of 
diagnosis, such as immunological examination assays and antibiotic resistance tests. 
The use of these tests have contributed towards the reduction of the percentage of TB 
deaths by 45% according to WHO, as 65 million of TB cases were diagnosed and 
treated between 1995 to 2012 [4, 20] (Figure 1.4). 
1.1.4 Vaccine development against M.tuberculosis 
Albert Calmette and Camille Guerin developed a vaccine against TB in 1906 [23]. 
The vaccine is known as "BCG" (Bacillus of Calmette and Guerin) and is based on 
the administration of a prophylactic weakened live bacillus to newborn babies [7]. 
Although the vaccine has several advantages, such as its cheap cost and long lasting 
activity with the same immunization efficiency, and has been approved to stop 
children from being infected with meningitis TB, it also has several disadvantages 
preventing it being used, such as the possibility of developing a new strain of high 
virulence after long term administration [7, 24]. Also, the vaccine is useless in adults, 
and doesn’t seem to save them from being infected with TB [7, 23]. 
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Figure 1.3 The chemical structures of compounds used for tuberculosis treatment. 
 
Antibiotic Mode of action Inhibited targets. 
Isoniazid (INH) Inhibit cell wall synthesis. Mycolic acid 
synthesis 
Ethambutol (EMB) Inhibit cell wall synthesis Arabinogalactan. 
Pyrazinamide (PZA) Disrupt plasma membrane and energy metabolism. Not known. 
Rifampicin (RIF) Inhibit RNA synthesis. RNA polymerase. 
Streptomycin  Inhibit protein synthesis. S12 rRNA 
Table 1. 1 The main drugs used for TB treatment and their mode of action and 
inhibited target. 
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Figure 1.4 M.tuberculosis cell wall composition. Drug used in the treatment of patients 
with multi-drug resistant TB and their modes of actions are shown in the highlighted panels. 
Figure obtained from the Centers for Disease Control and Prevention website). &&&&&&&&&&
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1.2 The bacterium 
1.2.1 Mycobacterium tuberculosis 
M.tuberculosis belongs to the Actinobacteria genus, it is a rod shaped aerobic 
bacteria, and sized 0.5 um in diameter and 1-4 um long [7]. The bacteria are neither 
motile nor sporulated and the genomic DNA is guanine and cytosine rich 
(approximately 65% of the total genome) [25, 26]. M.tuberculosis does not contain 
either a capsule or a flagellum. Also, it has a slow replication time of 24hs due to the 
waxy cell wall.  The organism is found in environments, such as soil, water and in 
host cells, such as alveolar macrophages and has been characterized as an acid-fast 
Gram-positive bacterium [27]. M.tuberculosis was first detected by Robert Koch in 
1882, and thus TB is known as Koch's disease [28]. M.tuberculosis is resistant to 
standard Gram staining, since the violet colour of the stain is not retained in the cell 
envelope [29].  
 
 
Figure 1.5 Schematic diagram of the cell wall structure of both Gram positive (a) and 
Gram negative (b). The main difference observed is the lack of the outer cell membrane 
from the cell wall of gram-positive bacteria. 
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1.2.2 Structure of mycobacterium cell envelope 
The structure of cell wall is unique, compared with other bacteria. It is composed of 
a long chain of mycolic acid, a fatty acid that contains 60-90 carbon atoms [25]. The 
mycolic acid is bound to arabinogalactan molecules that make a phosphodiester link 
with the peptidoglycan [25, 30]. The peptidoglycan of the cell wall of most 
organisms consists of N-acetylmuramic acid, whereas in mycobacterium cell wall, 
this is replaced by N-glycolylmuramic acid [7]. The cell wall of M.tuberculosis has 
mycolic acid forming 60% of its lipid compounds that are present as a mix of two 
chains of 24 and 64 carbon atoms, respectively, and are attached to the cell wall 
polysaccharides by covalent bonds [25, 30]. Additionally, the cell wall also consists 
of two other glycolipid molecules, such as lipoarabinomanan (LAM) and the 
lipomannan (LM) that are attached to the phosphatidyl-myoinositol mannoside and 
anchored to the plasma membrane with non-covalent bonds [25, 31] (Figure 1.6).  
 
 
Figure 1.6 Schematic structure of the cell wall in M.tuberculosis. The cell membrane is 
composed of mycolic acids, which are linked to the arabinogalactan that is attached to the 
peptidoglycan by covalent bonds to form the inner layer of the cell membrane.  Also, the cell 
wall consists of other glycolipid molecules, such as lipoarabinomanan (LAM), and 
lipomannan (LM) that is anchored to the plasma membrane [7]. 
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1.3 Membrane proteins 
Proteins are classified in nature into three main classes, globular, fibrous and 
membrane proteins. Membrane proteins are responsible for numerous types of 
function, such as cell signaling, transport of nutrients and cell adhesion. In addition, 
approximately 30% of the genomes of most organisms code for membrane proteins 
and over 50% of pharmaceutical drug targets are membrane proteins [32-34].   
Membrane proteins can be classified into two main classes; integral membrane 
proteins and peripheral membrane proteins. Integral membrane proteins (IMPs) are 
proteins that are embedded in the cell membrane, and their removal from the 
membrane usually requires the use of detergents. Further, they also can be divided 
into six groups based on their embedded domain structures and location. The first 
and the second group are described as a single trans-membrane helix that passes 
through the cell membrane with the C-terminus either inside or outside the cell. The 
third and fourth groups contain either a single domain that is composed of several 
transmembrane helices and can pass through the membrane many times, or by 
multiple protein domains that can pass through the membrane once but with 
separated trans-membrane helices or β-pleated sheets, such as MSPA porins [35]. In 
groups five and six, the protein can either attach to the membrane by covalent bonds, 
with their lipids as membrane anchors, such as glycosylphosphatidylinositol (GPI) 
anchors [36] or can pass through the membrane and interact with the membrane 
phospholipids by an amphipathic helix interaction. However, integral membrane 
proteins can also consist of multiple β-strands, instead of α-helices, that can cross the 
phospholipids bilayer of the outer cell membrane of mitochondria and Gram-
negative bacteria or the cell wall lipids of Gram-positive bacteria. Therefore, 
purification process of these types of protein is often very difficult, and requires 
special detergents, due to the presence of hydrophobic amino acid sequences, which 
help proteins to interact with the phospholipids bilayer of the cell membrane. 
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Figure 1.7. Schematic diagram of the possibilities attachments of membrane protein to 
lipid bilayer. Membrane protein might attach to membrane by covalent interaction of (1) 
single trans-membrane α-helix or (2) as multiple helices into the cytoplasm. Also, membrane 
protein might interact covalently by attachment of prenyl molecule or lipid fatty acid as in 
(3), or (4) by oligosaccharide into the phospholipid bilayer. (5 & 6) represent the non 
covalent interactions with other integral proteins [2]. 
 
The second class of membrane protein is that of peripheral membrane proteins 
(PMPs). This type of protein is attached to the cell membrane by other molecules 
that are already bound to the cell membrane, such as integral membrane proteins or 
membrane lipids. This interaction often occurs by electrostatic interaction, or by 
polar interaction, forming hydrogen bonds. PMPs thus can be extracted easily from 
soluble cell fractions by changing pH, or by addition of salt. In addition, PMPs can 
function as regulator enzymes for different membrane proteins, which work as 
receptors and channels, such as the Kinase C enzyme that is involved in signal 
transduction (Figure 1.7) [37]. 
Finally, lipoproteins, the subject of this thesis, are defined as types of membrane 
proteins that interact with the cell membrane lipids by a set of hydrophobic residues 
within their N or C-terminal sequence known as a signal sequence. The signal 
sequence enables the lipoprotein to be attached into the cell membrane by post-
translational modification of a cysteine residue with fatty acyl molecules of the 
membrane lipid bilayer (N-acyl-S-diacylglyceryl-Cys) [38]. 
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1.3.1 Lipid anchored proteins 
A lipid-anchored protein is a class of protein that is produced in the cytoplasm as 
pre-prolipoprotein and attached to the cell membrane by post-translational 
modification (lipidation). Functionally such proteins are heterogeneous and represent 
about 3% of bacterial genomes [1]. Furthermore, all bacteria apparently allocate 
particular proteins to the cell envelope by a process called post- translational lipid 
modification in order to produce membrane-anchored lipoproteins that are able to 
work in the aqueous environment of the membrane interface [2].  
Analyzing the sequences of potential bacterial lipoproteins to identify possible signal 
sequences is the first step in identifying their roles and significance. The signal 
peptide sequence of a lipoprotein consists of different features that can be used to 
identify lipoprotein from any organism (Figure 1.8). Firstly, they contain an n-region 
that consists of 5-7 amino acids and usually contain at least two positively charged 
amino acids. The next part of the sequence contains the h-region (hydrophobic 
region). This region is composed of around 7-22 amino acids that are mainly 
uncharged and hydrophobic. Finally, the c-region, called the lipobox, and the first 
sequence to be identified in bacterial lipoproteins by Hayashi et al, in 1993 [39]. The 
lipobox consists of a four-amino-acid sequence at the C-terminal end of the signal 
peptide sequence, including the modified Cys at position +1 and is known as the 
lipobox [L- (A or S) - (G or A) - C] [38].  
 
Figure 1.8 The signal sequence composition of bacterial lipoproteins. The sequence 
composed of three regions [43]. The first region (n-region, green) includes the positive 
charge residues within the first four residues. The second region (h-region, blue) includes 
strong hydrophobic residues and the third region (c-region, red) have the lipobox that 
includes the conserved Cysteine residue [38]. 
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1.3.2 The lipoprotein biosynthetic pathway  
There are two pathways that control the translocation of any protein through the 
inner membrane but do not verify their final site. The first pathway is known as the 
Secretory translocon pathway (Sec pathway), which functions as a pathway for 
unfolded proteins through the inner membrane to outside the cell after synthesis in 
the cytoplasm [40]. The second pathway is known as the Twin-arginine translocation 
pathway (Tat system), this system requires the presence of two arginine residues 
within the n-region of the N-terminal signal sequence, and translocates a folded 
protein through the inner cell membrane into the outside of the cell [41].  
 Lipid modification then takes place in order to translocate the lipoprotein either 
within the inner or outer cell membrane. Three enzymes are engaged in the lipid 
modification of lipoprotein. The signal peptidase II enzyme (LspA) cleaves the pre-
prolipoprotein in a specific cleavage site sequence [L- (A or S) - (G or A) C] that is 
found after the H-region of the signal peptides [42, 43]. This cleavage is carried out 
after the addition of a diacylglyceride unit into the conserved cysteine of the Lipobox 
(c-region) by a thioether linkage, resulting in the mature protein with a modified 
cysteine in the N-terminal portion of the protein sequence [44, 45]. This process is 
called lipidation, and is catalyzed by the enzyme prolipoprotein diacylglyceryl 
transferase (Lgt) [46, 47] (Figure 1.9).  
The process of lipidation is completed by the addition of three fatty acyl chains, that 
are derived from the phospholipids of the bacterial cell membrane, to the cysteine of 
the N-terminal protein sequence, by the enzyme phospholipid–apolipoprotein N- 
acyltransferase (Lnt) [48] (Figure 1.9). An additional system called the localization 
of lipoprotein system (LoI) is responsible for translocating the mature protein to 
either the outer membrane or inner membrane. However, it is based on the type of 
residue following the N-terminal Cys of the signal sequence [49]. If this residue is an 
Asp, the protein embeds itself in the inner membrane and if it is a Ser, then the 
protein translocates to the outer membrane [50, 51]. 
In mycobacterium genomes, lipoproteins have been characterized with features of 
type II peptide sequence at the N terminal sequence [42]. Furthermore, both enzymes 
(Lgt and LspA) that are involved in lipoprotein biosynthesis have been found in the 
                           
 
39&
genomic DNA of mycobacteria and other bacteria [52]. This might suggest that their 
functions are significant for anchoring of lipoprotein in all organisms [52, 53]. 
However, the third enzyme of phospholipid–apolipoprotein N- acyltransferase (Lnt) 
was found only in Gram – negative bacteria and is responsible to add a third acyl 
residue to the amino group of the modified cysteine [54]. 
Further, membrane lipids in mycobacteria and the conserved cysteine are linked 
covalently and considered to make lipoproteins attached to the biological membranes 
by hydrophobic interaction. In Gram-positive bacteria, lipoproteins are attached to 
the plasma membrane (inner) and in Gram-negative bacteria most of lipoproteins are 
found in the outer cell membrane [52]. 
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Figure 1.9 Bacterial lipoprotein biosynthesis pathway. Lipoprotein is synthesized in the 
cytoplasm as a pre-prolipoprotein with N-terminal signal peptides. Lipid modification of the 
lipoprotein precursor is intermediated by regular activity of three different enzymes (pre-
prolipoprotein diacylglyceryl transferase (Lgt), prolipoprotein signal peptidase (LspA) and 
apolipoprotein N-acyltransferase (Lnt). [55]. 
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1.3.3 Examples of Lipoprotein in Mycobacterium  
In mycobacteria lipoproteins have been characterized that have a wide variety of 
different functions [47, 48]. For example, lipoproteins that are involved in cell 
adhesion, such as LpqH from M.tuberculosis. This lipoprotein has an immunologic 
role in phagocytosis stimulation, when it binds to the cell receptors of monocytes 
[56]. Also, lipoprotein functions as receptors of several molecules, such as the 
phosphate transport receptor (Pst) of M.tuberculosis, which causes a significant 
immune response when used as a vaccine in mice [57]. Lipoproteins can also interact 
with other proteins and function as ligand binding protein, such as LprF and LprJ 
lipoproteins of M.tuberculosis and M.smegmatis, which interact with histidine kinase 
(KdpD) [58]. Furthermore, lipoproteins are involved in the transport and synthesis of 
cell envelope and be a lipid essential constituent, such as LpqW and LpqX 
lipoproteins from M.tuberculosis [59]. Thus, lipoproteins can be considered as 
potential targets for drug design. Finally, lipoproteins also can be designed as a 
potential vaccine target, such as the Lpp20 lipoprotein, the Helicobacter pylori 
vaccine candidate [60, 61]. 
1.4 Fundamental nutrient pathways of mycobacterium cell envelope 
The mycobacterium cell envelope contains a layer of mycolic acid that is unique 
among all bacteria. This mycolic acid layer functions as a protector for the organism 
from toxins and other external agents and is suggested to be resistant against several 
antibiotics and common disinfectants [25]. The function and structure of this layer 
are equivalent to the outer cell membrane of the Gram-negative bacteria [62]. Gram-
negative bacteria use several pathways to transport solutes in and out of the cells. 
Examples of these pathways include the lipid pathway, where hydrophobic 
compounds are dissolved in the lipid bilayer temporarily to enable transport [62]. 
The porin pathway, where specific hydrophilic compounds pass through a protein 
channel into the cell and by a process called self – promoted, where polycationic 
compounds disorder the external membrane in order to pass through [63] [64]. 
Furthermore, some compounds are transported by integral membrane protein 
transporters, such as FhuA, which is the protein responsible for the uptake of iron 
ions and the transport of them into the cell [65]. In addition, in M.tuberculosis, 
essential substances are transported throughout the mycolic acid to the periplasm, 
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and then transported into the cells by lipoprotein transporters, however, it is still 
unknown how molecules are transported to the periplasm [62]. 
1.5 M.tuberculosis and structural genomics 
The aim of structural genomics is to determine the structure of most of the proteins 
that are expressed in a particular organism [66]. The Haemophilus influenza genome 
was the first to be completed in 1995, while today, there are more than 100 
completed sequences of bacterial genomes [67]. The isolation of M.tuberculosis was 
first conducted in 1905 and H37Rv was the first sever pathogenic and widely spread 
strain to be isolated and used in research [68]. The sequence of M.tuberculosis was 
first completed in 1998 with 3974 genes identified [53]. In 2002 the genome was 
reannotated and 82 extra genes were added [53, 68]. The accessibility of the 
M.tuberculosis genome enables the life cycle and virulence of Mycobacterium to be 
studied in greater depth. This also has enabled structural genomic programs to be 
developed on M.tuberculosis. In this procedure all or a certain subset of genes from 
an organism are overexpressed, proteins purified and their structure determined. In 
favorable circumstances, the structure obtained can be used to predict the function of 
unknown proteins, or be used in structure based inhibitor design programs to develop 
new drugs [69].            
For mycobacterium organisms, structural studies have led to the discovery of many 
targets for drug design, such as the mycobacterial domain of carboxyl transferase 
[70] and the alternative NADH: ubiquinone oxidoreductase (NDH2) [70]. Also, the 
completion of mycobacterium genome sequencing in 1998 has a positive effect on 
mycobacterium research as several genes that are involved in the pathogenicity and 
life of the organism have been identified. Mycobacterium proteins structures in the 
protein data bank have risen significantly from less than 100 in 1998 to almost 900 in 
2010 [71].  
1.6 Identification of drug target 
According to McDevitt and Rosenberg [67], there are four different factors to be 
considered in selecting a drug target in an organism. Firstly, a target should be 
present in a required variety of organisms. Secondly, a target should not be found in 
humans or if it is, the protein (s) must be totally different [67, 71]. Thirdly, a target 
should be essential for the growth of the particular bacterium during infection. 
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Fourthly, the function of a target should be partially known and understood in order 
to develop a good high - throughput screen [67]. Most of the available antibiotics 
which are currently in use, interact with specific proteins that are either involved in 
processes in the cell, such as transcription or the synthesis of the cell wall [67]. 
Rifampicin is a transcription inhibitor and Ethambutol (EMB) and isoniazid (INH) 
are cell wall biosynthesis inhibitors, that are all used as the main drugs for targeting 
M.tuberculosis infection [18].                                                                                      
!
!
!
!
Figure 1.10 The iterative process of structure based drug design discovery. 
!
!
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1.7 Aim of project 
The high number of deaths caused by tuberculosis, the emergence of new strains 
resistant to the available antibiotics, as well as the persistence of the bacteria, have 
together contributed towards the urgent need for new antibiotics, which have the 
ability to eliminate the pathogenic strain.                                                                                                                                
Developing new drugs was a costly (> $300m) and time consuming (> 20 years) 
process involving many steps, any of which could fail, leading to a failure in drug 
development. Therefore, it is very important to find another way to develop new 
drugs in less time and with less money. Although research into tuberculosis and its 
causative bacterium has been continuing for a very long time, information about the 
relationship between the pathogen and the host is still not well understood. Also, 
aspects of the bacterial life cycle and its interaction mechanisms are also still 
ambiguous. Thus, the need to understand more about the bacterial life cycle is 
required in order to be able to identify novel targets for drug design and for use in 
treatment. Within the proteome of an organism the membrane proteins are still 
poorly understood biologically compared to globular proteins due to problems in 
their solubility and isolation. The Mycobacterium genus is composed of about 120 
species [72]. M.tuberculosis genome encodes about 4000 proteins, and only 8.5 % of 
these proteins have structures known in the protein data bank, with about 898 
M.tuberculosis protein structures [68].  Some of which occur in multiple entries, 
such as shown in Table 1.2. Out of the total number of structures, only 327 structures 
are unique [68, 71]. Lipoproteins account for about 2.5% of the total number of 
proteins in the mycobacterium genome [68, 73]. Lipoproteins that are present in 
mycobacterium species are double the number of lipoproteins that found in other 
bacteria [52]. Many of lipoproteins have an unknown function [52, 68]. Therefore, 
the aim of this project was to identify lipoproteins from M.tuberculosis based on 
their attachment to the cell membrane, and then to identify the similar lipoproteins 
from M.smegamtis.  The target proteins then enter a process of gene amplification, 
protein overexpression, protein purification, and crystallization and structure 
determination, with the aim of identifying their function. 
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Class Function ORFs Structures in PDB 
0 Virulence, detoxification, adaptation 99 20 
1 Lipid metabolism 233 31 
2 Information pathways 229 25 
3 Cell- wall and cell processes 708 31 
6 PE and PPE proteins 170 2 
7 Intermediate metabolism and respiration 894 143 
8 Proteins of unknown function 272 0 
9 Regulatory proteins 189 32 
10 Conserved hypothetical proteins 1053 43 
- Total protein encoding ORFs 3845 327 
  
Table 1.2 The number of all proteins encoded in the genomic DNA of M.tuberculosis.  
Proteins were classified and arranged according to their functions and solved structures in 
the PDB [68].  
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1.7.1 Target selection 
All targets were selected for their attachment to the cell membrane and defined as 
potentially lipid anchored proteins. To determine this, hydrophobicity plots of all the 
protein sequences encoded within the M.tuberculosis genome were generated using 
the hydropathy scale of Kyte and Doolittle [74]. Each plot was inspected to select the 
most probable targets that are defined as membrane attached proteins. Targets with a 
high hydrophobicity in the first 20-50 residues of the protein sequence are considered 
to be possible lipid anchored proteins.  In this way, 55 possible lipid anchored 
proteins were selected out of 4000 translated proteins. These selected targets were 
further filtered by checking the availability of their 3D structure. Also, some targets 
were selected based on their essentiality for M.tuberculosis bacterial growth. 
Essential proteins were identified using Himar1-based transposon mutagenesis [75]. 
Using this method, three targets were selected as both essential and lipid anchored 
proteins (Rv1274, Rv2700 and Rv2903c). Further targets (Rv0583c Rv1275 
Rv2041c and Msmeg_6050) were identified as lipoproteins and, lastly, Rv1854c, 
which encodes the NDH2 protein, was added to the list, because of its interest as a 
drug target [76]. The target genes, which have been studied in this thesis, are shown 
in table 1.3. 
 
 
Figure 1.11 A schematic diagram of the predicted way of the lipoprotein membrane 
attachment. Hydrophobic part that is anchored to the membrane with hydrophobic part of 
signal sequence while the rest of protein is soluble in the aqueous medium. 
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No. Of 
targets 
M-Tb 
targets 
M.smegmatis 
targets 
Seq. 
identity 
Number of 
A. acids 
(Da) 
 
Gene 
Length 
Predicted 
function 
1 Rv1854c Msmeg_3621 63% 463 1392 Probable 
NADH 
dehydrogenase 
(NDH2) 
2 Rv1274 Msmeg_5007 69% 185 558 
 
Unknown 
 
3 Rv2700 Msmeg_2761 63% 216 651 Unknown 
 
4 Rv2903c Msmeg_2441 76% 294 885 Probable signal 
peptidase I 
(LepB) 
5 Rv0583c Msmeg_5456 48% 228 687 MK35 unknown 
6 - Msmeg_6050 - 300 903 Solute-binding 
lipoprotein 
 
7 Rv1275 Msmeg_1395 27% 193 582 Unknown 
8 Rv2041c Msmeg_0515 22% 425 1278 Probable sugar 
transporter 
sugar binding 
lipoprotein 
 
Table 1.3 All targets were selected to run this project. Eight targets were selected to work 
on from M.smegmatis with their similar proteins from M.tuberculosis and their protein 
sequence identity and length with their predicted functions. 
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Chapter 2 
 
Material & Methods 
This chapter gives a general description of all the materials and procedures that have 
been utilized to run this project including the experimental techniques for cloning, 
over expression, purification, and crystallization of all targets from M.smegmatis. &&&&&&&&&&&&&&&&&&
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2.1 DNA cloning 
2.1.1 Recombinant DNA technology and protein production 
The study of protein structure using X-crystallography usually requires a high 
amount of soluble, stable and well-folded pure protein. As producing enough protein 
from the native source is difficult and can be dangerous (in case of pathogenic 
organisms), molecular biology is routinely used to produce high amounts of the 
required protein target for use in structural studies. Recombinant DNA technology 
has enabled us to extract and amplify the gene of interest from any organism, by 
introduction into an expressing plasmid, which is then transformed into a host to be 
expressed, thus producing the required amount of a target protein.    
2.1.2 Genomic DNA Extraction of M.smegmatios 
An M.smegmatis streak plate was obtained from the laboratory of Prof. J.Green in 
Sheffield. A colony was inoculated using a sterile loop into 5 ml of Luria-Bertani 
(LB) medium (Table 2.1), and incubated at 37°C for 3 days. 1 ml of this culture was 
used to extract genomic DNA using a keyPrep bacterial genomic kit (ANACHEM). 
The manufacturer’s protocol was followed to give a final concentration of 20-70 µg 
in 100 µl of genomic DNA for use in the Polymerase chain reaction (PCR). 
Component g/L 
Lysogeny broth media 20 
Tryptone 10 
Yeast extract 5 
Sodium chloride 5 
Agar  
Tryptone 10 
Yeast extract 5 
Sodium chloride 5 
Agar 15 
 
Table 2.1 The composition of agar and lysogeny broth media. 
 &
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2.1.3 Polymerase chain Reaction (PCR) 
In order to successfully amplify the gene of interest, PCR is routinely used. The 
components required are the DNA template, the primers designed to be 
complementary to the DNA template region, heat stable DNA polymerase, such as 
Tag polymerase, deoxynucleoside triphosphates (dNTPs), deionized autoclaved 
water and an appropriate buffer containing Mg+2, to set up the reaction.  
The PCR proceeds through a number of cycles for amplification. Every cycle is 
composed of three stages, completed by varying the reaction temperature.  The first 
stage is denaturation, where the reaction temperature is raised to 95°C in order to 
break hydrogen bonds between DNA bases to end with single stranded DNA. The 
second stage is annealing, where the reaction temperature is decreased to less than 
the DNA primers melting temperature, allowing the primers to bind to their 
complementary bases on the region of the DNA template. The final stage is 
elongation, where the DNA polymerase enzyme binds to the DNA and moves 
forward along the DNA, in order to produce a new duplicate of the preferred region 
and a temperature suited to the polymerase used. 
The extracted M.smegmatis genomic DNA was used to amplify all target genes in a 
PCR reaction of Biomix Red 25 µl as final volume (Bioline) or 50 µl total volume 
using standard PCR components as shown in (Table 2.2). For each reaction 7 µl of 
genomic DNA was used and 1µl of 10 pmol forward and reverse primers were 
added. The reaction was set up using gradient PCR machines as shown in table 2.3.  
Initial Denaturation 95°C for 5 minutes 
Further Denaturation 95°C for 30 seconds / 35 cycles. 
Gradient Annealing Start from 55°C to 65°C. 5°C < than Tm of primer pair. 
Elongation 72°C for 1 minute. 
Final Elongation 72°C for 7 minute. 
Table 2.2 Gradient PCR condition of the M.smegmatis genes amplification. &
&
Table 2.3 The composition of a standard PCR reaction mixture 
 
Reagents Volume 
DNA template 1-7 µl 
Forward and reverse primers 1ul each of 10pmol stock. 
10mM dNTPs 1µl 
10x buffer contain MgCl2 5µl -10 µl 
ddH2O To 50 µl total volume. 
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2.1.4 pET vectors 
A large variety of different expression systems have been designed. One example of 
these systems is the pET system (Novagen). The pET28a vector (Figure 2.1) has 
been used exclusively in this project. This vector contains multiple restriction sites to 
be used for cloning and the T7 promoter sequence. The lac operator, ribosomal 
binding site and a T7 terminator sequence are located after the T7promoter. The 
BL21 (DE3) bacterial strain was used as a host for protein over expression. 
2.1.5 Cloning with pET28a 
The pET28a plasmid was used to clone all gene targets with restriction enzyme 
digestion. Primers were designed for each gene with restriction enzyme sites NdeI 
and HindIII in the forward and reverse primers, respectively, based on their presence 
in the pET28a plasmid. The primers were also designed to incorporate a His-tag 
sequence at the N or C-terminal of the protein. As a result of digestion of both 
plasmid and gene of interest, a sticky end of both plasmid and insert was used for the 
ligation reaction using T4 DNA ligase. Successful clones were then transformed into 
BL21 (DE3) E.coli cells that lack the T7 polymerase gene, to avoid any disturbance 
background expression that may possibly be problematic.  
2.1.6 pET expression hosts 
The E.coli DE3 strain is considered as a vehicle that contains the essential genes for 
protein expression in its chromosomal DNA, including T7 RNA polymerase gene 
copy and the lacI gene. IPTG is used to induce RNA polymerase that is under 
lacUV5 control. Once the polymerase is expressed, plasmid DNA can be transcribed 
into mRNA, which is translated and results in a large quantity of the desired protein 
(Figure 2.1). 
2.1.7 Purification of PCR product 
In order to visualize the resultant PCR product, a 1% TAE agarose gel was run at 
100 V for 50 minutes with Ethidium bromide. The positive bands that appeared at 
the expected size were cut from gel and transferred to an eppendorf tube. DNA was 
recovered from these samples using QiaQuick® Gel Extraction Kit (Qiagen) 
following the manufacturer’s protocol. Briefly, The protocol used was; add three 
volume of buffer QG and incubate at 50°C for 10 minutes. Then add 1 volume of 
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Isopropanol with mixing. The mixture is then transferred into a QIAquick® column 
and centrifuged at 14,000 xg for 1 minute. All the liquid was discarded and 500 µl of 
QG buffer was added to the column and centrifuged again at 14,000 xg for 1 minute. 
Then the column was washed with 750 µl of PE buffer. The flow through was 
discarded after centrifugation, of the columns twice, to make sure that all ethanol 
was removed from the column. The column was transferred into a new Eppendorf 
tube and DNA was eluted by adding 50 µl of EB buffer and incubating at room 
temperature for 2 minutes and centrifugation for 1 minute. The final concentration of 
DNA extracted varied between 20-50 ng µl-1. 
2.1.8 Restriction digestion for vector pET28a and PCR product 
In order to be able to produce a sticky end for cloning, both vector and PCR product 
were double digested with 4 units of restriction enzymes Nde1 and HindIII (NEB) 
(Table 2.4). The reactions were incubated at 37°C for 3 hours. Then a 1% TAE 
agarose gel was run at 100 V for 50 minutes in order to remove unwanted enzymes. 
DNA was then extracted out of the gel by using QiaQuick® Gel Extraction Kit 
(Qiagen) and stored at -20°C. 
 
Component Volume 
Vector/PCR product 1µl (5ng/ul) 
10x NEB Buffer 4 2 µl 
NdeI enzyme 1 µl 
HindIII enzyme  1µl (4-12 U/µl) 
DdH2O To 20 µl 
Total  20 µl 
Table 2.4 The composition of a typical double restriction digestion reaction. 
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(a) 
 
  (b)  
Figure 2.1 The pET28a plasmid. a. A circle map of the plasmid shows the essential cloning 
regions, such as a copy of lacI gene and multiple cloning sites (black arrow), replication 
regions (f1phage) and pBR322, antibiotic selection gene (Kanamycin) and selection of two 
three tags (N and C terminal 6xHis tags) and one T7 tag. b. The plasmid cloning sites 
include a T7 promoter sequence and a lac operator sequence and ribosomal-binding site. 
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2.1.9 DNA Ligation and transformation into DH5α 
The ligation reaction of the target insert into the pET28a vector was performed in an 
Eppendorf tube containing different concentrations of plasmid and insert (3:1, 1:3 
and 3:0). The reaction was also done using T4 ligase enzyme with its appropriate 
buffer and incubated at room temperature for one hour. After incubation, 1-5 µl of 
the ligation mixture is added into 50 µl of E.coli strain DH5α that had been defrosted 
gently on ice for 5 minutes. The transformed mixture was incubated on ice for 2-5 
minutes and then heat shocked at 42°C in a water bath for 90 seconds. Then, the 
mixture was placed back on ice for 2 minutes. 450 µl of LB medium containing 50 
µg ml-1 kanamycin (room Temp) was added to 50 µl of cells and incubated at 37°C 
with shaking at 200 RPM. After one hour cells were centrifuged at 3.600 xg for 2 
minutes. The LB medium was then discarded and 50 µl of fresh LB was used to re-
suspend cells, which were spread onto 50 µg ml-1 kanamycin agar plates. 
Component Amount 
DNA 50ng/ųl Msmeg_gene /pET28a 5-10 µl/5 µl 
10X T4 Ligase 2 µl  
T4 Ligase 1µl 
ddH2O To 20 µl 
Total 20 µl 
Table 2.5 The composition of a typical ligation reaction. 
 
 2.1.10 Confirmation of successful cloning  
In order to confirm successful cloning, several colonies were inoculated into separate 
5ml of LB medium containing 50 µgml-1 kanamycin and incubated at 37°C 
overnight. The cells were pelleted by centrifugation at 3.600 xg for 5 minutes and the 
supernatant was discarded. Vector isolation was carried out using a QIAprep Spin 
MiniPrep Kit (QIAGEN) by following manufacturer’s protocol. Cells were re-
suspended with 250 µl of buffer P1, containing RNase. Then 250 µl of alkaline lysis 
buffer P2 was added followed by 350 µl of buffer N3. The samples were centrifuged 
at 13,000 RPM for 10 minutes to remove broken cells debris. The supernatant was 
applied onto miniprep spin column and centrifuged again at 13,000 RPM for 1 
minute.  The column was washed by 740 µl of buffer PE and centrifuged twice to 
remove ethanol. Finally, column was transferred into clean 1.5 eppendorf tube and 
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DNA was eluted by 50 µl of buffer PE and incubated at room temperature for 2 
minutes before been centrifuged for 1 minute. The purified vector was digested using 
Nde1 and HindIII as described previously, and incubated at 37°C for one hour. The 
resultant cut vector was checked using 1% TAE agarose electrophoresis gel run at 
100 V for 50 minutes. 
2.2 Protein over-expression 
2.2.1 Transformation 
The competent E.coli strain BL21 (DE3) is normally used for the over expression of 
the desired protein (Novagen). The plasmid containing the desired insert was 
transformed into competent cells by the heat shock method. After removing an 
eppendorf tube containing 20 µl of Bl21 (DE3) from -80°C and defrosted on ice, a 
small amount of the desired plasmid DNA (10 ng/µl) was added to the cells and 
incubated on ice for 15-30 minutes. The mixture was then incubated at 42°C for 30 
seconds and returned back to ice for 2 minutes. 480 µl of LB was added to the cells 
and incubated for one hour at 37°C, before being pleated onto LB agar containing 
35-50 µg ml-1 kanamycin. 
2.2.2 Small-scale over-expression trials 
A small-scale over-expression was carried out to identify the best conditions for each 
protein. This was done by changing the induction time, temperature and the IPTG 
concentration. The successful optimized condition was then used to scale the culture 
up, to produce enough protein for structural studies.  A starter culture made with an 
appropriate antibiotic (50 µg ml-1 kanamycin) and incubated overnight at 37 °C. This 
culture was then used to make a secondary culture, (with 1-2% inoculation) with the 
same selected antibiotic. The secondary culture was incubated at 37 °C and shacker 
at 250 RPM. Once an OD600 of 0.5-0.8 was reached, several concentrations of IPTG 
(0.1-1 mM), temperature (4-37 °C), shaker speed (150-250 RPM) and time of 
induction (1-24 hours) were tested to identify the best conditions. A small amount of 
cells (1.5 ml) were taken before induction to be used for the expression analysis. 
After expression, all induced cultures were centrifuged at 17,000 xg for 10 minutes. 
The supernatant was discarded and the pellets stored at -20°C. The cells paste was 
removed from the freezer and re-suspended in lysis buffer or bug buster (Novagen) 
and incubated for 30 minutes to break the cell membrane. The soluble fractions of 
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protein were separated from cell debris and insoluble protein by centrifugation at 
70,000 xg for 10 minutes. The supernatant, the cell debris and the un-induced 
samples were all analyzed for protein expression by running on SDS PAGE.  
2.2.3 Large-scale over-expression 
After finding the best condition for protein expression, a large-scale over-expression 
was carried out. The primary culture of 50 ml was grown overnight at 37 °C in a 250 
ml conical flask with an appropriate antibiotic and used to inoculate 500 ml LB 
media in 2l flask to make the secondary culture.  Then protein was induced based on 
the small-scale expression results and centrifuged at 5,000 xg for 30 minutes. The 
supernatant was discarded and cell paste were stored at -20 °C for protein 
purification. 
2.2.4 Production of Seleno-L-methionine incorporated proteins 
A primary culture was grown overnight in LB medium containing 50 µgml-1 
kanamycin and used for 2% inoculation of (3 l) secondary culture supplemented with 
500 µg per 500 ml LB medium in (2l) flask. After reaching a suitable optical density 
(OD600 of 0.6), cultures were harvested by centrifugation at 5,000 g for 30 minutes. 
The cell pastes were re-suspended in minimal media containing Potassium 
dihydrogen phosphate (KH2PO4 4.5 g/l), Dipotassium phosphate (K2HPO4 10.5 g/l), 
Tri-sodium citrate (Na3C6H5O7, 0.5 g/l), Ammonium sulfate  ((NH4) 2SO4 1 g/l), 
Adenine (0.5 g/l), Guanosine (0.5 g/l), Thymine (0.5 mg/l), (Uracil 0.5 mg/l), 
Magnesium sulphate (MgSO4·7H2O, 1 g/l), Thiamine (4 g/l), L-lysine (100 mg/l), L-
phenylalanine (100 mg/l), L-threonine (100 mg/l), L-valine (50 mg/l), L-isoleucine 
(50 mg/l), L-leucine (50 mg/l) and Glycerol (5.0 g/l). Then cells were pelleted again 
for 30 minutes at 5.000 g and resuspended again in minimal media containing 40 
mg/L of Seleno-L-methionine. The culture was then divided into several 2 l conical 
flasks and incubated at 37 °C until OD600 reached 0.8. The cultures were induced 
with IPTG with a doubling of the induction time. The cells were harvested and the 
cell paste was stored at -20 °C for protein purification. 
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2.3 Protein purification techniques 
In this project two techniques were used to purify the various proteins and are 
explained as follows. 
2.3.1 Cell disruption 
Cells were disrupted by sonication (3x-20 seconds) at a volume of 16-micron 
amplitude on ice in order to purify a protein of interest. Sonication is a technique 
where the high frequency of sonic pulses is used to break the cell membrane of 
bacteria. The cell paste was re-suspended first with a proper buffer before cell lysis. 
The cell debris, insoluble protein and soluble protein were separated by 
centrifugation at 70.000 xg for 10 minutes and the supernatant used for protein 
purification.  
 
2.3.2 Nickel- NTA chromatography 
The first technique was used in this project is Ni- affinity chromatography.  The 
protein of interest contained six histidine residues at its N or C-terminus, known as a 
6-His-tag. This tag has the ability to interact with nickel bound to agarose beads by 
nitroloacetic acid (NTA) creation inside the column. Molecules that have no affinity 
or low affinity to the beads are first to be eluted easily from the column either by 
washing with buffer or with a low concentration of Imidazole. Molecules that have 
high affinity to the beads are then eluted by increasing the Imidazole concentration. 
Commonly, a 250 mM concentration of Imidazole is usually able to elute His tagged 
proteins. 
2.3.3 Size exclusion chromatography (Gel filtration) 
Further purification of the desired protein can be achieved by applying the sample 
through a 16x60 Superdex200 gel filtration column (GE Healthcare). This technique 
is based on the theory of separation of molecules upon their shapes and sizes. The gel 
filtration column contains porous beads that can be loaded first with small molecules. 
Larger molecules stay outside the beads, as they are larger than the pores of the 
beads. Thus they are likely to be eluted out first from the column.  
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2.3.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) 
SDS PAGE was used to evaluate protein purification progress by loading 20 µg of 
protein sample in 4x NuPAGE buffer (Invitrogen) containing a 10x reducing agent 
(such as β- mercaptoethanol) and 2 µl of bromophenol blue dye. The protein mixture 
was boiled before loading to allow the protein to be denatured, at 100 ˚C for 5 
minutes. Two types of SDS PAGE were used, a 12% resolving gel and a 6% stacking 
gel (Table 2.6). The mark 12™ (Invitrogen) protein standards were used to evaluate 
the protein bands size. The SDS gel was run at 200 Volts for 50 minutes in 1x SDS 
buffer. Then, the gel was removed, washed and stained with 0.1% (w/V) Coomassie 
Brilliant Blue, in 20% (v/v) methanol and 10% (v/v) acetic acid and put on a shaker 
to clarify the protein bands. 
 
 
12% resolving gel Gradients 
30% Acrylamide / bisacrylamide (29:1) 2.5 ml 
1 M Tris- HCL buffer, pH 8.8 2.35 ml 
10% SDS solution 62.5 µl 
10% Ammonium persulphate solution 6.25 µl 
TEMED 6.25 µl 
MilliQ water 1.28 ml 
6 % stacking gel  
30% Acrylamide / bisacrylamide (29:1) 0.75 ml 
1 M Tris- HCL buffer, pH 6.8 0.47 ml 
10% SDS solution 37.5 µl 
10% Ammonium persulphate solution 37.5 µl 
TEMED 3.75 µl 
MilliQ water 2.46 ml 
 
Table 2.6 Recipes of 12 and 6 % SDS Page ingredients. 
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2.3.5 Protein concentration  
The use of X-ray crystallography technique requires crystals, prepared from a high 
concentration solution of protein. Therefore, in order to increase the concentration of 
a given protein a Vivaspin sample concentrator (size based on molecular weight of 
protein 10.000 to 30.000 Da) (GE Healthcare) was used. It is composed of two filters 
separated by a membrane of polyethersulfone that contains pores of several sizes. 
The centrifuge is used to force the solution to pass through this membrane. A small 
molecule together with the solvent will pass thorough the membrane but larger 
molecules will not be allowed to pass and will remain on the top of the membrane 
leading to a more concentrated solution. Also, this concentrator can be used to 
exchange the buffer before crystallization trials. 
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2.4 Protein Crystallization 
 
2.4.1 Introduction 
The determination of the molecular structure of the protein can be carried out using 
the popular method of X-ray crystallography. In this method, X-rays are diffracted 
by atoms of the protein in a single crystal. If the intensities of the X-rays are 
measured and the phase of each reflection can be determined, an electron density 
map of the crystal can be calculated, leading to a molecular model. However, in 
order to successfully crystallize a protein, several conditions should be met, 
including a high amount of concentrated, pure, stable and correctly folded protein 
and a set of buffer and precipitant conditions, which favor the crystalline form of the 
protein. 
Crystallographic theory is covered in a number of textbooks, including 
Crystallography Made Crystal Clear [77]. This chapter will cover the methods used 
in the determination of the protein structures described in this thesis. 
2.4.2 Protein crystals 
 A protein crystal consists of millions of molecules repeated regularly in a specific 
array of three dimensions, known as a lattice. All molecules inside the protein crystal 
are interacting with those around them by means of non-covalent interactions, such 
as hydrogen bonds and the ionic interactions. A protein crystal can contain between 
30-90% solvent [78] and thus is fragile and easily broken. The crystal can be defined 
by its unit cell, which is the simplest and smallest unit that can be repeated by 
translations along x, y and z. Each unit cell is measured by the length of its three 
axes, a, b and c and the angles between them, α, β and γ. Furthermore, each unit cell 
can have internal symmetry, such as rotations. In these cases, the unit cell can be 
further broken down to the asymmetric unit, which is related to the unit cell by the 
symmetry operation of the cell. The seven crystal systems with their measurements 
are described in (Table 2.7). However, along with these crystal systems, there are 
four different types of lattice: primitive (P) where only one lattice point is found in 
each corner of the unit cell and body centered (I) where another point in the center of 
each cell unit is included. The last two lattice types are called all-face centered (F) 
and c-face centered (C). Because protein molecules are chiral, they can only be 
crystallized in one of 65 of the total of 230 space groups.  
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One common method for growing protein crystals is the vapour diffusion method, 
which was used exclusively in this project. In this method the protein solution is 
mixed with the precipitation solution in a normally, 1:1 ratio and sealed in the 
presence of a much larger reservoir of precipitation solution. During the course of the 
experiment, the protein concentration gradually increases, as water vapour passes 
from the crystallization drop to the reservoir. As this process occurs, the protein 
gradually enters the supersaturation zone (Figure 2.2).  
 
Crystal class Axis system 
Cubic a=b=c. α= β= γ =90° 
Tetragonal a=b≠c, α= β= γ =90° 
Trigonal  a=b, α= β= γ =120° 
Hexagonal  a=b≠c, α=β=90°, γ=120° 
Orthorhombic a≠b≠c, α= β= γ =90° 
Monoclinic a≠b≠c, α=γ=90, β≠90° 
Triclinic a≠b≠c, α≠β≠γ≠90° &
Table 2.7 The seven protein crystal system lattices. 
 
2.4.3 Growing protein crystals 
Producing a crystal is difficult because of several factors that affect protein 
crystallization, such as the size, stability, mobility and purity of proteins. In order to 
successfully form protein crystals, several parameters should be considered; the 
concentration and purity of the protein and the solution used for protein 
crystallization, such as the buffer, pH, temperature and other factors that are hard to 
be controlled or manipulated, such as the age and source of purified protein, sound, 
vibration and the source of the protein as well as the presence of a ligand. Other 
factors, which are significant for forming crystal, are the type and concentration of 
the precipitant agents, such as the salts, organic solvents and agents with high 
molecular weight, such as poly ethylene glycol (PEG). Moreover, many attempts 
must be performed in order to identify the proper conditions for the protein to form a 
crystal in combination with all these agents.  
As a crystal grows, the solution passes through two different phases until the crystals 
are formed (Figure 2.2). The first phase is known as the nucleation phase, where 
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molecules clump together to form nucleii (the nucleation zone). As the experiment 
continues, the concentration of the precipitant further increases, and the protein 
concentration decrease, as either crystals (metastable zone), or amorphous precipitate 
(precipitation zone) are formed.  
 
 
 
 
 
Figure 2.2 A diagram illustrating the protein crystallization phases. As a crystal grows, 
the solution passes through two different phases (zones) until the crystals are formed. As the 
experiment continues, the concentration of the precipitant further increases, and the protein 
concentration decrease, as either crystals (metastable zone), or amorphous precipitate  
(Precipitation zone) are formed.  
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2.4.4 Vapour diffusion methods 
Two main vapour diffusion methods are commonly used, the sitting drop method and 
the hanging drop methods (Figure 2.3). 
 
2.4.4.1 Sitting drop method 
In this method a small volume of protein solution is mixed with a similar volume of 
precipitant solution and placed adjacent to a reservoir of the precipitant solution and 
the system is sealed. This method is easily automated and for this project a Matrix 
Hydra II PlusOne robot was used to screen against a series of commercially available 
crystallization conditions in 96 well crystallization plates (Qiagen®). The robot 
dispensed 200 µl of protein sample and 200 nl of precipitant solution into the drop. 
The plates were sealed with tape and stored at 17 ˚C.   
 
2.4.4.2 Hanging drop method 
This method is a variation on the sitting drop, where the protein and precipitant are 
mixed on a cover slip, which is then inverted over a well containing the precipitant 
solution and sealed with oil or grease. This method is ideal for optimizing promising 
conditions seen in initial robot screens and volumes are larger, with typically 1ul of 
protein solution over 1 ml of reservoir.  
 
 
 
Figure 2.3 A diagram illustrate the main techniques used in protein crystallization. (a) 
The hanging drops crystallization method. (b) The sitting drops crystallization methods.    
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2.5 Crystal mounting and cryoprotectants 
When X-rays hit protein atoms, free radicals are produced, which react with the 
protein, breaking bonds and gradually degrading the crystal [77]. This radiation 
damage can be decreased by keeping the sample at very low temperature, which 
slows the diffusion of the radicals through the crystal lattice [77].  However, the 
crystal lattice can be disrupted by the formation of ice around the crystal, which 
damages the diffraction pattern. Therefore, crystals are placed in a special 
cryoprotectant solution that contains the crystallization conditions and a small 
molecule cryoprotectant, such as glycerol, low molecular weight PEG or alcohols, to 
stop ice crystals forming when the crystal is cooled. The crystal is looped from the 
drop in a fiber loop, placed for a short time in cryoprotectant solution and then either 
placed directly in a stream of nitrogen gas at 100 K on the diffractometer, or flash 
frozen in liquid nitrogen and stored for later use on a synchrotron source.  
2.5.1 Data collection apparatus 
Different detectors are used for collecting data from a single protein crystal and in 
this thesis, two types of X-ray source were used, the Rigaku MM007 copper-rotating 
anode system in Sheffield and the Diamond Light Source near Oxford. 
2.5.1.1 Copper-rotating anode system 
In a rotating anode, electrons are produced by a heated filament  (cathode) and then 
accelerated in a vacuum through a large potential difference (40 kv) to strike a metal 
anode, which in the case described here was copper. The impinging electrons have 
sufficient energy to expel an electron from the K shell of the copper anode. A high-
energy electron from a different shell of copper falls back into the vacant K shell, 
and the excess energy is emitted as an X-ray. For copper, the L-K transition is the 
most common, resulting in X-rays of a wavelength of 1.54 Å. These are separated 
from other, less common, energies by the use of a monochromator, Ni filter or coated 
focusing optics.  
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2.5.1.2 Diamond light source (Synchrotron) 
Additionally, the Diamond light source was used throughout this project for high-
resolution data collection. In a synchrotron, electrons are injected by an accelerator 
into a storage ring (Figure 2.4). In the storage ring the electrons are kept in a 
continuous circular motion by bending magnets. As the direction of the electron 
beam is changed by the magnet, electromagnetic radiation is given of tangentially to 
the storage ring, and the X-ray part of the spectrum is used for the diffraction 
experiments. Additional magnetic devices called undulators or wigglers can be 
inserted between the bending magnets; these can increase the intensity of the X-rays. 
The use of Synchrotron radiation has reduced the time of data collection to minutes 
compared to > 24 hours using a rotating anode. As different X-ray energies 
(wavelengths) can be selected, synchrotron radiation is ideal for anomalous 
scattering experiments, as energy close to the absorption edge of the anomalous 
element can be chosen. 
 
 
 
Figure 2.4 A schematic diagram of the Diamond Light Source (synchrotron). Figure 
adapted from the College of Life Sciences  website, University of Dundee. 
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2.5.1.3 Detectors 
In this thesis two detectors were used in the diffraction experiments. For the in house 
data collection a Mar Research image plate was used. In this detector, the diffracted 
X-rays hit a thin phosphor layer on the detector surface, doped with Eu2+. On 
irradiation, the Eu2+ loses an electron, forming Eu3+. At the end of the exposure, the 
image is read out, by scanning the detector with a red laser (λ=633 nm), which 
returns the Eu3+ to Eu2+, releasing radiation of 390 nm, which is counted by a 
photomultiplier.  
For data collected at the Diamond synchrotron, Pilatus pixel detectors were used. 
These detectors use hybrid pixel technology, where direct detection of the X-rays is 
achieved using a silicon solid state sensor bonded to a CMOS readout chip. This 
results in a high dynamic range, zero readout noise, and very short readout times, 
resulting in high signal/ noise ratio and the ability to use shutterless data collection 
methods, where the crystal is continuously rotated and the images read out every 0.1 
second. 
 
2.5.2 Data collection strategy 
A diffraction test is usually carried out to collect information about the crystal and its 
symmetry. For a data collection experiment, the rotation technique has been used 
throughout this study. This technique is based on a slight incremental rotation of the 
crystal during the X-ray beam exposure, so that all the diffracted beams can be 
measured. Several factors should be considered for data collection to assure that a 
complete data set is collected. The first factor is the crystal symmetry. According to 
Friedel’s law a complete data set can be collected in a maximum of 180° rotation.  
This rotation can be reduced by the crystal symmetry, which is described by the 
space group of the crystal. The second factor is the size of the rotation angle for each 
exposure called the incremental ϕ angle.  This angle used depends on the unit cell 
dimensions.  The length of the unit cell dimensions contributes to the space between 
each reflection; for instance, the crystal with long dimensions will result in very 
small separation between the reflections. Therefore, a reduction of the rotational 
angle for each image can decrease reflection overlap. The last factor that should be 
considered is the strength of the X-ray beam. Stronger X-rays are preferred for data 
collection, as they will result in high reflection intensities and improved resolution 
limit for the collected data. 
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2.5.3 Data collection 
 
Data collection on single protein crystals was carried out after transferring the crystal 
from its mother liquor into a cryoprotectant solution, which consisted of the mother 
liquor plus 20-30% of ethylene glycol. X-ray diffraction images were taken at 
different ϕ angles of 0˚ and 90° and then analyzed by the use of the auto-indexing 
routine in MOSFLM software [79]. MOSFLM estimates the dimensions of unit cell, 
mosaicity and the predicted space group. Using this information, the strength of 
beam and exposure time a strategy of data collection was made. For high quality data 
collection, crystals were sent to the Diamond synchrotron source of beam lines I02, 
I03, I24 and I04-1. 
!
2.6 Processing data from diffraction images 
All data obtained through this project were automatically indexed and integrated by 
the use of the software MOSFLM and XDS [79, 80].  At this step, the program 
analyzes the diffraction patterns to determine the distances between all reflections 
and their symmetry to produce unit cell dimensions and the space groups they belong 
to. Among the several selections of predicted solutions, that with the highest possible 
symmetry was routinely selected. Further MOSFLM refinement of the unit cell 
dimensions was undertaken using more diffraction images. Using these parameters, 
the data for every image was integrated, using Mosflm [79] or the xia2 pipeline [81] 
at Diamond, which uses XDS [80] for integration. The data were scaled, merged and 
analyzed with SCALA [82]. Phase determination was undertaken using either phaser 
[83] for molecular replacement or SHELX C, D and E for SAD experiments [84, 85]. 
These techniques are described in the appendix.  
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2.7 Structure building and refinement 
The COOT program was first used to visualize the electron density map and to build 
a model of the protein structure backbone [86, 87]. Then, the suite of CCP4 
programs was used to refine the model to be in agreement with the electron density. 
The structure refinement was carried out using REFMAC5 in the CCP4 suite [88]. 
Several cycles of structure refinement and rebuilding were run in order to improve 
the agreement between the model and the data.  In each round of rebuilding the 
position of the amino acid residues were adjusted to the map, and water molecules 
and other solvent were added to features in the difference electron density map, 
where they made sensible interactions with the protein. Progress of refinement was 
made by comparing the change in R-factor and free R-factor.  
 &&&&&&&&&&&&&&&&&&
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Chapter 3 
Cloning, over expression, purification and crystallization 
of protein targets from M.smegmatis. 
This chapter describes the bioinformatics study on the selected targets of the 
M.smegmatis structural genomics project and their progress of cloning, over 
expression, purification and crystallization. The target that successfully led to a 
solved structure will be discussed in chapter 4. 
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3.1 Target selection 
The rationale behind the project described in this thesis was to determine the 
structure of proteins associated with the membrane by either an N or C terminal 
helix, or by a lipid anchor. It was hoped that by analysis of the sequences of these 
types of protein that constructs could be designed that were solely the soluble part of 
these proteins, and thus might be more favorable towards crystallization than the 
entire gene product. The initial analysis was thus a hydropathy plot of all of the 
proteins encoded by the M.smegmatis genome. 
3.1.1 Hydrophobic plots analysis 
The hydropathy scale is a commonly used measure to define hydrophobic sites along 
protein sequence and is calculated by the relative hydrophobicity of the amino acids 
[74].  The hydrophobicity is calculated for a window of 19-20 residues, stepping 
along the sequence. A value > 2.5 for this window often indicates the presence of a 
transmembrane alpha helix. However, such analyses will also identify N-terminal 
lipid anchored proteins as they usually contain a hydrophobic portion in the signal 
sequence, prior to the cysteine residue that is the site of lipidation.  
3.1.2 Generating a truncated protein for selected targets  
In order to successfully obtain a highly soluble and stable protein that is suitable for 
crystallization and biochemical studies, attempts were made to truncate all target 
proteins by cleaving out the hydrophobic part located either at the N-terminal or C-
terminal regional of the protein sequence. For this purpose, a wide range of programs 
was used to help predict the right site for truncation. These included the lipoP 1.0 
server that helps to predict and identify a lipoprotein signal peptide, and Signal-3L, 
SignalP and TMHMM that are designed to predict signal peptides and trans-
membrane helices for a given protein sequence, respectively. Furthermore, the Phyre 
server was also used to help predict the secondary and tertiary structure of the 
unknown protein, based on its homology with known structures in the protein 
database [89]. Based on these studies, seven targets were selected, namely 
Msmeg_1395, Msmeg_2441, Msmeg_3621, Msmeg_5007, Msmeg_6050, 
Msmeg_5456, and Msmeg_0515. Five of these targets are described individually. 
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3.2 From DNA to protein 
3.2.1 Target amplification 
The M.smegmatis bacterial agar was used to inoculate 5 ml of primary culture which 
was then incubated at 37°C for 3 days. The culture was checked by eye every day for 
contamination, as the culture had no antibiotic selection. After 3 days, M.smegmatis 
genomic DNA was extracted using the keyPrep bacterial genomic kit 
(ANACHEM®). 
For each individual target, forward and reverse primers were designed for constructs 
encoding both the full length and truncated proteins, lacking the hydrophobic 
residues at the N- or C-terminal region. The selected target gene sequences were 
obtained from the KEGG database [90].  Both forward and reverse primers were 27-
30 base pairs in length and were synthesized by Eurofins MWG Operon Company.  
All synthesized primers were stored as a stock solution of 100 µM at -20 °C. The 
working stock was prepared by diluting of the original stock to 10 µM using 
sterilized water. To amplify the gene of interest, gradient PCR was used testing 
different annealing temperatures to find the best conditions for gene amplification. 
The purity of the resultant PCR product was evaluated and checked using 1% 
agarose gel electrophoresis. The PCR product was extracted from the gel using a gel 
extraction kit as mentioned detailed in section 2.1.7. 
 
Target Annealing temperature (˚C) 
Msmeg_3621 61 
Msmeg_5007 58 
Msmeg_2441 61 
Msmeg_2761 59 
Msmeg_6050 61 
Msmeg_5456 59 
Msmeg_1395 58 
  
Table 3.1 The best PCR annealing temperature used for gene amplification of the 
target full-length and truncated proteins.   &
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Oligoname (restriction site) Sequence 
NDH2 forward (NdeI) (T) 5’GCGCCATATGAGCCATCCCGGAGCTACGGC3’ 
NDH2 reverse HindIII 5’-GCGCAAGCTTGGACGCGGCTTTCTCGGTGT-3’ 
Msmeg_5007 forward NdeI (F) 5’-GCGCCATATGTTGGCGGTTCTGGCG-3’ 
Msmeg_5007 reverse HindIII 5’-GCGCAAGCTTAAACCTTAAGTGTTA-3’ 
Msmeg_6050 forward NdeI (F) 5’-GCGCCATATGGTGACGCGGCGGTGC-3’ 
Msmeg_6050 forward NdeI (T) 5’-GCGCCATATGGGCAGCGACGGCAG-3’ 
Msmeg_6050 Reverse HindIII 5’-GCGCAAGCTTAATGAGGTTGTTCGCAATGG-3’ 
Msmeg_5456 forward NdeI (F) 5’-GCGCCATATGATGATCACGACATTTC-3’ 
Msmeg_5456 forward NdeI (T) 5’-GCGCCATATGACGACCGGGGACCAG-3’ 
Msmeg_5456 Reverse HindIII 5’-GCGCAAGCTTGGGTGTGATGACG-3’ 
Msmeg_0515 forward NdeI (F) 5’-CCCCATATGGTGATACGACGCTGGTTG-3’ 
Msmeg_0515 forward NdeI (T) 5’-CCCCATATGTCGTCATCGGGTCC-3’ 
Msmeg_0515 Reverse HindIII 5’-GGGAAGCTTTTTGCCGGCCAGGG-3’ 
Msmeg_1395 forward NdeI (F) 5’-GCGCCATATGATGTGCCGGCGTGTTGTT-3’ 
Msmeg_1395 forward NdeI (T) 5’-GCGCCATATGTCGCACACCGTCACCG-3’ 
Msmeg_1395 Reverse HindIII 5’-GCGCAAGCTTCAGTTCCGACTGCAG-3’ 
  
Table 3.2 The primer sequences used in this thesis for gene amplification. The sequences 
written from 5’ to 3’ with restriction enzyme sites highlighted in bold. Two forward primers 
with an NdeI restriction site were designed for full-length gene (F) and truncated gene (T), 
respectively, and reverse primer with HindIII restriction site.  
 
3.2.2 Gene cloning 
To successfully clone all the PCR products into the pET28a expression vector, 
restriction digests using the enzymes NdeI and HindIII were carried out, to cut both 
the PCR product and the pET28a plasmid. The reaction resulted in a sticky end 
within both gene and plasmid, which, in turn, could be ligated together using T4 
DNA ligase (NEB). The mixture then was transformed into DH5α competent cells 
and plated on LB-agar containing 500 µg/ml kanamycin for selection and incubated 
overnight at 37 °C. Cells from a single colony were transferred to a primary culture 
of 5ml and incubated overnight at 37°C in a 250 RPM shaker. Plasmid DNA was 
extracted using a QIAprep® Miniprep kit (Qiagen). Successful cloning was 
confirmed by a restriction digestion experiment using the same restriction enzymes 
(NdeI and HindIII) and agarose gel electrophoresis was run for visualization purpose 
(Figure 3.1). The plasmid DNA was transformed into a BL21 (DE3) expression 
strain for gene expression. 
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Figure 3.1 Electrophoresis gels showing the PCR products of gene amplification for all 
selected targets. Bands highlighted in square boxes are the gene targets. Hyper ladder I 
DNA marker is shown on each gel. 
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3.2.3 Small and large scale protein expression 
Small scale overexpression trials were attempted, by inoculating a single colony of 
pMsmeg_(gene) into 5ml of LB media containing 50 ugml-1 kanamycin and 
incubated at 37°C overnight. Each gene was expressed using three 50 ml of LB 
medium in 250 ml flasks and supplemented with 50 ugml-1 kanamycin, which were 
then incubated in three different temperatures 37, 25 and 18°C and with variable 
IPTG concentration 1.0 mM, 0.5 mM and 0.1 mM and for 4 hours induction. 
The results revealed that no expression was observed for the full-length protein of 
any target except for Msmeg_5007, which was expressed in the soluble form only at 
18 C˚ and after 10 hours induction. Thus, small-scale expression trials of the 
truncated form of the targets were carried out using a similar protocol. However, 
only three (Msmeg_3621, Msmeg_6050 and Msmeg_5456) could be expressed at 
low level in the soluble form and thus tested for large-scale expression. The other 
two targets (Msmeg_1395 and Msmeg_2441) were expressed in the insoluble 
fraction and attempts to produce soluble proteins by optimizing the expression 
conditions failed. They were therefore excluded from further studies (data not 
shown).  The expression conditions for each truncated target protein are given in 
Table 3.3.  
 
Target Temp 
 
(°C) 
Induction 
time 
(hours) 
IPTG 
concentratio
n (mM) 
Culture 
volume 
(l) 
Optical 
Density  
OD600  
Shaker 
speed 
(RPM) 
Msmeg_3621 
(NDH2) 
37 10 0.5 7 1.00 200 
Msemg_5007 18 6 0.1 10 0.5 200 
Msemg_6050 25 5 1 2 0.5 200 
Msemg_5456 25 5 1 2 0.5 200 
Msemg_0515 37, 25 
& 18  
4 1 1 0.6 200 
  
Table 3.3 Over-expression conditions for all truncated target proteins from 
M.smegmatis. &
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3.3 Studies on the Msmeg_3621 (NDH2) protein 
3.3.1 Introduction 
The M.tb gene Rv1854c encodes the NDH2 enzyme, which has not been found in 
mammalian cells, has been shown to be essential in bacteria, including pathogens 
such as M.tuberculosis. NDH2 and is thus a potential drug target [75, 76]. This 
enzyme is involved in the respiratory chain of mycobacterium and is found in all 
Mycobacterium species including M.smegmatis. Msmeg_3621 where it shares a high 
protein sequence identity (63%), with NDH2 from M.tuberculosis. Although this 
selected target is not identified as a lipoprotein, it is predicted to attach to the 
bacterial cell membrane by a transmembrane helix in the C-terminal region (Figure 
3.2). The hydropathy plot of NDH2 revealed hydrophobic residues (360-430) at its 
C-terminal sequence, which may be involved in anchoring the protein to the cell 
membrane (Figure 3.2a). In addition, these residues are also predicted as a 
transmembrane helix using the TMHMM server (Figure 3.2b). 
 
3.3.2 Cloning and expression of the full length NDH2 
The full-length gene of NDH2 was cloned into a pET28a plasmid with an N-terminal 
6xHis-tag as mentioned in section 3.2.2; however, no expression was observed for 
the full length NDH2. Therefore, it was decided to cut the protein before the C-
terminal α-helix in an attempt to produce a soluble protein suitable for crystallization 
experiment. The truncation site was identified using a combination of the predicted 
structure from the Phyre server and the hydropathy plot (Figure 3.2).  Therefore, 
NDH2 was truncated at G380 and cloned into pET28a plasmid using the same 
restriction sites. The truncated NDH2 was overexpressed using the same protocol for 
the full length as described in section 3.2.3. 
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a.  
b.  
Figure 3.2 Hydropathy (a) and transmembrane helix prediction (b) plots of NDH2 from 
M.smegmatis. (a) The hydrophobicity plot was generated by using the Kyte-Doolittle 
hydropathy scale program [74], and indicates a stretch of hydrophobic residues in the C-
terminal protein sequence region (380-420). (b) TMHMM plot indicates a potential 
transmembrane helix at the same place in the sequence [32].  
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3.3.3 NDH2 Structure and function 
 NDH2 is a 50-KDa flavoenzyme that plays a significant role in the respiratory 
chain, where it catalyzes the oxidation of NADH [91]. Significantly, NDH2 appears 
in the electron transport chain (ETC) of M.tuberculosis together with the type 1 NDH 
(complex1), however, NDH2 is different from complex1, since it is not involved in 
pumping protons across the membrane and is thus considered as a potential drug 
target [91]. The electron transport chain of the bacterial cytoplasmic membrane is 
considered as a factory to generate energy for cellular growth. The respiratory chain 
usually catalyzes the transportation of electrons, which are produced by oxidizing 
organic substrates, such as NADH or succinate to an electron acceptor, such as 
oxygen [92].                                                                                 
 
The ETC of M.tuberculosis is composed of several complexes, which are involved in 
the power supply. Each of these complexes binds small molecules, such as heme, a 
flavin prosthetic group or copper atoms [76, 93]. These complexes include four 
dehydrogenases that are work as a complex to transfer electrons from the NADH 
electron donor in the cytoplasm into the ordinary quinone pool, which is found in the 
center of the ETC [93]. These dehydrogenases are known as Succinate menaquinone 
oxido reductase (SQR), type 1 NDH (NDH-1) that is involved in proton translocation 
during redox activity and two types of NDH2 enzyme (NDH2 & NDH-2A). NDH2 
enzymes both work as a single individual subunit, and are not involved in proton 
translocation as NDH-1[93].  The oxidation of the quinol is performed either by a 
reductase bound into the membrane to transfer electrons directly into the cytochrome 
bd oxidase or by cytochrome bc1 complex that transfers electrons into cytochrome c 
oxidase (aa3), to be then transferred to oxygen, which is an electron acceptor [93]. In 
addition, the movement of electrons along the chain contributes to the protein 
movement across the membrane, which helps to form an electrochemical gradient, 
which is in turn used by ATP synthase to produce ATP from ADP in the cytoplasm 
[93]. 
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Figure 3.3 The pathway of aerobic electron flow in mycobacterium. Complexes are 
shown in boxes, with corresponding gene names. The figure was taken from [93].  
 
At present, neither the 3D structure of M.tuberculosis nor M.smegmatis NDH-2 has 
been determined and their structure–function relationships have been predicted by 
the use of sequence similarity to other flavoenzymes, such as the lipoamide 
dehydrogenases [91, 94, 95]. The protein has been predicted to contain two domains, 
each with a central β-sheet flanked by helices [96]. Both domains contain the 
GXGXXG Rossmann fold motif, with one domain binding NADP (H) and the other 
FMN or FAD [91, 96]. 
The Phyre server was used to predict a structure for M.smegmatis. The best hit 
(100% confidence) was with the Ndi1 protein that catalyses the NADH oxidation in 
mitochondria of the Saccharomyces cerevisiae. 424 residues (93%) of the 
M.smegmatis NDH2 sequence were covered in the comparison with sequence 
identity of 28% (Figure 3.4). Structure analysis based sequence alignment and 
structure prediction to identify the predicted transmembrane α-helix of NDH2 is 
described below in section 3.3.7. 
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Figure 3.4 The predicted 3D structure fold of Msmeg_3621 (NDH2). The Phyre result 
revealed that the NDH2 of M.smegmatis is predicted to share similar fold with structure of 
the ndi1 protein from Saccharomyces cerevisiae in complex with NAD and FAD (PDB code 
4GAP) with 424 residues of NDH2 sequence covered in the comparison (93%) and with low 
sequence identity 28% and 100% prediction confidence [89]. FAD and NAD are shown as 
red and orange sticks in the center [97]. Figure was made using Pymol [98]. 
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3.3.4 Protein purification of NDH2 enzyme 
3.3.4.1 Ni-NTA chromatography  
As the construct of truncated NDH2 contained a N-terminal 6×His tag, a Ni-NTA 
affinity chromatography column was used as the initial purification step. Thus, 4 g of 
cell paste was removed from -80°C and resuspended on ice using 10 ml of 50 mM 
Tris buffer, pH 8.0. Then, cells were sonicated three times on ice at 16-micron 
amplitude, each for 20 seconds. Cell debris then were removed by centrifugation at 
70,000 x g for 10 minutes at 4°C. The soluble protein fractions (~20 ml/ 50 mg) were 
applied to 5 ml Ni-HP cartridge column after measuring the protein concentration by 
the Bradford assay. NDH2 enzyme was eluted from the column using 50 ml of 0.35 
M imidazole. Fractions of 8 ml were collected. The protein was anlaysed by SDS-
PAGE (Figure 3.5), which showed the presence of lower molecular weight 
contaminants, thus, a further purification step was used. 
 
 3.3.4.2 Gel filtration of pMsmeg_NDH2 
Fractions 7 - 14, which had the highest protein concentration (Figure 3.6) were 
combined for further purification using gel filtration.  The sample was reduced to 1 
ml using a Viva spin concentrator (MWCO 30000) and injected into a 16x60 
Superdex200 column (GE Healthcare), equilibrated with 50 mM Tris, pH.8.0 and 0.5 
M NaCl buffer. Gel filtration was performed at a flow rate of  1.5 ml/min and 2ml 
fractions were collected. The progress of the purification was analysed by SDS-
PAGE (Figure 3.5).  
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&
Figure 3.5 SDS gel showing protein purification steps of truncated NDH2. Lane 1; 
Mark12, lane 2; insoluble fraction of NDH2, lane 3; soluble fraction of NDH2, which 
indicated a weak expression of soluble NDH2 (~45kDa), lane 4; unbound materials of Ni-
NTA affinity column, lane 5; compound fractions 8-11 of Ni-NTA affinity column, lanes 6-
13; collected fractions from gel filtration column. 
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a) 
 
b) 
 
Figure 3.6 Chromatograms obtained during the purification of NDH2. Blue line 
represents absorption at 280nm, brown line represents conductivity and green line represents 
gradient of Imidazole concentration: a. Chromatography on HisTrap HP column; b. Gel 
filtration on HiLoad Superdex200 column. The gel filtration column step succeeded in 
removing contaminants left after the initial Ni-NTA purification.  &
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3.3.5 Sample preparation and crystallization of NDH2 
To prepare samples for crystallization, the protein from gel filtration was 
concentrated using a Viva spin column for 10 minutes at 4,500 xg. Subsequently 7ml 
of 10mM Tris buffer, pH8.0 was added to the 400 µl of protein solution and spun 
again for 20-30 minutes at 4500 xg, during this process NDH2 was partially 
precipitated, but the final sample contained ~10 mg/ml NDH2 in 10mM Tris-HCL 
buffer, pH 8.0. 
Crystallization was undertaken using a Hydra II Robot, and the sitting drop vapor 
diffusion method, with 96 well MRC sitting drop plates. Each reservoir contained 
400 µl of precipitating solution, and the drop was composed of 200 nl of well 
solution with 200nl of protein solution. Plates were spun at 2000 g prior to 
incubation at 17˚C. Crystallization trials with the JCSG, PACT, PEG and Classic 
screens (Qiagen Nextal®) were attempted, with both apo NDH2 and NDH2 plus 5 
mM FAD+ and NAD+. The plates were incubated at two temperatures 17˚C and 7˚C, 
respectively. However, no crystals were observed in any condition, even after 
repeating the experiment using the optisalts condition kit (QIAGEN®). The project 
was thus suspended.  
3.3.7 Discussion 
During the final stages of writing this thesis, the structure of NDH2 from 
Caldalkalibacillus thermarum was published [99]. This protein shares 23% and 31% 
sequence identity with NDH2 from M.smegmatis and M.tuberculosis, respectively. 
Also, similar enzyme type-II NADH dehydrogenase (NDi1) is found in the 
mitochondria of S.cerevisiae and has been structurally determined [100]. This protein 
shares 26%, 28% and 29% sequence identity with NDH2 from C.thermarum, 
M.tuberculosis and M.smegmatis. A structure based sequence alignment between the 
four structures revealed a similar secondary structure, but with a number of slight 
deletions between the yeast Ndi1 and bacterial NDH2 (Figure 3.7). However, the 
structure of C.thermarum NDH2 and S.cerevisiae Ndi1 align well with an (r.m.s.d of 
1.7Å) [99]. Furthermore, sequence alignment of all these four enzymes revealed that 
the binding sites of FAD+ and quinone are conserved in all of them. Superimposition 
the two structures of NDH2 and NDi1 also revealed that the FAD+ molecules are 
aligned well (Figure 3.9) [99, 100]. 
  
86&
M.tb         1  M---------------------------------------SPQQEPTAQPPRRHRVVIIGSGFGGLNAAK   31 
M.smegmatis  1  ------------------------------------------MSHPGATASDRHKVVIIGSGFGGLTAAK   28 
C.thermarum  1  --------------------------------------------------MSKPSIVILGAGYGGIVAAL   20 
S.cerevisiae 1  MLSKNLYSNKRLLTSTNTLVRFASTRSTGVENSGAGPTSFKTMKVIDPQHSDKPNVLILGSGWGAISFLK   70 
Consensus_ss:                                                          eeee   hhhhhhhh 
 
M.tb         32  KLKRA----DVDIKLIARTTHHLFQPLLYQVATGIISEGEIAPPTRVVLRKQ-RNVQVLLGNVTHIDLAG  96 
M.smegmatis  29  TLKRA----DVDVKLIARTTHHLFQPLLYQVATGIISEGEIAPATRVILRKQ-KNAQVLLGDVTHIDLEN  93 
C.thermarum  21  GLQKRLNYNEADITLVNKNDYHYITTELHQPAAGTMHHDQARVGIKELIDEK--KIKFVKDTVVAIDREQ  88 
S.cerevisiae 71  HIDTK----KYNVSIISPRSYFLFTPLLPSAPVGTVDEKSIIEPIVNFALKKKGNVTYYEAEATSINPDR 136 
Consensus_ss:    hhhh       eeeee           hhhhh     hhhhhh hhhhhhhh    eeeeeeeeeee    
 
M.tb          97 QCVVSELLGH-----------------TYQTPYDSLIVAAGAGQSYFGNDHFAEFAPGMKSIDDALELRG 149 
M.smegmatis   94 KTVDSVLLGH-----------------TYSTPYDSLIIAAGAGQSYFGNDHFAEFAPGMKSIDDALELRG 146 
C.thermarum   89 QKVTLQN---------------------GELHYDYLVVGLGSEPETFGIEGLREHAFSINSINSVRIIRQ 137 
S.cerevisiae 137 NTVTIKSLSAVSQLYQPENHLGLHQAEPAEIKYDYLISAVGAEPNTFGIPGVTDYGHFLKEIPNSLEIRR 206 
Consensus_ss:     eeeeee                     eeee  eeee                  eee  hhhhhhhhh 
 
M.tb         150 RILSAFEQAERSSD-PERRAKLLTFTVVGAGPTGVEMAGQIAELAEHTLKGAFRHIDSTKARVILLDAAP 218 
M.smegmatis  147 RILGAFEQAERSSD-PVRRAKLLTFTVVGAGPTGVEMAGQIAELADQTLRGSFRHIDPTEARVILLDAAP 215 
C.thermarum  138 HIEYQFAKFAAEP----ERTDYLTIVVGGAGFTGIEFVGELADRMPELCAEY—DVDPKLVRIINVEAAP  201 
S.cerevisiae 207 TFAANLEKANLLPKGDPERRRLLSIVVVGGGPTGVEAAGELQDYVHQDLRKFL-PALAEEVQIHLVEALP 275 
Consensus_ss:    hhhhhhhhhh       h     eeeee   hhhhhhhhhhhhhhhhhhhhh         eeeeee    
 
M.tb         219 AVLPPMGAKLGQRAAARLQKLGVEIQLGAMVTDVDRNGITVKDSD----GTVRRIESACKVWSAGVSASR 284 
M.smegmatis  216 AVLPPMGEKLGKKARARLEKMGVEVQLGAMVTDVDRNGITVKDSD----GTIRRIESACKVWSAGVSASP 281 
C.thermarum  202 TVLPGFDPALVNYAMDVLGGKGVEFKIGTPIKRCTPEGVVIEVDG-----EEEEIKAATVVWTGGVRGNS 266 
S.cerevisiae 276 IVLNMFEKKLSSYAQSHLENTSIKVHLRTAVAKVEEKQLLAKTKHEDGKITEETIPYGTLIWATGNKARP 345 
Consensus_ss:           hhhhhhhhhhhhh   eeee  eeeeee   eeeeee        eeee  eeee       h 
 
M.tb         285 LGRDLAEQSRVELDRAGRVQVLPDLSIPGYPNVFVVGDMAAVE------GVPGVAQGAIQGAKYVASTIK 348 
M.smegmatis  282 LGKDLAEQSGVELDRAGRVKVQPDLTLPGHPNVFVVGDMAAVE------GVPGVAQGAIQGGRYAAKIIK 345 
C.thermarum  267 IVEKSGFET-----MRGRIKVDPYLRAPGHENIFIVGDCALIINEENNRPYPPTAQIAIQHGENVAANLA 331 
S.cerevisiae 346 VITDLFKKIPEQNSSKRGLAVNDFLQVKGSNNIFAIGDNAFAG-------LPPTAQVAHQEAEYLAKNFD 408 
Consensus_ss:    hhhh hhh          eee           eeeeeeee            hhhhhhhhhhhhhhhhhh 
 
M.tb         349 AELAGANP----------------AEREPFQYFDKGSMATVSRFSAVAKIGP-----VEFSGFIAWLIW 396 
M.smegmatis  346 REVSGTSP----------------KIRTPFEYFDKGSMATVSRFSAVAKVGP-----VEFAGFFAWLCW 393 
C.thermarum  332 ALIRGG-------------------SMTPFKPHIRGTVASLGRNDAIGIVGG-----RKVYGHAASWLK 376 
S.cerevisiae 409 KMAQIPNFQKNLSRKDKIDLLFEENNFKPFKYNDLGALAYLGSERAIATIRSGKRTFYTGGGLMTFYLW 478 
Consensus_ss:   hhh                           eee    eeeeee   eeeee       eee  hhhhhhh 
 
M.tb         397 LVLHLAYLIGFKTKITTLLSWTVTFLSTRRGQLTITDQQAFARTRLEQLAELAAEAQGSAASAKVAS  463 
M.smegmatis  394 LVLHLVYLVGFKTKIVTLLSWGVTFLSTKRGQLTITEQQAYARTRIEELEEIAAAVQDTEKAAS---  457 
C.thermarum  377 KLIDMRYLYLIGGLSLVLKKGRF--------------------------------------------  399 
S.cerevisiae 479 RILYLSMILSARSRLKVFFDWIKLAFFKRDFFKGL--------------------------------  513 
Consensus_ss:      hhhhhhhhhhhhhhhhhhhhhhhhhh                                          
 
Figure 3.7 Protein sequence alignment based on secondary structures of bacterial 
NDH2 protein from C.thermarum, M.tuberculosis and M.smegmatis and the Ndi1 
protein from S.cerevisiae. The α-helices residues are highlighted as red colour and β-sheets 
residues are highlighted as blue colour. The conserved binding motifs of FAD, NAD and 
quinone are black boxed. The residues involved in binding FAD and located in the C-
terminal membrane attachment α-helix are black boxed. The c-terminal membrane attached 
structure is highlighted as cyan.   
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Furthermore, structural analysis of NDH2 enzyme from C.thermarum and 
Ndi1enzyme from yeast indicated that both enzymes are attached to the membrane 
by amphipathic helices that are rich with hydrophobic residues [99, 100], and by 
comparing their secondary structures with NDH2 from M.tuberculosis and 
M.smegmatis, a longer C-terminal domain is observed in Mycobacterial NDH2. 
Also, it was shown that the α-helix, which is involved in membrane anchoring of 
NDi1, is longer than its equivalent from NDH2 of C.thermarum. These membrane-
anchoring domains were also shown to be significant for the stability and activity of 
both enzymes [99, 100]. Therefore, Truncated NDH2 from C.thermarum refused to 
bind FAD as one of the coordinate moiety (K376) was lost [99, 100]. This residue is 
replaced by W478, which interacts with the FAD by an adjacent Y476. Also, the 
equivalent C-terminal helices of the NDH2 and NDi1structures are involved in 
binding quinone molecules [99, 100]. In Mycobacterial NDH2, the C-terminal 
domain is longer than both enzymes and contains one more helix. M.smegmatis 
NDH2 was truncated at residue V379 based on the hydropathy plot and Phyre 
prediction result to obtain a soluble enzyme. However, the truncation included all the 
equivalent α-helix that is significant for membrane anchor and FAD and quinone 
binding, and thus affected the stability of the enzyme and may prevent the 
crystallization of NDH2.   
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Figure 3.8 The 3D structures of NDH2 enzyme from C.thermarum (top,) and Ndi1 
enzyme from S.cerevisiae (bottom,). The NDH2 is in complex with FAD and Ndi1 is in 
complex with FAD and NAD. Both structures have been solved recently under (PDB code 
NDH2; 4NWZ and Ndi1; 4GAP [99, 100]. Figures were produced using Pymol [98]. 
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Figure 3.9 Structural superposition of NDH2 enzyme in complex with FAD+ and Ndi1 
in complex with FAD+ and NAD+. The two structures overlapped into RMSD of 1.73Å [99, 
100]. The C-terminal membrane attached α-helices are highlighted in NDH2 (green) and 
Ndi1 (grey). The α-helix residues that are involved in FAD binding are shown as sticks. 
 
 
 
 
 &
C-terminal 
domain  
C-terminal 
domain  
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3.4 Studies on the Msmeg_5007 protein  
3.4.1 Introduction 
Msmeg_5007 (LprB) is a ≈ 19 KDa, putative uncharacterized lipoprotein, with 178 
amino acids and 534 bp DNA size. It is only found in Mycobacterium species and no 
homolog has been detected in other organisms. The lprB gene has been shown to be 
essential for mycobacterium survival [75].  The hydropathy plot of LprB revealed 20 
hydrophobic residues at its N-terminal, which may be involved in anchoring the 
protein to the cell membrane (Figure 3.10.a). In addition, no transmembrane helices 
are predicted using the TMHMM server, which might suggest that these hydrophobic 
residues refer to a short signal sequence (Figure 3.11.b). Therefore, the full-length 
protein sequence and a truncated protein at Cys 15 were attempted to be expressed. 
a) 
 
b) 
 
Figure 3.10 Hydropathy (a) and transmembrane helix prediction (b) plots of LprB 
from M.smegmatis. a) The hydrophobicity plot was generated by using the Kyte-Doolittle 
hydropathy scale program [74], and indicates a stretch of hydrophobic residues in the N-
terminal protein sequence region (1-20 residue).b) TMHMM plot indicates no 
transmembrane helix at the same place in the sequence [32]. 
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3.4.2 Bioinformatics study on LprB 
A Blast search of LprB against proteins of known structure and function in the PDB 
revealed that LprB has no similarity with any other structures. However, a Blast 
search against the non-redundant proteins revealed that LprB is a conserved protein 
in most mycobacterium species including M.tuberculosis with a high sequence 
identity of 79% (Figure 3.11). Furthermore, the LprB protein shows between 40%-
48% sequence identity with a number of other proteins from different species 
including some RNA binding proteins (Table 3.4).  
 
M.tb         1  MRRKVRRLTLAVSALVALFPAVAGCSDSGDNKPGATIPSTPANAEGRHGPFFPQCGGVSDQTVTELTRVT  70 
M.smegmatis  1  ---------MAVLA-AAMVPVFAACSTDEPASPEVPQSESPSAGAPTHGPFFPQCGGISDQTVSELTQVP  60 
Consensus_aa:  .........hAV.A.hAhhPhhAtCSss.sspP.hsbspoPtst.spHGPFFPQCGGlSDQTVoELTpVs 
Consensus_ss:        hhhhhhhhhhhhhhhhhhh                                   hhhhhhhh 
 
M.tb         71 GLVNTAKNSVGCQWLAGGGILGPHFSFSWYRGSPIGRERKTEELSRASVEDINIDGHSGFIAIGNEP-SL  139 
M.smeg       61 GLVNTATNSSGCQWLQGGSILGPHFSFTWFRGSPIGRERKTEELSRASVEDINIEGHGGFIAVGEDPLKP  130 
Consensus_aa: GLVNTApNSsGCQWL.GGtILGPHFSFoW@RGSPIGRERKTEELSRASVEDINI-GHtGFIAlGp-P.p. 
Consensus_ss:     ee  ee  eeeeeee      eeeeeeeee   hhhhhhhhhhh    eeeee    eeeee 
 
M.tb         140  GD-SLCEVGIQFSDDFIEWSVSFSQKPFPLPCDIAKELTRQSIANSK  185  
M.smegmatis  131  GDVTLCEIGIQFDDDFIEWSVSYSQKPFPDPCEVAKELTRQSIVNSK  177 
Consensus_aa:       GD.oLCElGIQFsDDFIEWSVS@SQKPFP.PC-lAKELTRQSIhNSK 
Consensus_ss:            eeeeee    eeeeeee        hhhhhhhhhhhhhhh 
 
 
Figure 3.11 Protein sequence alignment based on secondary structures of LprB from 
M.tuberculosis and M.smegmatis. Both structures share 79% sequence identity. The 
predicted α-helices residues are highlighted as red color and β-strands residues are 
highlighted as blue color. Also, the consensus sequence (ss) are shown underneath the 
protein sequence.  &
&
Table 3.4 A Blast search against the non-redundant protein sequence. The highest 
identity is with the putative RNA binding domains from Gordonia species. 
 
Protein Organism Sequence identity % 
Hypothetical protein Nocardia sp. 348MFTsu5.1 45% 
 (77/170) 
RNA-binding S4 domain-
containing protein 
Gordonia bronchialis DSM 43247 46%  
(83/181) 
RNA-binding protein S4 Gordonia rhizosphera 44%  
(83/181) 
Putative RNA-binding protein Gordonia soli 48%  
(68/143) 
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Figure 3.12 A Blast search against the non-redundant protein sequence. The highest 
similarity is with putative RNA binding domains from Gordonia species. 
 
Additional Genetic analysis revealed that the lprB gene is located within an operon 
that contains pesticide degrading monooxygenase (Msmeg_5001), O-
methyltransferase (Msmeg_5003), DNA repair Exonuclease (Msmeg_5004), and 
phosphohistidine phosphatase (Msmeg_5006). Furthermore, the structure of LprB 
was predicted using the Phyre server. This suggested that LprB shares a similar 
structure of beta hairpin fold with RNA binding domain (mog1p) and   a protein 
involved in oxygen enhancement (PsbP), with 33.5 % prediction confidence and 
14% sequence identity. 
 
                           
 
93&
 
 
 
 
 
 
 
 
 
Figure 3.13 The predicted 3D structure of LprB. Phyre results revealed that LprB is 
predicted to share similar hairpin fold with RNA binding protein from corynebacterium 
diphtheriae (PDB code 2I8G) with 133 residues of LprB sequence were covered in the 
comparison (86.0 %) and low sequence identity of 14 % and 33.84 % prediction confidence.  
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3.4.3 Protein Purification of Msmeg_5007 (LprB) 
3.4.3.1 Ni-NTA chromatography  
As the expression level of soluble LprB (full length) was very low, the amount of 
cells was increased to produce more protein suitable for a crystallization experiment. 
Therefore, 10L of LB medium was used and cells were induced by 0.1mM IPTG at 
18 C˚ and for 10 hours to produce 3g of cell paste. Cells were then transferred into 1 
l Beckman centrifuge tubes in order to spin down all cells at 3,600 ×g for 20 minutes. 
Then, all LB media were discarded, except a little to be used for the resuspension of 
the cells. Cells were centrifuged again using table top centrifuge (Sigma 3-16K) at 
4,500 ×g for 20 minutes and were stored at -80°C. 
Cells of LprB were defrosted and resuspended in a buffer containing 50mM Tris-
HCl, pH 8.0, and 0.5M NaCl. Then, cells were disrupted on ice by sonication (3x-20 
seconds) at a volume of 16-micron amplitude. Cell debris was removed at 4°C by 
centrifugation at 70,000 xg for 10 minutes. The cell free extract were measured with 
a Bradford assay with a total protein concentration of 8.2 mg/ml. Then, the 
supernatant of LprB was applied onto a 5ml Ni-HP cartridge affinity column, which 
was equilibrated with the same buffer. LprB was eluted from the column by 50ml 
gradient Imidazole (0 - 0.5M) Tris-HCL buffer, pH 8.0, 3ml fractions were collected 
(7-11) and were pooled together, with a total protein concentration estimated at 12 
mg/ml by Bradford assay.  
3.4.3.2 Gel filtration purification 
The Volume of the LprB was reduced to 2ml using a Vivaspin concentrator with 
MWCO 30000 size and applied on a 16x60 Superdex200 gel filtration column (GE 
Healthcare), equilibrated with 50 mM Tris-HCl, pH 8.0, and 0.5M NaCl buffer. Gel 
filtration was performed at flow rate 1.5ml/min with the same buffer and 2ml 
fractions were collected. The fractions 22-24 with the highest peaks of protein 
concentration were combined and further concentrated using VivaSpin concentrator.  
To prepare sample for crystallisation, the buffer was exchanged in the sample with 
10mM tris-HCl pH8.0 using diafiltration cup with Viva Spin concentrator. Finally, 
the LprB protein was concentrated to 12mg/ml. The purification progress was 
analysed by 12% SDS-gel (Figure 3.14). 
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(a) 
 
(b) 
Figure 3.14 SDS gel showing protein purification steps of LprB (full length). The 
molecular weight of LprB is ~19 (kDa). a. An SDS gel showing the steps of Ni-NTA affinity 
column purification, which indicates LprB expressed in both fractions soluble and insoluble 
form (lanes 2 and 3, respectively), Lane 4; unbound materials, lanes 5-15 collected fractions. 
b. An SDS gel showing the gel filtration purification. Lane 1; Protein marker SM#811, 
lane2; fractions of Ni-NTA column, lanes 3-10; collected fractions. 
 
!""""#"""""$""""%"""&"""""'"""""("""")""""*"""!+""!!""!#""!$""!%"""!&""""
!""""""""#""""""""$"""""""%""""""""&""""""""'"""""""(""""""")"""""""""*"""""""!+""""""
  
96&
3.4.4 LprB protein crystallization 
LprB crystallizations were undertaken using the same protocol as described for 
NDH2 (Section 3.3.6). Several hits with flexible plate like morphology and micro 
crystals were identified with different conditions within the PEG screen A2 (0.1 M 
Sodium acetate pH 4.6, 30% PEG300), A4 (0.1 M Sodium Acetate pH4.6, 
25%PEG1000), and F5 (0.2 M Magnesium chloride, 0.1M Tris pH 8.5, 50% ethylene 
glycol) and the PACT screen A7 (0.2M Sodium chloride, 0.1M Sodium Acetate pH 
5.0, 20% PEG 6000) and the JCSG screen A9 (0.2 M Ammonium chloride + 20% 
PEG3350) (Figure 3.15). Hanging drop methods were used to optimize several 
crystal conditions by varying the pH between 4 and 7 and the PEG concentration 
from 10 to 40%, however, the same crystal morphology was obtained. These crystals 
failed to diffract in initial X-ray diffraction experiments.   
 
 
 JCSG–A9  
(0.2M Ammonium 
chloride+ 20% 
PEG3350). 
 
PACT-A7  
(0.2M Na chloride, 
0.1M Na acetate pH 
5, 20% PEG 6000). 
 
PEG- F5 (0.2M 
Magnesium chloride, 
0.1M Tris pH8.5, 
50% ethylene glycol) 
 
PEG-A2 
(0.1 M Sodium 
acetate pH 4.6, 30 
%(v/v) PEG 300). 
 &
Figure 3.15 Photographs of LprB native crystals. Crystals were grown over a three 
months period in different conditions and showed different morphology; however, no 
diffraction could be recorded from these crystals. Crystals were grown within three months. 
 &
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3.4.5 Identification of more crystal hits 
 More crystals were observed after one year and two years incubation time at 17C˚. 
Crystals were mounted in a loop within their mother solution and 25% ethylene 
glycol. Then, they were flash cooled and stored in liquid nitrogen to be sent to 
Diamond for X-ray diffraction testing (Figure 3.16). However, the X-ray diffraction 
tests revealed that all crystals were actually salt crystals and thus, this project also 
has been suspended. 
PACT-H1 
(0.2M Na fluoride, 
0.1M Bis Tris 
propane pH 8.5, 
20% PEG 3350). 
 
PEG-F8 
(0.2 M Magnesium 
formate, 20 %(w/v) 
PEG 3350). 
 
PEG-A4 
(0.1 M Sodium 
acetate pH 4.6, 25 
%(v/v) PEG 550 
MME). 
 
PEG-A2 
(0.1 M Sodium 
acetate pH 4.6, 30 
%(v/v) PEG 300). 
 
 
Classic-E11 
(0.1 M HEPES 
sodium salt pH 7.5, 
1.5 M Lithium 
sulfate). 
 
MPD-F6 
(0.1 M BICINE pH 
9.0, 40 %(v/v) 
MPD). 
 
 
 
MPD-E9 
(0.1 M MES pH 
6.0, 20 %(v/v) 
MPD). 
 
 
 
MPD -E6 
(0.1 M BICINE pH 
9.0, 10 %(v/v) 
MPD). 
 
 
 
 
MPD-F6 
(0.1 M BICINE pH 
9.0, 40 %(v/v) 
MPD). 
 
 
 
MPD-G4 
(0.1 M Imidazole. 
HCl pH 8.0, 15 
%(w/v) MPD, 5 
%(w/v) PEG 4000). 
 
 
PEG-A2 
(0.1 M Sodium 
acetate pH 4.6, 30 
%(v/v) PEG 300). 
 
 
PEG-A2 
(0.1 M Sodium 
acetate pH 4.6, 30 
%(v/v) PEG 300). 
 
 
JCSG-E8 
(1 M di-
Ammonium 
phosphate, 0.1 M 
Na acetate pH 4.5). 
 
  
 
Figure 3.16 Photographs of LprB native crystals. Crystals were grown within different 
conditions and with different crystal forms. 
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3.5 Studies on the Msmeg_6050 protein  
3.5.1 introduction  
Msmeg_6050 is ≈ 32.0 (kDa), 300 amino acids and 903bp DNA size putative solute 
binding lipoprotein that belongs to the ABC transport system, Msmeg_6050 has been 
annotated as non-essential gene of mycobacterium [75]. Msmeg_6050 was assigned 
as a potential target due to the presence of highly hydrophobic N-terminal 20 
residues, (Figure 3.14). The analysis of these hydrophobic residues using the 
TMHMM sever revealed no potential transmembrane helix and thus, these residues 
are highly likely to form an N-terminal signal sequence [32, 101]. Analysis using the 
signal peptides prediction SignalP server, showed that the first 20 residues were 
probably a signal sequence, and that the signal would be cleaved after residue A20 
[102]. However, analysis of the sequence of Msmeg_6050 using the DOLOP server, 
which predicts lipid-anchored proteins, suggested that Cys 18 would be the site of 
lipid attachment and that the signal would be cleaved between Ala17 and Cys18 [1, 
38]. In addition, DOLOP clearly showed the presence of the n-region, h-region and 
C-region of the lipoprotein sequence (Figure 3.17).  
In the light of these analyses, it was decided to produce a construct that started at 
Ala20 to the C-terminus in an attempt to obtain a soluble protein for crystallization.  
However, this was not the case for this construct as a truncated protein was produced 
with the protein sequence starts from the amino acid Thr 33. 
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 nFregion&&&&&&hFregion&&&cFregion&&&&&&
     
        10         20         30         40         50         60 
MTRRCIAACL AILLLAACGA PDGSDGRRQI VVTTTILGDV VSEVVGDTAD VRVMMKPNAD  
 
        70         80         90        100        110        120  
PHSYGLSAAD AAEMARADLV IYNGLGLEES MQRHVDAAAE NGVRTLPVGD HVDPLQFSAD  
 
       130        140        150        160        170        180  
EHGAADPHFW TDPQRMILAV DAITGRVAEL PGIDRAAVAA NAARYRDELN NLSAHMTDRF  
 
       190        200        210        220        230        240  
AAIPAQRRKL VTNHHVLGYL ADRFGFTVIG AVIPSGTTLA SPSASDLESL AGAIRDAGVK  
 
       250        260        270        280        290        300  
AIFVDSSQPD RLARVLAEQS GVRVNVVSLY SESLSAPGTE ADSYLGMMRT NTETIANNLI 
Figure 3.17 Hydropathy plot of Msmeg_6050 and protein sequence. The hydrophobicity 
plot was generated using Kyte-Doolittle hydropathy scale program [74], and indicated a high 
value of hydrophobic residues within the first 20 residues. Protein sequence shows the signal 
peptides (underlined) within the first 20 residues. The lipoprotein features are highlighted 
and boxed based on DOLOP server. Red colour residues indicated the start of truncated 
construct and predicted cleavage site. 
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     (a)  
 
(b) 
Figure 3.18 Transmembrane (a) and signal peptides (b) prediction plots of 
Msmeg_6050. A. The transmembrane plot was generated using the TMHMM server [32], 
which indicated no significant sign for the presence of transmembrane helix within the first 
20 residues of the N-terminal protein sequence. b) The prediction of signal peptides and 
cleavage site of truncated protein using SignalP server [102]. 
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3.5.2 Bioinformatics study on Msmeg_6050 
Msmeg_6050 is annotated in the M.smegmatis genome as a putative solute binding 
lipoprotein that belongs to ABC transporter family. Blast search of Msmeg_6050 
against proteins of known structure and function in PDB revealed several hits of 
metal binding protein and transporter structures with sequence identity of 21-37%, 
including the crystal structure of the sulfur oxidation protein (SOXB) from 
T.thermophilus (PDB code 2WDD), and the zinc binding protein from Treponema 
pallidum (PDB code 1TOA) these have protein sequence identity of 37% and 32%, 
respectively (Figure 3.19).  
 
 
Ms_6050          1  MTRRCIAACLAILLLAA---CGA---PDGSDGRRQIVVTTTILGDVVSEVVGDTADVRVMMKPNADPHS-   63 
TroA             1  MIRERICACVLALGMLTGFTHAFGSKDAAADGKPLVVTTIGMIADAVKNIAQGDVHLKGLMGPGVDPHL-   69 
SoxB             1  MNRRELLQLLSALAVLGPRGWAR---ALEDPRS------------LYD--LPPYGDATLLYFS--DLHGQ   51 
Consensus_ss:        hhhhhhhhhhhhhhhhhhhh             eeeee hhhhhhhhhh    eeeeeee          
 
Ms_6050         64  -----YG-----------------LSAADAAEMARA-----DLVIYNGLGLEESMQRHVDAAAENGVRTL  106 
TroA            70  -----YT-----------------ATAGDVEWLGNA-----DLILYNGLHLETKMGEVFSKLRGSRLVVA  112 
SoxB            52  AFPHYFMEPPNLIAPKPLMGRPGYLTGEAILRYYGVERGTPLAYLLSYVDFVELARTFGPI---------  112 
Consensus_ss:                                 hhhhhhhh        eeeee   hhhhhhhhhhh       ee 
 
Ms_6050        107  PVGDHVDPLQFSADEHGAADPHFWTDPQRMILAVDAITGRVAELPGI------------DRAAVAANAAR  164 
TroA           113  VS-ETIPVSQRLSLEEAEFDPHVWFDVKLWSYSVKAVYESLCKLLPG------------KTREFTQRYQA  169 
SoxB           113  ------------------------GGMGALTALIRDQKARVEAEGGKALVLDGGDTWTNSGLSLLTRGEA  158 
Consensus_ss:       e                     eee hhhhhhhhhhhhhhhhhh                hhhhhhhhhh 
 
Ms_6050        165  YRDELNNL---------------------SAHMTDRFAAIPA------------------QRRKLVTNHH  195 
TroA           170  YQQQLDKL---------------------DAYVRRKAQSLPA------------------ERRVLVTAHD  200 
SoxB           159  VVRWQNLVGVDHMVSHWEWTLGRERVEELLGLFRGEFLSYNIVDDLFGDPLFPAYRIHRVGPYALAVVGA  228 
Consensus_ss:       hhhhhhhh                     hhhhhhhhh                         eeeee   
 
Ms_6050        196  VLGYLADRFGFTVIGAVIPSGTTLASPSASDLESLAGAIRDAGVKAIFVDSSQPDRLARVLAEQSGVR--  263 
TroA           201  AFGYFSRAYGFEVKGL--QGVSTASEASAHDMQELAAFIAQRKLPAIFIESSIPHKNVEALRDAVQAR--  266 
SoxB           229  SYPYVKVSHPESFTEG----LSF--ALDERRLQEAVDKARAEGANAVVLLSHNGMQLDAALAERIRGIDL  292 
Consensus_ss:       hhhhhhhh                    hhhhhhhhhhhhh    eeee     hhhhhhhhhhh      
 
Ms_6050        264  ------------------------------VNVVSL-------------YSESLSAPGTEADSYLGMMRT  290 
TroA           267  ------------------------------GHVVQI--GGEL-------FSDAMGDAGTSEGTYVGMVTH  297 
SoxB           293  ILSGHTHDLTPRPWRVGKTWIVAGSAAGKALMRVDLKLWKGGIANLRVRVLPVLAEHLPKAEDVEAFLKA  362 
Consensus_ss:                                     eeeee                            hhhhhhh 
 
Ms_6050        291  NTET-----------------------------IANNLI-------------------------------  300 
TroA           298  NIDT-----------------------------IVAALAR------------------------------  308 
SoxB           363  QLAPHQDHLFTPLAVSETLLYKRDTLYSTWDQLVGEAVKAIYPEVEVVFSPAVRWGTTILPGQAITWDHL  432 
Consensus_ss:       hhhh                             hhhhh                                 
 
 
Figure 3.19 Protein sequence alignment based on secondary structures of Msmeg_6050 
from M.smegmatis and other metal binding proteins, such as SoxB from T.thermophilus 
and TroA from Treponema pallidum. Msmeg_6050 shares 37% and 32% sequence 
identity, with SoxB and TroA, respectively. The α-helices residues are highlighted as red 
color and β-sheets residues are highlighted as blue color. The consensus secondary structure 
(ss) is shown underneath the aligned sequences. 
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In addition, Msmeg_6050 shares considerable sequence identity with the surface 
antigen (PSAA) from S.pneumoniae (PDB code 2ZK7) and the DNA repair protein 
from Bacillus caldotenax (UvrB) (PDB code 1D9X) with 27% sequence identity 
(Figure 3.20). 
 
 
Figure 3.20 A Blast search against the PDB protein structures. Additional sequence 
similarity (27%) is detected with a surface antigen protein structure from S.pneumoniae 
(PDB code 2ZK7). 
 
Furthermore, a Blast search against the non-redundant protein database revealed that 
Msmeg-6050 has homology with several ABC metal transporters from 
mycobacterium species and other organisms, such as Streptomyces species and 
Amycolatopsis azurea with high sequence identity of between 54-59%, respectively 
(Figure 3.21). 
The structure of Msmeg_6050 protein was predicted using the Phyre server. This 
suggested that Msmeg_6050 shares a similar structure fold with various metal 
binding proteins, such as the zinc binding protein from Treponema pallidum (PDB 
code 1TOA) with 100% prediction confidence and 27% sequence identity [89, 103] 
(Figure 3.22). 
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Figure 3.21 A Blast search of Msmeg_6050 against the non-redundant protein 
database. The highest similarity is with the putative zinc binding proteins from several 
organisms, such as Streptomyces species and Amycolatopsis azurea with sequence identity of 
between 54 and 59 %, respectively. 
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Figure 3.22 The predicted 3D structure fold of Msmeg_6050. Phyre results revealed that 
Msmeg_6050 is predicted to share similar fold with metal receptor from Treponema 
pallidum (PDB code 1TOA) with 271 residues of Msmeg_6050 sequence were covered in 
the comparison (90%) and low sequence identity of 27% and 100% prediction confidence 
[89]. Zinc is shown as a gray sphere in the center. Figure was made by using Pymol[98]. 
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3.5.3 Purification of Msmeg_6050 
The truncated Msmeg_6050 construct (20-300 a.a) has been purified using two steps 
of Ni-NTA affinity column and gel filtration. The same protocols were followed as 
given in section 3.2.2. 0.5 ml of protein at a final concentration of 10.5 mg/ml was 
produced using 1g of cell paste and prepared for crystallization experiment. SDS 
PAGE was used to evaluate the purification progress. 
 
Figure 3.23 SDS gel showing protein purification steps of truncated Msmeg_6050. The 
molecular weight of Msmeg_6050 is ~32 (kDa). Gel-representing Ni-NTA affinity column 
purification, indicating Msmeg_6050 expressed in both soluble and insoluble fractions. The 
gel filtration purification step indicated high-purified protein fraction was obtained. 
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Figure 3.24 Chromatograms obtained during the purification of Msmeg_6050. Blue line 
represents absorption at 280nm, brown line represents conductivity and green line represents 
gradient of Imidazole concentration: a. Chromatography on HisTrap HP column; b. Gel 
filtration on HiLoad Superdex200 column. The gel filtration column step succeeded in 
removing low molecular weight contaminants left after the initial Ni-NTA purification.  &&&&&&&&&
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3.5.4 Crystallization of Msmeg_6050 
The truncated Msmeg_6050 (20-300 amino acids) was put into crystallization 
screens following the same protocols as given in section 3.3.3. Crystals were 
observed after one year incubation in two different crystallization condition of JCSG 
screen (Figure 3.25). However, X-ray diffraction test experiments showed that they 
were salt crystals. Thus, this project was suspended.  
 
 
Figure 3.25 Photographs of Msmeg_6050 crystals that were observed after one-year 
incubation. However, X-ray diffraction test revealed that these are salt crystals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
JCSG-A  
(0.2 M Lithium sulfate, 
0.1 M Na acetate pH 
4.5, 50% PEG 400). 
 
 
 
JCSG-A6  
(0.2 M Lithium sulfate, 
0.1 M Phosphate-citrate 
pH 4.2, 20% PEG 
1000). 
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3.6 Studies on the Msmeg_5456 protein 
3.6.1 Introduction  
Msmeg_5456 (LpqN) is ≈ 24.7 (kDa), putative uncharacterized lipoprotein, with 238 
amino acids and 717bp DNA length. LpqN has been annotated as a non-essential 
gene of M.tuberculosis [75]. LpqN was assigned as a potential target due to the 
presence of highly hydrophobic N-terminal 35 residues, (Figure 3.26). These 
hydrophobic residues were analyzed using the TMHMM sever and revealed no 
potential transmembrane helices and thus, these residues are highly likely to form an 
N-terminal signal sequence [32, 101]. Analysis using the signal peptide prediction 
server SignalP showed that the first 32 residues were probably a signal sequence, and 
that the signal would be cleaved after residue Q32 [102].  
However, analysis of the sequence of LpqN using the DOLOP server, revealed that 
LpqN does not meet the same criteria of a lipoprotein and thus a truncated LpqN was 
made based on the predicted cleavage site by the SignalP server [1, 38]. This 
construct (A33-P238) was made in an attempt to obtain a soluble protein for 
crystallization. 
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a)  
 
b) 
 
Figure 3.26 Hydropathy (a) and signal peptides (b) prediction plots of Msmeg_5456 
(LpqN). a. The hydrophobicity plot was generated using the Kyte-Doolittle hydropathy 
scale program (Kyte and Doolittle 1982[74], which indicated hydrophobic residues within 
the first 32 residues of the N-terminal protein sequence. b) The prediction of signal peptides 
and the cleavage site required for the truncated protein [102] 
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3.6.2 Bioinformatics study on LpqN 
A Blast search of LpqN against proteins of known structure and function in the PDB 
revealed only five hits to different crystal structures with sequence identity between 
38 and 43%. The crystal structure of the putative regulator from E.coli CFT073 
(PDB code 3HFI), and crystal structures of the interferon inhibitory domain and 
RNA domain from Reston Ebola virus (VP35) (PDB code 3L2A and 3KS4 
respectively) share the highest identity of protein sequence of 43%, 39% and 39% 
respectively. In addition, LpqN shares a lower sequence identity with other RNA 
binding domains from human Homo sapiens (PdB code 4KRE) and the membrane 
rotor of the V-type ATPase from Enterococcus hirae (PdB code 2BL2) with 31% 
and 28% sequence identity, respectively. However, only a small part of the LpqN 
sequence (< 80/238) was covered in the alignments. 
Furthermore, a Blast search against the non-redundant proteins revealed that LpqN is 
closely related to proteins among several mycobacterium species with sequence 
identity between 40-67%. These proteins include Mk35 antigen protein of 
Mycobacterium vulneris (67% sequence identity for 161 residues), the conserved 
LpqN protein from M.tuberculosis (48% sequence identity, 109 residues) and serine- 
threonine protein kinase of M.smegmatis  (47% sequence identity, for residues 
107/238) (Figure 3.27). 
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Figure 3.27 A Blast search of LpqN against the non-redundant protein database. The 
highest sequence similarity is with putative Mk35 antigen lipoprotein from M.vulneris, and 
serine / threonine protein kinase from M.smegmatis with sequence identity of 67 and 47 %, 
respectively. 
 
The structure of LpqN protein was predicted using the Phyre server. The result 
suggested that LpqN shares a similar structure fold with the uncharacterized protein 
from Jonesia denitrificans (PDB code 3LDY) and with the PA94 putative regulator 
from Pseudomonas aeruginosa (PDB code 3LDY) with 100% prediction confidence 
and 26% sequence identity, respectively (Figure 3.28) [89] [104]. 
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Figure 3.28 The predicted 3D structure fold of Msmeg_5456 (LpqN). Phyre results 
revealed that LpqN is predicted to share similar fold with uncharacterized protein from 
Jonesia denitrificans (PDB code 3LDY) (not published) with 153 residues of LpqN 
sequence were covered in the comparison (66%) and low sequence identity of 21% and 
100% prediction confidence [89]. Figure was made using Pymol. 
 
 
 
 
 
 
 
 
                           
 
113&
3.6.3 Protein purification of LpqN 
 The truncated LpqN (residues Q33-P238) was purified using a one step of Ni-NTA 
affinity column. The same protocol has been followed as described in section 3.2.2. 
LpqN protein of high concentration fractions were combined and transfer into 10 
mM Tris-HCL buffer pH 0.8, and concentrated to 26 mg/ml for crystallization 
experiment. SDS PAGE was used to evaluate the purification progress (Figure 3.29). 
 
 
 
Figure 3.29 Chromatogram analysis of LpqN purification. a. SDS gel showing protein 
purification of truncated LpqN, the gel was run 4 days after the purification, an additional 
band with lower molecular weight appear, which might suggested some degradation has 
occurred. b. Chromatography on HisTrap HP column. Blue line represents absorption at 
280nm, brown line represents conductivity and green line represents gradient of Imidazole 
concentration. 
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3.6.4 Crystallization of LpqN 
For crystallization the truncated construct of LpqN (26 mg/ml protein in 10 mM 
Tris-HcL, pH 8.0) was put into crystllization screens following the same protocols as 
given in section 3.3.3. A single crystal was observed after one year incubation in one 
crystallization condition of PEG screen (Figure 3.30). However, X-ray diffraction 
test experiment showed that they were salt crystals. Thus, this project was 
suspended.  
 
Crystal  Condition PEG-G10 
 
 
 (0.2 M Potassium sulfate, 
20 %(w/v) PEG 3350). 
 
 
 
Figure 3.30 A photograph of LpqN crystal that was observed after one-year incubation. 
However, X-ray diffraction test revealed that this is a salt crystal. &&&&&&&&
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Chapter 4 
 
AgaE structure determination 
This chapter explains the materials, procedures and results of the cloning, over-
expression, purification and crystallization of the Putative sugar binding protein 
Msmeg_0515 (AgaE). &&&&&&&&&&&&&&&
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4.1 Bioinformatics studies on Msmeg_0515 protein  
4.1.1 Target selection 
Msmeg_0515 protein is one of the eight selected targets for structural studies. The 
original criteria for target selection was based on hydropathy plots of the entire gene 
produced in M.smegmatis. Msmeg_0515 was assigned as a potential target due to the 
presence of highly hydrophobic N-terminal 30 residues (Figure 4.1). This suggested 
that the N-terminal residues might be a trans-membrane helix or perhaps a signal 
sequence. Analysis using the TMHMM server indicated (not surprisingly) that the 30 
N-terminal residues had a high potential of being a trans membrane helix (Figure 
4.2a) [32, 101]. Analysis using the signal peptides prediction SignalP server [102] 
showed that the first 27 amino acid residues were probably a signal sequence, and 
that the signal would be cleaved after S27 (Figure 4.2b). Analysis of the sequence of 
Msmeg_0515 using the DOLOP server, which predicts lipid-anchored proteins, 
suggested that cysteine 21 would be site of lipid attachment and that the signal would 
be cleaved between Ala 20 and Cys 21 [1, 38]. In addition, DOLOP clearly showed 
the presence of the n-region, h-region and C-region of the lipoprotein features 
(Figure 4.1).  
In the light of these analyses, it was decided to produce a construct that started from 
Ser 28 to the C-terminus in an attempt to obtain a soluble protein for crystallization. &&&&&&&&
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(a) 
 n-region      h-region    c-region     cleavage site 
      
     
        10        20       30         40         50         60  
MIRRWLCLAVVTAVACLLTACGGGSSSSGP VEIAVWHGYQ DTEGEAFKGL IDQYNKEHPD  
 
        70         80         90        100        110        120  
VHVTDLYSSN DLVLQKVLTA VRGGSAPDVA YMFGSWSPNI AKIPQVVDMS DVVSQSDWNW  
 
       130        140        150        160        170        180  
DDFYPAEREA ATVGDKIVGI PALVDNLAIV YNKKLFADAG IAPPTADWTW DDFRAAAAKL  
 
       190        200        210        220        230        240  
TDPAKGQYGW LIPADGSEDT VWHYVPMLWE AGGDILTPDN EKAAFNSEAG VTALTMLQDM  
 
       250        260        270        280        290        300  
AVTDKSLYLD TTNENGPKLM NSGKVGMLIT GPWDLSQLSD IDYGVQVMPT FAGSSGAHQT  
 
       310        320        330        340        350        360  
ISGPDNWVVF DNGDKRKQAS IDFVKWLTAP EQVKAFSLQT GDLPTRSSVG DDQAVRDQLD  
 
       370        380        390        400        410        420  
QKLPGSSVFV ENLNNAKKAR PAVEQYPAIS EALGQAIVAV MLGKEQPAAA LNSAAEAADS  
 
    425 
ALAGK                          (b) &
Figure 4.1 Hydropathy plot of Msmeg_0515 and protein sequence. a) The 
hydrophobicity plot was generated by using Kyte-Doolittle hydropathy scale program and 
indicated high value of hydrophobic residues within the first 30 residues. b) The protein 
sequence shows the signal peptide (underlined) within the first 20 residues. The lipoprotein 
features are highlighted and boxed based on DOLOP server. Red colour residues indicate the 
predicted transmembrane helix and the cleavage site is assigned by a red coloured arrow. 
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Figure 4.2 Predicted signal peptide and transmembrane helix within the first 30 amino 
acids of Msmeg_0515 (AgaE) protein sequence. a) A trans-membrane helix is predicted 
using TMHMM server, described by red lines at the N-terminal of the other protein sequence 
with pink lines showing the soluble part of protein. b) Prediction of signal peptides located 
within the first 27 residues of the sequence. The truncation of Msmeg_0515 (AgaE) was 
made based on this result. &&&&&&&
!"#$%$$&'()*+,-(,&',(./.-0-1+)&2(,&$3)4+536787&)+9:+;<+&
Truncation site 
!"#$%&'()#*+*,-+.#*/+-%0,1'#21/#34.5+&46787#.+9:+'0+#
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4.1.2 Further analysis of Msmeg_0515 
The primary sequence of Msmeg_0515 was compared against all non-redundant 
proteins in the NCBI database. The results revealed that Msmeg_0515 shares 
sequence homology to a putative extracellular solute binding protein of different 
Gram-positive bacteria species that belong to Actinobacteria genus, such as Frankia 
sp, Conexibacter woesei, Catenulispora acidiphila, Salinibacterium sp, with high 
sequence identity of 52%, 46%, 46% and 41%, respectively (Figure 4.3). Moreover, 
the Msmeg_0515 protein sequence showed homology with several putative sugar 
binding proteins and ABC type sugar dependent ABC transporters of the Gram 
positive Streptomyces sp and the gram variable –staining Gardnerella vaginalis, with 
sequence identity 41% and 29%, respectively.  
Furthermore, in order to investigate the possible function and structure of 
Msmeg_0515, the primary sequence was also applied against all proteins with 
structures known in the protein data bank (PDB), which in turn, may lead to a 
predicted function or substrate specificity [105]. The results indicated several hits of 
numerous crystal structures that have similar structure but low sequence identity of 
between 31-21 % (Table 4.1). The most significant homology structure was with the 
crystal structure of ABC maltooligosaccharide / Acarbose binding protein (GacH) 
from S.glaucescens with 27% sequence identity (PDB code. 3K01). Additionally, the 
result of the Blast searches also indicated other crystal structures that are predicted to 
have a similar structure with Msmeg_0515, which are bound to different sugars, such 
as maltodextrin, acarbose, and D-glucose.  
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Figure 4.3 Sequence alignments of Msmeg_0515 against all non-redundant proteins in 
the NCBI database. The results suggested that Msmeg_0515 is a sugar binding protein. &&&&&&&&&
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Protein Organism Ligand Sequence 
identity % 
PDB 
code 
GacH Receptor S.glaucescens Malto-
oligosaccharide-
Acarbose 
27% 
(105/396) 
3k01 
Maltose binding 
protein (PfMBP) 
P.furiosus Maltotriose 22% (74/333) 1ELJ 
XOS BINDING 
PROTEIN 
Bifidobacterium 
animalis subsp. lactis 
Bl-04 
Xylotetraose 26% 
(110/428) 
3ZKK 
UgpB binding 
protein  
E.coli Sn-glycerol-3-
phosphate 
24%(98/412) 4AQ4 
Maltose binding 
protein 
(TvuCMBP) 
Thermoactinomyces 
vulgaris 
Gamma-
Cyclodextrin 
26%(79/299) 2ZYK 
TMBP T.litoralis Trehalose 24% (97/402) 1EU8 
Maltose binding 
protein (MalE) 
Alicyclobacillus 
acidocaldarius 
MALTOSE 27%(105/36) 1URG 
Maltose binding 
protein (MalE) 
The Phytopathogen 
X.citri 
Unknown 22% (88/399) 3UOR 
Extracellular 
Solute-binding 
Protein 
S.aureus PEG 23%(92/407) 4HS7 
&
Table 4.1 Results from Blast search of Msmeg_0515 against all PDB structures. The 
first 10 hits revealed that Msmeg_0515 might well share similar structure with other 
carbohydrate binding proteins from different organisms. 
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4.1.3 ABC transport system 
As the sequence alignment suggested that Msmeg_0515 might possibly be part of an 
ABC transport system, a brief overview of these proteins is given below: 
The ATP binding cassette is a very large super- family of proteins that are expressed 
in all Kingdoms of life, including bacterial and eukaryotic species [106]. They 
function as transporters of different macromolecules, such as carbohydrates, amino 
acids, ions and antibiotics. They are divided into two subfamilies based on their 
function, substrate direction and translocation as importers and exporters [107]. In 
the E. coli and Bacillus subtilis genomes, ~5% of the expressed gene encode ABC 
transporters [108, 109] whereas, in M. tuberculosis, 2.5% of its genome encodes 
putative ABC transporters, only one of which has been recently characterized 
structurally and biochemically [110, 111].  Most ABC transporters in bacteria are 
importers and they function to uptake essential molecules into cells, such as the 
maltose permease of E coli. In contrast, ABC transporters in eukaryotic systems only 
function as exporters of essential nutrients [107, 112]. In addition, ABC exporters 
have been found in all organisms, whereas, importers are only present in prokaryotes 
[113].   
 
4.1.4 Structure of ABC transporters 
In general, the structure of the ABC transporters system is composed of four domains 
joined together (figure 4.4); the first two domains are called the membrane spanning 
domain (MSDs) and they function as a translocation pathway. The second two 
domains are called nucleotide binding domains (NBDs) or ATP hydrolyzing domains 
and they function as energy providers to transport specific substrates through ATP 
binding and hydrolysis. An additional domain is found in the bacterial ABC 
transporter called the periplasmic binding domain (PBD) or the substrate binding 
domain (SBD). This domain is the most studied and divergent one among the ABC 
transporters in bacteria. It is found in the periplasm of Gram negative bacteria as a 
soluble protein, and as a cell membrane lipid-anchored protein in Gram positive 
bacteria and Mycobacterium [114, 115].  
In bacteria, the domains of MSDs and NBDs are either organized as two domains 
encoded within the same gene of a specific DNA cluster or as individual domains 
within two separate genes of the same DNA cluster. However, in eukaryotes both 
MSDs and NBDs are encoded in one gene as multi-domains [110, 116, 117]. 
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Furthermore, the membrane-spanning domain MSDs is less well conserved than the 
nucleotide-binding domain NBDs among the ABC transporters in eukaryotes [116, 
117]. 
 
  
Figure 4.4 A schematic diagram of ABC transporter structure and the transport 
process. The first step of transportation of a specific substrate is the binding of the substrate 
into its extracellular receptor (yellow). Then, the receptor binds to its second component of 
membrane spanning domains (green) to be passed through the cell membrane. The third 
component of ABC transporters is the Nucleotide binding domains (cyan) or ATPase, which 
receives the substrate and transports it into the cell cytoplasm by ATP hydrolysis ATPs 
hydrolyse action; it also contributes to the dissociation of the extracellular receptor with 
unliganded form. The figure was adapted from [118, 119]. 
 
In E.coli and B.subtilis, the ABC transporters have been divided based on the type of 
their substrates into 10 and 12 subgroups, respectively; however, in Mycobacterium, 
only nine subgroups are found [108-110]. Five families of mycobacterium ABC 
transporters are involved in the import of the wide range of nutrients, such as 
peptides, amino acids, sugars, iron and anions, whereas the other four families are 
thought to be responsible for the export of antibiotics, drugs and other unknown 
substrates [110].  
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4.1.5 The Substrate binding domain (SBD) 
The substrate binding protein is a significant domain of the ABC transporter system 
that imports and exports essential nutrients through the permeable barrier of the cell 
membrane [120, 121]. The binding proteins exist in both the Gram negative and 
Gram-positive bacteria; however, they are diverse in their location in both 
organisms. They have been found in the periplasmic space of Gram-negative bacteria 
and anchored to the inner cell membrane of Gram positive bacteria as a lipoprotein 
[115]. These types of lipoprotein are attached to the membrane by the conserved 
cysteine that is found in the N-terminal of the protein as part of the signal peptide 
that directs and translocates the protein. A lipid is covalently attached to the cysteine 
and this lipid embeds itself in the membrane [122]. It has been suggested that each 
binding protein has its own affinity that is specific to the particular substrate or to 
several substrates of the same class [123]. 
 
4.1.6 Carbohydrate binding protein dependent ABC transporters 
The ABC Carbohydrate transporters are divided into two subfamilies: CUT 1 and 
CUT2, based on their substrate specificity [124]. The CUT 1 family is responsible 
for the transportation of di and oligosaccharides and many other nutrients, such as 
polyols, whereas, the CUT 2 family is responsible for the transport of 
monosaccharide only [124, 125]. 
M.smegmatis possesses 28 putative systems of carbohydrate transporters that belong 
to five different families, such as the ABC family (figure 4.5), the 
phosphotransferase system (PTS), the major intrinsic protein family (MIP), the major 
facilitator superfamily (MFS), and the sodium solute superfamily (SSS) [3, 126-129]. 
Nineteen of these systems belong to the ABC family. All ABC carbohydrate protein 
components are encoded within the same operon including the substrate binding 
protein [110, 126]. The genomic DNA of M.smegmatis possesses 18 genes that 
encode sugar-binding proteins belonging to the ABC permease family, based on 
sequence homology with other ABC transporters from different organisms, such as 
E.coli and Streptomyces species [3]. The substrate specificity for several binding 
proteins encoded in the M.smegmatis genome have been determined on the basis of 
the sequence and genetic similarity with other carbohydrate binding proteins. These 
ABC permease proteins are predicted to be responsible for the transport of sugars, 
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such as α-glucosides, sugar alcohol, xylose, β-galactosides and arabinose in 
M.smegmatis [3]. 
 
Figure 4.5&Carbohydrate binding proteins encoded by different transport systems with 
their putative predicted substrates in both (a) M.smegmatis and (b) M.tuberculosis. 
M.smegmatis possesses 28 putative systems involved in carbohydrate transport, 19 of which 
are ABC transporter (dark red). M.tuberculosis has only four ABC carbohydrate transporters. 
Figures were adopted from [3]. 
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4.1.7 Genetic analysis of Msmeg_0515  
Msmeg_0515 is one of the predicted ABC permease proteins located in cluster two 
of the sugar transporters of the M.smegmatis genome; it is called agaE [3]. The 
operon that contains the Msmeg_0515 (agaE) gene was predicted to be a α-
galactosides uptake operon, located downstream of the first cluster that is responsible 
for β-glucoside uptake genes [3]. The operon contains several genes agaR, Z, S, X, P, 
A, E, F, G, K and B (Figure 4.6). The first six genes of the operon that are located 
upstream of Msmeg_0515 (agaE) gene are predicted to have several functions as 
follows: Msmeg_0509 or agaR is predicted to function as a transcriptional regulator 
for the whole operon [3]. The second gene in the operon known as Msmeg_0510 or 
agaZ was predicted to be a D-tagatose –bisphosphate aldolase binding protein that is 
followed by Msmeg_0511 or agaS gene that encodes isomerase enzyme [3]. Both 
Msmeg_0512 that is predicted to belong to the ATPase family and Msmeg_0513 that 
is also, predicted to be integral to the membrane protein are of unknown function. 
The sixth gene in the operon is called Msmeg_0514 or agaA; it encodes an enzyme 
that functions as hydrolyzing enzyme for α-galactoside sugars [3, 130]. Downstream 
of the Msmeg_0515 (agaE) gene are further genes that belong to the components of 
the ABC transporter family, such as Msmeg_0516 and Msmeg_0517 (agaF and 
agaK), respectively (Figure 4.7). These proteins are predicted to encode the 
membrane spaning domains (MSDs), and Msmeg_0518 (agaG) is predicted to 
encode the nucleotide binding domains (NBDs), with predicted substrate specificity 
for glycerol 3-phosphate transport.  The last gene in the operon located downstream 
of Msmeg_0515 (agaE) is a gene that encodes a porin; it has been suggested that this 
protein works as a gate for the sugar to get in and to be transported by the ABC 
permeases, including Msmeg_0515 (AgaE) [3, 131].  
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Figure 4.6 The operon that encodes the Msmeg_0515 gene and the neighboring genes.  
The dark arrow color indicates the regulatory gene (agaR), the light blue indicates the 
carbohydrate metabolic genes and the dark blue indicates the genes involved in the transport 
system ([3].  
 
 
 
 
Figure 4.7 A schematic diagram of the putative ABC components, structure and 
organization of AgaEFKG. The first component is the extracellular binding protein (AgaE, 
green), which is predicted to be membrane anchored by the fatty acyl chain linked to the 
conserved cysteine in the N-terminal protein sequence. The second and third components are 
the membrane spanning domains (AgaF & K, red) and the nucleotide binding domains 
(AgaG, grey). 
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4.2 Cloning of Msmeg_0515 (agaE) gene 
4.2.1 Genomic DNA preparation 
 The fast growing M.smegmatis MC2 155 strain was kindly provided by Prof. Jeff 
Green (Sheffield University) in an agar plate, which was used to grow a primary 
culture in 5ml LB medium. One colony was inoculated into a 5 ml LB medium and 
incubated at 37˚C for 3 days. As the culture did not have an antibiotic selection gene, 
the culture was daily checked by the eye to see if there was any contamination. After 
3 days, genomic DNA from the cells was extracted using keyPrep bacterial genomic 
kits (ANACHEM®) as pointed out in section 2.1.2. The genomic DNA was stored at 
-20˚C. 
4.2.2 primers design and gene amplification of agaE 
To aid in the purification of the AgaE protein, it was decided to clone the AgaE 28-
425 truncated protein into a pET28a vector, this plasmid contains NdeI and HindIII 
restriction sites and so primers were designed with an NdeI site in the forward primer 
and an HindIII site in the reverse primer (Table 4.2). These restriction enzymes were 
selected, as the gene itself did not contain these cut sites. The designed construct was 
missing the N-terminal 1- 27 amino acid residues and the primers were designed 
lacking the first 81 bases of the agaE gene, which lacks its own methionine as a start 
codon (Figure 4.1). The restriction site of Nde1enzyme was used to provide an 
alternative start codon for gene expression. All primers were synthesized by Eurofins 
MWG Operon Company in 100 µM stock and stored at -20°C.  
To amplify the agaE gene, various gradient PCR runs were undertaken with different 
annealing temperatures between 55 and 65°C, in order to optimize the quality of the 
PCR product. The agaE gene was amplified best at an annealing temperature of 58°C 
(Figure 4.8). 1% agarose gel electrophoresis was used to evaluate and check that the 
resulting PCR product was pure enough to be used for an efficient ligation reaction 
with the pET28a vector.  The PCR product then was extracted using gel extraction 
kit as described in section 2.1.7. 
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Primers Sequence 
Msmeg_0515 forward NdeI (F) 5’-CCCCATATGGTGATACGACGCTGGTTG-3’ 
Msmeg_0515 forward NdeI (T) 5’-CCCCATATGTCGTCATCGGGTCC-3’ 
Msmeg_0515 Reverse HindIII 5’-GGGAAGCTTTTTGCCGGCCAGGG-3’ 
 
Table 4.2 Primers of the full length and truncated genes of AgaE.  The forward primers 
contain the NdeI restriction site (red litters), and the reverse primer contains the HindIII 
restriction site. 
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pET28agaE 
6511 bps 
agaE 
Kan 
lacI 
T7  
His  
NdeI&
HindIII&
 
 
 
 
 
 
 
 
 
 
 
(a) 
     
(b) 
Figure 4.8 A schematic represntation for the DNA cloning of the agaE (full length) gene 
to pET28a plasmid . A. displays the circle pET28agaE (6511 bp) that contains the agaE 
gene with 6×His tag at C-terminal and  kanamycine resistant gene. B. the genomic DNA 
extraction of the M.smegmatis (left) and the PCR purification of the Msmeg_0515 gene 
using 1% agarose electropherosis gel stained with ethidioum bromide, and analyzed under 
UV light. 
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4.2.3 Restriction digestion of the PCR product and pET28a plasmid 
Both the PCR product and plasmid were double digested by Nde1 and HindIII in 
order to provide a sticky end suitable for cloning purposes. The PCR product and the 
plasmid were incubated with enzymes and the required buffer at 37°C for 2 hours. 
1% of agarose gel electrophoresis was used to recover the DNA fragments and to 
remove the enzymes. The DNA was extracted from a gel by using the Qiagen DNA 
gel extraction kit. The restriction digestion reaction was set up based on the New 
England Biolabs protocol as described in section 2.1.8. 
4.2.4 Sticky end ligation into pET28a plasmid 
In two separate eppendorf tubes, a ligation mixture of 3:1 and 1:3 of the digested 
pET28a plasmid and PCR product, respectively were added in order to provide 
sticky end ligation. A T4 ligase (New England Biolabs) was added to the reaction 
and the mixture was incubated at 37°C for 1 hour as described in section 2.1.9. 
4.2.5 Sub-cloning into Dh5α 
The E.coli DH5α strain was used for sub-cloning the ligation mixture of pET28a and 
Msmeg_0515 gene. One of the 50 µl pre-aliquoted tubes stored at -80°C was used to 
transform the 1µl of the ligation mixture after 5 minutes of gentle resuspension on 
ice. The cells were incubated on ice for 30 minutes, and heat shocked at 42°C for 30 
seconds. The cells were then incubated back on ice for 2 minutes to complete the 
transformation. Then, 450 µl of LB media stored at room temperature was added to 
50 µl of cells to reach a final volume of 500 µl. The cells were incubated at 37°C for 
one hour. The transformed culture was then centrifuged for one minute to collect the 
cells. The media was discarded and the cells were re-suspended in 50 µl of LB 
media. Finally, LB media plates containing 50 µg of kanamycin were used to grow 
the cells overnight at 37°C. 
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4.2.6 Identification of Successful cloning 
Successful clones were identified by a restriction digestion experiment. Several 
colonies of the transformed cells were inoculated into 5 ml of LB media containing 
50 µg of kanamycin and incubated at 37°C overnight. Then, the culture was 
centrifuged at 4000 ×g for 5 minutes. The LB media were discarded and the plasmid 
in the cells was recovered using a Qiagen mini prep kit (section 2.22). The resulting 
DNA plasmid was digested using Nde1 and HindIII enzymes and incubated at 37°C 
for 2 hours. The reaction mixture was loaded onto a 1% agarose gel, which showed 
two clear bands, of the correct size for plasmid and the insert (Figure 4.9). 
 
!
Figure 4.9 Restriction digestion of pET28a that contains AgaE. The top band 
corresponds to the pET28a vector (~ 5314 bp), and the lower band corresponds to the AgaE 
(1197 bp). 
!
!
!
!
!
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4.3. Protein expression and purification of AgaE 
4.3.1 Transformation of pET28agaE to Bl21 (DE3) strain 
In order to be able to test the expression of the cloned AgaE truncated protein, the 
successful cloned gene was transformed to a competent bacterial strain of BL21 
(DE3) using the protocol described in 4.2.3. After transformation, LB media 
containing 50 µgml-1 kanamycin was added to 80 µl of cells, to reach a final volume 
of 100 µl and incubated at 37 °C for further cell growth. After 1 hour of incubation, 
the cells were centrifuged and discarded. All cells were re-suspended by 50 µl of the 
LB media and spread onto 50 µgml-1 kanamycin LB plates. Finally, the plates were 
incubated at 37°C overnight. 
4.3.2 Optimization of AgaE overexpression 
One colony of the transformed AgaE in Bl21 (DE3) strain was inoculated in 5 ml of 
LB media supplemented by 50 µgml-1 kanamycin; it was incubated overnight at 37 
°C as a primary culture. This culture was used to make a secondary culture using 250 
ml flasks. 500 µl of the primary culture were inoculated into 50 ml of fresh and 
sterile LB media supplemented by 50 µgml-1 of kanamycin. The secondary culture 
was then incubated for 2 hours until an optical density of 0.6 (OD600) was reached. 
Before induction, 1ml of the culture was taken and the cells were stored at -20°C to 
be used in an evaluation expression as a pre induction fraction. In order to find out an 
optimal temperature for the AgaE protein expression, the cultures were induced with 
50 µl of 1mM IPTG and incubated at different temperatures of 18 °C, 25 °C and 37 
°C. After 4 hours of induction, the cultures were transferred into Falcon tubes and 
centrifuged at 3600 xg for 20 minutes at 4°C by using sigma 3-16k centrifuge. The 
LB media were discarded and the cells were stored at -80°C. The cells were thawed 
on ice in the next day and re-suspended with 2ml of Tris-HCL buffer, pH 8.0. The 
cells were sonicated on ice 2x at 16 microns for 20 seconds. In addition, the pre-
induction fraction was resuspended in 100ųl of Tris buffer to be run on SDS gel. 5 µl 
of SDS loading buffer and 1ųl of DTT were added to 15 µl of (15 µg) all fractions; 
they then were boiled at 95°C for 5 minutes. Protein concentration was assayed using 
the method of Bradford. Finally, a 12 % of SDS-PAGE gel was run at 200 for 45 
minutes to monitor the protein expression. As demonstrated by the SDS-gel, the 
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protein was highly expressed at all temperatures (figure 4.10); thus, 37˚C was 
selected for large-scale protein purification. 
 
Figure 4.10 SDS gel showing the small-scale over-expression of AgaE. The highlighted 
boxed bands indicate the expression of AgaE in soluble fractions at three different 
temperatures 37, 25 and 18°C. The molecular weight of AgaE is 45.5 kDa. 
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4.3.3 Large scale overexpression of AgaE 
For large scale overexpression, 2 l of LB media were prepared using 4 flasks of 500 
ml. The primary culture was prepared by the inoculation of one colony of the 
transformed clone in BL21 (DE3) to 50 ml of the LB media supplemented by 50 µl 
of 50 µgml-1 kanamycin in 250 ml flask and incubated overnight (15-18 hours) at 
37°C at 250 RPM. 5 ml of this culture was used to inoculate 500 ml of LB media 
supplemented with 50 µgml-1 kanamycin. The secondary culture was incubated at 
37°C and 200 RPM for approximately 2 hours to reach an optical density (OD600) of 
0.6. The cells were induced by the addition of 1mM of IPTG and incubated at 37 °C 
and 200 RPM for an additional 4 hours. 1ml of non-induced cells was taken for 
expression analysis. After 4 hours induction, the cells were transferred into 1 l 
Beckman centrifuge tubes and spun at 3,600 ×g for 20 minutes. Most of the LB 
media was discarded, the cells resuspended and centrifuged again using Sigma 3-
16K centrifuge at 3,600 ×g for 20 minutes and stored at -80°C. 
4.3.4 Ni-NTA Affinity Chromatography purification of AgaE 
As the construct of AgaE contained a N-terminal 6×His tag, Ni-NTA affinity 
chromatography was used as the initial purification step. 1 g of the cell paste was 
removed from -80°C and re-suspended on ice using 10 ml of 50 mM Tris buffer pH 
8.0. Then, the cells were disrupted on ice by sonication (3x-20 seconds) at a volume 
of 16-micron amplitude. The cell debris was then removed at 4°C by centrifugation 
at 70,000 xg for 10 minutes. The soluble protein fractions (~20 ml / 50mg) were 
applied to the 5 ml Ni-HP cartridge column after measuring the protein concentration 
using the Bradford assay. The AgaE protein was eluted from the column with 50 ml 
of 0.35M imidazole. 3 ml fractions were collected and pooled together. The protein 
was anlaysed by SDS-PAGE gel, which displayed lower molecular weight 
contaminants; thus, a further purification step was used.  
4.3.5 Gel filtration of AgaE 
The fractions from the Ni-NTA affinity chromatography step were measured using 
the Bradford assay and fractions 13 and 14, which had the highest protein 
concentration (Figure 4.12) were combined for further purification by gel filtration. 
The sample was reduced to 1 ml using a Viva spin concentrator (MWCO 30000); it 
was then injected into a 16x60 Superdex200 gel filtration column (GE Healthcare), 
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which was equilibrated with 50 mM Tris pH.8.0 and 0.5 M NaCl buffer.  The Gel 
filtration was performed at a flow rate of 1.5 ml/min and 2 ml fractions were 
collected. Fractions 21-24 were combined based on the recording fraction peak of the 
protein predicted size. The progress of the purification was analysed by SDS-PAGE 
using 12% Bis-Tris NOVAX gel (Invitrogen) (Figure 4.11).  
&&
Figure 4.11 SDS gel viewing the protein purification steps of Msmeg_0515 (AgaE). The 
molecular weight of AgaE is 45.5 (kDa). Samples were taken from the crude extract, Ni-
column and gel filtration respectively to be analyzed. &
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Figure 4.12 Chromatograms obtained during the purification of AgaE. Blue line 
represents absorption at 280nm, brown line represents conductivity and green line represents 
gradient of Imidazole concentration: a. Chromatography on HisTrap HP column; b. Gel 
filtration on HiLoad Superdex200 column. The gel filtration column step succeeded in 
removing low molecular weight contaminants left after the initial Ni-NTA purification.  &&&
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4.4 Initial automated crystallization screening of truncated AgaE 
4.4.1 Preparation of the protein sample 
To obtain protein for crystallization experiments, fractions 21-24 from the gel 
filtration were pooled and concentrated to 11.5 mgml-1 using a Viva spin 
concentrator. The purification buffer was exchanged to one with low salt by adding 
7ml of 10mM Tris buffer pH 8.0 to the 400 µl of protein solution and centrifuging 
again for 20-30 minutes at 4500 rpm.  
4.4.2 Crystallization of AgaE 
Sitting drop vapour diffusion trials were carried out in order to identify an optimal 
condition for the protein to be crystallized. The Hydra II crystallization robot system 
was used together with several commercial screen conditions, such as JCSG+, 
PACT, PEG and classic (Qiagen Nextal®) using 96 well MRC plates a drop sized 
200 nl and reservoir size of 200 nl. The plates were sealed using a special sheet 
(Molecular Dimension) in order to prevent the drop from being dried and to view it 
clearly. All the plates were centrifuged for 2 minutes and at a speed of 2000 rpm to 
make sure that the two drops of buffer and protein were mixed well using a Grant- 
Bio LMC-3000 R-2 rotor. Finally, all the plates were placed in a crystallization room 
at 17°C. 
4.4.3 Identifying of successful crystallization 
The crystallization plates were viewed after 24 hours, 3 days and 7 days for crystal 
growth.  After 3 days of incubation, the recombinant AgaE protein started to form 
crystals under different conditions of the JCSG screen (A9, B9, H6, 7,8). The trays 
were left to equilibrate further, and the crystal grew bigger. In addition, after 1 
month, crystals were also observed in a number of further conditions in the JCSG, 
PACT and PEG screens (Figure 4.13). &
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Figure 4.13 Photographs of AgaE native crystals; the crystals were grown within different 
conditions and with different crystal forms. &&&&&&&&&
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4.4.4 Crystal diffraction test 
Crystals were selected for data collection according to their size and quality. Single 
octahedral shaped crystals were obtained from wells A9 and B9 of the JCSG screen 
with dimensions 0.3mm×0.2mm×0.2mm. These crystallization conditions contained 
0.2 M Ammonium chloride pH 6.3, 20% PEG 3350 and 0.1M citric acid pH5.0, 20% 
PEG600, respectively. 
In order to test the diffraction, crystals were washed with a cryoprotectant solution 
(crystallization buffer and 25% ethylene glycol), mounted onto the diffractometer 
using a fiber loop and flash cooled to 100K with an Oxford Cryo-systems Cryo-
stream 700.  
The X-ray generator of Sheffield University (Rigaku MM007 copper rotating anode 
generator and MAR345 Research image plate) was used for initial X-ray diffraction 
experiments. Two 1˚ rotation images at 90˚ to each other and 5 minutes exposure 
were obtained. The resulting diffraction was auto-indexed using the Mosflm software 
(Leslie & Powell, 2007). Using this procedure, the crystal of AgaE was determined 
to be in the orthorhombic class, in point group P222 with cell dimensions of a=63.88, 
b=69.15, c=100.71 Å and α=β=γ=90°. Data were collected 2.14Å and processed 
using the Mosflm software (Leslie & Powell, 2007)[79]. As only the even h00 0k0 
and 00l reflections were present; the space group was assigned to P212121 (Table 
4.4). All crystals were then saved in liquid Nitrogen to be sent to the Diamond 
synchrotron for high resolution data collection. 
             
Figure 4.14 Photographs of selected native AgaE crystals for data collection. Crystal (1-
left) was taken from JCSG – A9 and diffracted to 1.49 Å. Crystal (2) was taken from JCSG-
B9 and diffracted to 1.35Å. &&
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4.4.5 X-ray data collection of AgaE crystals 
In order to collect a high-resolution data, several native AgaE crystals were selected 
from the robot trials of the JCSG screen wells A9, B9 and H12. All the crystals were 
mounted and washed with a cryoprotectant solution made of a crystallization 
condition buffer with the addition of 25% ethylene glycol and flash cooled to 100 K 
with a gaseous nitrogen stream. The crystals were then stored in liquid nitrogen and 
sent to beam line I03 at the Oxford Diamond light source for data collection. Two 
diffraction images 90˚ apart and 1˚ oscillation were collected using a ADSC Q315r 
detector and auto-indexed using the Mosflm software to predict the best strategy for 
data collection [79]. Data collection strategies and statistics for all the three native 
crystals are shown in Tables 4.3 and 4.4 respectively. 
Table 4.3 The data collection strategies of several crystals of native AgaE 
 
 
 
  
 
 
 
 
 
Data strategies Crystal I Crystal II Crystal III 
Detector MAR345 image 
plate 
ADSC Q315r ADSC Q315r 
Phi start 273.0° 335.0° 335.0° 
Phi Oscillation 1.0° 0.5° 0.2° 
No of images 140 230 900 
Resolution 2.14 Å 1.48 Å 1.35 Å 
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Table 4.4 Data statistic of three native AgaE crystals.&
 
DATA SET Crystal I Native 
 
Crystal II Native 
 
Crystal III Native 
 
Wavelength (Å) 
Energy (KeV) 
0.97630 
 12.7 
0.96860 
12.8 
0.97620 
12.7 
Space group P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
Unit cell              
parameters                         
a (Å)                                      
b (Å)                                       
c (Å) 
                                               
α = β = γ (˚) = 
 
63.88                         
69.15                       
101.71 
 
90.000 
 
64.06                   
69.26                            
100.74 
 
90.000 
 
64.03                 
69.22              
100.47 
 
90.000 
Resolution range (Å) 53.94-2.14                  
(2.03-2.14) 
34.6-1.48                
(1.52-1.48) 
64.0-1.35                  
(1.39-1.35) 
Unique observation 28899                        
(3694) 
75131                  
(5493) 
91428                
(4448) 
Rmerge 0.103                        
(0.403) 
0.047                
(0.586) 
0.097              
(0.382) 
Rpim 0.059                        
(0.235) 
0.029                  
(0.352) 
0.048               
(0.43) 
Completeness (%) 98.1                            
(87.4) 
99.7                    
(99.9) 
92.8                 
(62.1) 
Anomalous completeness 
(%) 
95.7                            
(84.1) 
97.1                     
(99.3) 
82.5                 
(38.7) 
Multiplicity 3.9                                
(3.8) 
4.6                         
(4.6) 
5.3                      
(2.3) 
Anomalous multiplicity 2.0                                
(2.0) 
2.3                         
(2.3) 
2.6                      
(0.9) 
Mean (I)/σ(I) 8.4                                
(3.1) 
15.8                       
(2.3) 
11.0                    
(2.0) 
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Matthews Crystal   I Crystal II Crystal III 
Molecules in the AU 1& 1& 1&
Probability (based on data resolution) 1.00& 1.00& 1.00&
Probability (all proteins in the PDB) 1.00& 1.00& 1.00&
Vm (Å3 / Da) 2.4& 2.5& 2.5&
Solvent content (%) 49.7& 49.8& 50.4&
Molecular weight (Da) 45500& 42.734& 45500&
!
Table 4.5 Asymmetric unit contents and Matthews coefficient for AgaE crystals.  The 
results revealed one molecule only per asymmetric unit. 
 
4.4.6 Native data processing of AgaE crystals 
The native data from crystals I and II were processed automatically using the Xia2 
pipeline implemented at Diamond light source [81]. The processed data used in the 
structure solution of AgaE, came from the 3D mode of Xia2; XDS and XSCALE 
were used to process and merge data, respectively [80, 132]. The space group was 
checked using Pointless [82], which revealed that an orthorhombic P212121 system, 
with cell dimensions of a = 64.0 Å, b = 69.0 Å, c = 100.0 Å, and all angles 
α=β=γ=90˚ (Table 4.4) [79]. The asymmetric unit contents were estimated using the 
method of Matthews’s [78], which gave a Vm of ~2.5 for one AgaE in the A.U. 
(Table 4.5). 
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4.4.7 Structure determination 
4.4.7.1 Molecular Replacement: 
As the sequence comparisons of AgaE revealed that the most likely structure would 
be of a maltose- maltodextrin binding protein, attempts were made to determine the 
AgaE truncated structure by molecular replacement using a search model of a 
maltose binding protein from the thermoacidophilic bacterium Alicyclobacillus 
acidocaldarius (PDB code, 1URD). The search model had a sequence identity of 
27% to AgaE and it was predicted to share the same 3D structure as AgaE by the 
Phyre server [89]. The Chainsaw program of the Phaser was used to replace all the 
amino acids of the search model by a poly alanine chain [133]. Phaser was used to 
search for one copy of the molecule using the data of AgaE as an input [83]. 
Unfortunately, no convincing solution to the molecular replacement could be 
obtained.  
The resulting map of the best solution was poor and discontinuous; additionally, no 
improvement was seen after the refinement with an R-factor in Refmac5 of 0.52 
[134].   As there is some variation in the position of the two domains of this family 
of proteins, depending upon substrate binding, an alternative MR strategy was 
employed. The search model was split into two domains and attempts were made 
using the Phaser to find solutions for the individual domains. Again, no convincing 
solution could be found. It was thus decided to try to express the AgaE protein as a 
Seleno-methionine derivative, in order to obtain initial phases by exploiting the 
anomalous diffraction of the selenium atoms.     
4.5 Expression and purification of AgaE incorporated with Seleno-methionine 
The AgaE protein containing Seleno-L-methionine was overexpressed using the 
same protocol as that for the native protein over-expression. However, after reaching 
the suitable optical density of OD600 ~ 0.6, the cultures were harvested by 
centrifugation at 5.000 xg for 30 minutes. The LB media was discarded and the cells 
were re-suspended in minimal media supplemented with Seleno-methionine as 
detailed in (section 2.2.5). The expression was induced using 1mM IPTG for a 
further 8 hours. Using this protocol, 1g of Se-Met AgaE cell paste was obtained. The 
purification followed that for the native protein, with a Ni-NTA column followed by 
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gel filtration and buffer exchange to give a solution of Se-Met AgaE at 11 mg/ml in 
10mM Tris pH8.0. 
4.6 Crystallization of Seleno-methionine incorporated AgaE 
Several robot screens were used in order to identify suitable condition for Se-Met 
AgaE protein to be crystallized. The JCSG, PACT, PEG and classic screens were 
used with purified AgaE at 11.5 mg/ml in 10mM Tris pH8.0. 200 nl of the well 
solution were mixed with 200nl of the protein for each well. All trays were then 
incubated as the native protein at 17°C. Crystals were obtained under numerous 
conditions in the JCSG, PACT and classic screens. However, only a single crystal 
from JCSG – B2 (0.1M citric acid pH 4.0 and 20% PEG6000), was sent to the 
Diamond synchrotron for data collection and phase determination experiment.  &
Crystal& Condition&
 
& & JCSG&–&B9F&Robot&Screen&0.1M&citric&acid&pH&4.0&20%&PEG6000. 
 
 
Figure 4.15 Photograph of AgaE Se-MET crystals. Crystals were found under the same 
conditions as native crystal. &&&&&&&&&&&
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4.6.1 X-ray data collection of Seleno-Methionine AgaE crystals 
As crystals of the Se-MET protein grew under the same conditions as those seen for 
the native protein, single crystal was selected from JCSG-B9 for data collection. The 
crystal was mounted and saved in liquid nitrogen for data collection. The I04-1 beam 
line of the Diamond light source was used to collect data using a SAD experiment.   
The theoretical Se-K edge absorption spectrum is shown in figure 4.16-a. It can be 
seen that at energies above 12.66 KeV, a significant anomalous diffraction signal 
should be present in a protein crystal containing selenium, however, the exact extent 
of the contribution of the selenium anomalous diffraction depends on many factors 
including the number of selenium atoms compared to the other atoms in the unit cell, 
the quality of diffraction and the precise X-ray energy chosen. The amino acid 
sequence of AgaE contains ten methionine residues. The predicted signal was 
estimated for AgaE using the BMSC web server (Figure 4.16-b). It can be seen that 
at E=13.48 eV (the energy of beamline I04-1), the size of the anomalous signal 
should be approximately 4-10% at 2Å. 
Three initial images of 0.5˚ rotation and at 45˚ to each other were taken on beamline 
I04-1 to test the diffraction and crystal quality and to estimate a good strategy for 
data collection. These images showed that the crystal diffracted well (Figure 4.17), 
and so single wavelength (SAD) data at energy of 13.48 KeV (0.91997Å) were 
collected on this crystal.  To ensure that good quality anomalous data were collected, 
a total of 7200 images of 0.2˚ rotation were collected, so that each reflection was 
measured an average 30 times. The data was processed using the Xia2 Diamond 
system in its 3dii mode. Data were indexed in space group P212121 with similar unit 
cell dimensions to the native crystals (Table 4.4). Due to rotation damage of the 
crystal only the first 4268 images were processed, however this still gave an 
anomalous multiplicity of 15.8 (Table 4.6). 
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(a) 
&
 (b) 
Figure 4.16 The Se-K edge absorption spectrum of AgaE SAD experiment. a) The Se-K 
edge absorption spectrum. b) The predicted anomalous signal for AgaE. Figures were 
created using the BMSC web server. &
&&
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Figure 4.17 Example of data collection for the Se-MET AgaE crystal. A. Crystal was 
mounted onto a fiber loop and exposed to 100 µm X-ray beam. B. Diffraction image of the 
AgaE crystal; diffraction data were collected to a resolution of 1.77Å for of Se-MET crystals 
using ADSC Q315 CCD detector at the beam line I03 of the Diamond synchrotron source.     &&&&
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DATA!SET! Se(MET!Crystal!Energy&(KeV)& 13.48&Wavelength&(Å)& 0.91997&Space&group& P&21&21&21&&Unit&cell&parameters&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&a&(Å)&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&b&(Å)&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&c&(Å)&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&α&=&β&=&γ&(˚)&=&
&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&63.9&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&69.6&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&101.4&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&90.0&Resolution&range&(Å)& (57.4F1.77)&(1.82F1.77)&Observations& 1348574&&(86932)&Unique&reflections& 44560&&(3206)&Rmerge& 0.086&&&&&(0.877)&Rpim& 0.016&&&&&(0.167)&Completeness&(%)& 99.4&&&&&&&(97.6)&Anomalous&completeness&(%)& 99.4&&&&&&&(97.5)&Multiplicity& 30.3&&&&&&&(27.1)&Anomalous&multiplicity& 15.8&&&&&&&(13.8)&Mean&(I)/σ(I)& 30.5&&&&&&&(5.6)&&
Table 4.6 Data collection statistics of the Se-Met AgaE crystal data set (values in 
brackets refer to the high resolution shell). 
!
!
!
!
!
!
!
!
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4.6.2 Obtaining experimental phase for AgaE S-MET data 
In order to solve the phase problem, the three SHELX programs C, D and E were 
used in the graphical user interface of HKL2MAP [84, 85].  In the first step 
SHELXC was used to prepare the data from the scaled, unmerged file from Xia2 and 
to calculate the extent of the anomalous signal. This shows a strong anomalous signal 
with Dano / sig (Δano) > 1.2 to 1.9Å and a correlation coefficient of >30% to 2.2Å 
(Tables 4.7a). Then, SHELXD was used to calculate the positions of the 10 potential 
selenium atoms in the structure, with 100 tries and to a maximum resolution of 2.3Å. 
The SHELXD results (Figure 4.18), gave the position of 9 Se atoms with an 
occupancy > 0.6, with a steep fall off in occupancy to 0.1 for the next site. There was 
a high correlation of 49.8 % between the observed and calculated patterns. It thus 
seems likely that the crystals of AgaE contained nine selenium atoms, in good 
agreement with the 10 Met residues in the sequence, assuming the N-terminal 
methionine had been cleaved during experiment. The protein phases were then 
calculated for both hands of the selenium substructure, using SHELXE. 20 cycles of 
structure phasing and density refinement using a 50% fractional solvent content were 
run. It can be seen that the phases calculated from the inverted hand enantiomorph of 
the substrate gave substantially better mean figure of merit and correlation 
coefficient and the resulting map had a much higher connectivity and contrast than 
the map from the original hand substructure (Table 4.7b). The two SHELXE maps 
were inspected in coot to check for continuous good connectivity displaying a clear 
map for the protein structure (Figure 4.19). This clearly showed that the inverted 
hand map was correct. 
 &&&&&&&&&
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Dano / sig (Δano) vs. Resolution!
 
(a) 
 
(b) 
Figure 4.18 The output results of the SHELX C & D of AgaE SAD experiment. a. 
Shows the anomalous signal from the AgaE S_MET crystal datasets. A graph of Dano / sig 
(Δano) was plotted against the resolution which indicated a value of above 1.3 with a good 
anomalous signal. b. Peaks show the best solution of 9 sites of heavy atoms with 
occupancies between 0.6 and 1.0 [84]. &&
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Tables 4.7 The output result of SHELXE calculating of heavy atoms density and 
pseudo-free CC for the enantiomorphs of the determined electron density map. The 
original enantiomorph (Top) and the inverted enantiomorph (Bottom). &&&&&&&&&&&&&&
Hand! Original! Inverted!
Contrast! 0.22& 0.7&
Connectivity! 0.6& 0.8&
Mean!FOM! 0.31& 0.7&
Correlation!coefficient! 34.7& 72.0&
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(a) 
 
(b) 
Figure 4.19 Electron density model of the substructure atoms of both original and 
inverted hands enantiomorphs of AgaE selenium SAD experiment. Maps are contoured 
at 1.6 σ and viewing the same regions. a) Shows the original substructure hand from 
SHELXE. b) Shows the inverted substructure hand. &&&&&
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Figure 4.20 An example of the progress made with respect to the model building AgaE 
structure by electron density. Maps are shown for the same residues Tyr124, Pro125, 
Ala126, Glu127 and Arg128 for the same model after SHELXE and for the final mtz, both 
are contoured at sigma level of 1.5. a. The electron density of AgaE after SHELXE and b. 
the electron density of AgaE for the final mtz model [84]. Differences in electron density 
quality are highlighted by blue rings. 
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4.7 Structure refinement 
4.7.1 Structure building and refinement of AgaE 
SHELXE was run again on the inverted hand including autobuild of the main chain 
of the protein. The polyalanine model produced had 347 out of the expected 398 
residues, built in 8 chains. The model was completed in coot by manually adding 
side chains and missing residues using the position of the Selenium atoms as a guide. 
4.7.2 Phasing of native data by molecular replacement 
The complete refined Se-Met AgaE structure was used as a search model in 
molecular replacement to determine the structure of the three sulphur methionine 
crystals, for which data had been collected (Table 4.4).  In each case clear solutions 
for the rotation and translation functions could be seen, with each structure built 
using rounds of refinement in Refmac5 and rebuilding in Coot [87, 134]. Refinement 
statistics for only the highest resolution structure was shown in table 4.8. 
4.7.3 The final model of (agaE) 
The structure was built and refined further using Refmac5 in CCP4 with an initial R-
factor of 0.35 and R-free 0.35 [134]. 14 cycles of refinement were carried out in 
order to reduce the R-factor for best structure using coot for structure evaluation 
[87]. The final structure model has been built to an R-factor of 0.20 and R-free 0.23. 
Waters were added to the model with selected sigma level of 1.0; however, all waters 
were later checked manually and unsuitable water with poor density was removed. 
There was very little difference between the native structures, apart from the 
resolution. Each model of AgaE has 398 residues with well-defined electron density; 
however the two N-terminal residues (28 and 29) in crystal II have poor density. The 
final models have an RMSD deviation of bond lengths and angles of about 0.02 Å 
and 1.9˚, respectively (Table 4.8). The water molecules for all crystal structures were 
added to the models with discrete electron density over 3.4 sigma in the difference 
maps and checked that they made reasonable hydrogen bonds with the protein atoms. 
Finally, the models were validated using the programs PROCHECK and 
MOLPROBITY [135, 136]. The final model for crystal III at 1.35Å had 277 water 
molecules, one 6 carbon PEG molecule and 3 ethylene glycol molecules. This is the 
structure that is described in the following chapter. 
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Figure 4.21 The overall fold of the final structure model of AgaE. The position of PEG 
and ethylene glycol are shown as blue sticks. Cartoon image was made using Pymol 
[98]. 
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Model Crystal III Crystal S-MET 
Resolution (Å) 1.35Å 1.77Å 
Number of reflections 86449 42260 
Protein molecules per asymmetric 
unit 
1 1 
Number of atoms 3143 3296 
Number of waters 277 187 
Number of EDO 3 7 
Number of PEG 1 1 
Ramachandran favoured (%) 98.0 97.3 
Ramachandran outliers (%) 0 0.25 
Poor rotamers (%) 0.94 1.84 
RMSD bond (Å) 0.02 0.012 
RMSD angle (O) 1.9 1.3 
Average B-factors (A2)   
Main chain (A2) 18 29 
Side chain (A2) 22 30 
Waters 31 51 
EDO 25 36 
PEG 32 32 
R-factor 0.16 0.18 
R-Free 0.20 0.24 
Molprobity score 1.1        
   98th percentile* 
 
1.9 
90th percentile 
 &
Table 4.8 The final refinement statistics and validation for the different native crystal 
structures of AgaE as well as S_MET incorporated in the crystal structure. 
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Figure 4.22 The properties of the main chain and the side chain for the final refined 
AgaE structure. All residues were shown to be within the expected site. The figure was 
produced using PROCHECK program [136]. 
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(a)
 
Figure 4.23 Results of Molprobity and Ramachandran plot of the final native and Se-
met AgaE structures. The results indicated excellent score of Molprobity and all residues 
are within the favored regions. The figures were produced using Molprobity server [135].  
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4.7.4 Alternative conformation of residues in the AgaE structure 
The Se-MET structure of AgaE has a number of residues that were built with two 
conformations, as there was clear electron density (at a contour level of 1.5 σ) 
indicating this. The residues Leu-66, Trp-190 and Asp-119 were built to have two 
conformations, each of 50% occupancy (Figure 4.24).   
 
Figure 4.24 An alternative conformation of some AgaE residues. The Map was contoured 
at 1.5 σ.  &&
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Chapter 5 
 
Structure of AgaE 
In this chapter, a description of the truncated AgaE protein structure will be detailed, 
together with a comparison to other similar structures. Also, the analysis will include 
a discussion of the putative active site, and the protein possible function.  
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5.1 AgaE structure description  
5.1.1 Detailed features of AgaE Structure 
The AgaE Crystal structure (residues 28-425) was solved in space group P212121 
with one AgaE molecule in the asymmetric unit and with electron density present for 
all residues. The overall model structure of the truncated AgaE revealed that AgaE 
folds into two separate domains called as the N and C terminal domains.  
 
A schematic of the folding pattern observed in AgaE is shown in Figure 5.1. It can be 
seen that the N-terminal domain (residues 28-143 and 305-375) is constructed from a 
central five stranded β-sheet, surrounded by α-helices. Four of the β-strands are 
folded in the contiguous N-terminal domain, with the fifth strand interdigitating into 
the sheet after the residues in the C-terminal domain. This last strand runs 
antiparallel to the others, and a mixed parallel and antiparallel β-sheet is formed. 
In a similar fashion, the central β-sheet in the C-terminal domain (residues 148-286 
& 385-425) has one strand running in an opposite direction to the others, and this is 
the first strand after the linking loop (6 residues long) from the N-terminal domain. 
This arrangement again gives a mixed parallel and antiparallel β-sheet, with the same 
architecture as the sheet in the N-terminal domain. The strands in both domains are 
linked by α-helices and often more than one helix is present between strands. 
The connectivity between the two domains is rather complicated. From the N-
terminus, four β-strands and associated linking α-helices are folded in domain 1. An 
extended loop connects domain 1 with domain 2. The β-sheet of domain 2 and its 
linking helices is folded and then another extended loop folds the polypeptide chain 
back into domain 1, to form the extra strand of the sheet in this domain. The chain 
then folds five α-helices (α-13 to α-17), before a third loop runs back into domain 2, 
to finally fold two further α-helices (α-18 & α-19), and then to the C-terminus.    
 &
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Figure 5.1 Schematic representation of AgaE structure. The top view is a schematic 
diagram, two domains are circled, β-stands colored yellow and α-helices dark red, hinge 
region connected both domains are colored light red as L1, L2 and L3. The bottom view is 
the number of helices and beta strands based on the primary structure of AgaE. Figure was 
created using Pymol [98]. 
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Figure 5.2 Cartoon representation of the overall fold structure of AgaE.  The individual 
strands and helices are numbered. The molecule in the lower view has been rotated 180˚ with 
respect to the upper view. 
 
 
 
 
 
 
!"#$%!
                           
 
165&
5.1.2 Molecular surface  
The two domains of AgaE fold into a compact, ellipsoidal, structure of dimensions 
(70.7 Å, 53.7 Å), with a clear deep, cleft running between them (Figure 5.2). The 
electrostatic surface of AgaE was calculated using Pymol [98] and is shown in figure 
5.3. The surface has a mixed positively and negatively charged appearance, but at the 
base of cleft there is a deep negatively charged depression, formed by the side chains 
of residues (D41, E43, D71, D121, D122, D154, E198, D199, D274, D305, D342 
and D351), possibly indicating a binding site. Indeed, in the structure clear difference 
electron density could be seen in this area, which could be interpreted as a molecule 
of polyethylene glycol (6-carbons) (Figure 5.4). It can be seen that the PEG molecule 
makes hydrogen bond interaction with Ser 95 and packs against R380 and P381 in 
the cleft. &&&&&&&&&
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Figure 5.3 Surface electrostatic representation of the AgaE structure. The view in (a) is 
the front view, (b) is the back view of a. Positively charged residues are colored blue and 
negatively charged residues are colored red, respectively. The putative binding site is shown 
between the two domains in (a) with highly negatively charged site. The figure was 
produced using Pymol [98]. 
Putative Binding 
Site 
70.7 Å 
53.7 Å
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Figure 5.4 Cartoon representation of the putative active site between the two domains 
interface in complex with PEG. The PEG molecule is coordinated by two water molecules 
and makes hydrogen bond with Serine 95.& &  
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5.2 Crystal contact 
AgaE crystallizes with a monomer in the asymmetric unit, and so the crystal packing 
was analyzed to see if AgaE forms oligomers using the PISA server 
(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html) [137]. For chain A, which 
represents the AgaE protein structure, there are total of 398 residues in the protein 
chain and 354 of the residues contain some atoms that are exposed to the surface. 
The solvent accessible area for this protein is 16650 Å2, with solvation energy for 
folding (∆G) of -382.4 Kcal/mol. 
The PISA server revealed that the most extensive crystal packing occurs between 
AgaE molecules related to each other by a 2-fold screw axis of symmetry (Figure 
5.5).  This interface is formed by residues in α2, the loop between α2 and β3, α3 and 
the loop between β10 and α13 of the N-terminal domain, packing against residues 
from α1, α14 and α16 from the N-terminal domain and α12 from the C-terminal 
domain of the symmetry related molecule.  
A total of 15 residues from one molecule and 19 residues from the other are involved 
in the interface (Figure 5.6 a). The average interface area was calculated by PISA to 
be approximately 500 Å2, which represents 3% of the total surface area. This lies 
outside the normal buried surface area of protein oligomers (5-25%) [138] and 
therefore, AgaE most likely occurs as a monomer. This is in good agreement with 
results from gel filtration (section 4.3.5), where AgaE elutes as a monomeric species.   
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(a) 
 
(b) 
Figure 5.5 Cartoon representations of AgaE molecules packing in the crystal. a) A 
cartoon representation of the most extensive interface seen in the crystal packing of AgaE. b) 
A ribbon representation of both molecules with residues involved in the interface [137]. 
Figures were produced using Pymol [98]. 
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(a) 
 
(b) 
  
Figure 5.6 Cartoon representations of the residues involved in AgaE crystal interface. 
a) Residues that are involved in the interface between two subunits in the AgaE structure 
(raspberry) and its symmetry related molecule (pink). b) Residues that were predicted to 
form potential hydrogen bonds between the two monomers are shown as sticks. Results were 
predicted using PISA server [137]. Figures were produced using Pymol [98]. 
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Table 5.1 Accessibility and buried surface areas of residues on the monomer –monomer 
interface. 
 
Residues in monomer 1 Residues in monomer 2 Bond distance (Å) 
GLN 105[NE2] GLN 339[OE1] 3.06 
LYS 315[NZ] SER 279[OG] 2.79 
ARG 82[O] GLN 339[NE2] 3.00 
GLY 84[O] LYS 362[NZ] 2.98 
 
Table 5.2 The unique hydrogen bonds formed between the two monomers in the 
crystal. 
 
Residue Accessible surface 
area (Å2) 
Monomer I 
Buried surface 
area (Å2) 
Accessible surface 
area (Å2) 
Monomer II 
Buried surface 
area (Å2) 
ASP 41 118 - 118 14.5 
THR 42 83 - 83 47 
GLU 45 117 - 117 85.8 
ALA 46 4 - 4 3.4 
LYS 48 96 - 96 12.8 
GLY 49 39 - 39 16.9 
ASP 52 67 - 67 15.3 
GLN 53 63 - 63 25.3 
PRO 59 109 - 109 4.6 
VAL 81 26 9.5 26 - 
ARG 82 230 103 230 - 
GLY 83 63 41.5 63 - 
GLY 84 68 58.2 68 - 
SER 85 72 20.5 72 - 
ALA 86 9 0.37 9 - 
LYS 102 123 10.6 123 - 
ILE 103 7 - 7 - 
PRO 104 119.3 87.2 119.3 - 
GLN 105 77.4 62.5 77.4 - 
SER 276 80.5 - 80.5 6.3 
SER 279 96.1 - 96.1 27 
ASP 311 57.1 45.3 57.1 - 
ASN 312 44.4 20.3 44.4 - 
GLY 313 38 13.2 38 - 
ASP 314 119.2 12.2 119.2 - 
LYS 315 155.4 40.1 155.4 - 
ARG 316 86.3 27.2 86.3 - 
GLU 331 119.5 - 119.5 27 
GLN 332 15 - 15 2.5 
VAL 333 11.4 - 11.4 - 
LYS 334 76 - 76 - 
ALA 335 27 - 27 15 
LEU 338 57 - 57 38.3 
GLN 339 100 - 100 70 
GLN 358 102 - 102 34.0 
LYS 362 176 - 176 90.0 
LYS 425 234.5 5 234.5 5 
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5.3 Structure comparisons  
5.3.1 Functional prediction 
As the structure appeared to indicate that AgaE may well bind a small molecule in 
the cleft between the two domains, the structure was compared to others in the 
database to gain clues on possible function.  Therefore, the refined model of AgaE 
was submitted to the Dali server [139] to identify proteins with a similar 3D structure 
and also with known function. The Dali search revealed several hits with high Z-
scores, but each had low sequence identity (Table 5.3). These hits revealed that AgaE 
shares a similar structure with ABC sugar transporter proteins from several 
organisms, with the highest agreement with the Maltose binding protein from the 
phytopathogen Xanthomonas citri (PDB_code 3UOR; Z score 42.6; r.m.s.d. ≈ 2.1 Å 
for 356 of Cα-atoms), the Acarbose/Maltose binding protein from Streptomyces 
glaucescens (PDB_code 3K01; Z score 39.8; r.m.s.d. ≈ 1.9 Å for 336 of Cα-atoms), 
the cyclo/maltodextrin binding protein from Thermoactinomyces vulgaris 
(PDB_code 2ZYO; Z score 39.8; r.m.s.d. ≈ 3.0 Å for 319 of Cα-atoms), the 
trehalose/maltose-binding protein from Thermococcus litoralis  (PDB_code 1EU8; Z 
score 39.2; r.m.s.d. ≈ 2.9 Å for 334 of Cα-atoms) and the maltose-binding protein 
(MBP) (PDB_code 3MBP; Z score 39.8; r.m.s.d. ≈ 2.3 Å for 339 of Cα-atoms) [140-
143]. The AgaE structure is also similar to other solute binding proteins, such as 
sperimidine and putrescine binding domains from Streptococcus pneumonia 
(PDB_code 4EQB; Z score 23.7; r.m.s.d. ≈ 3.1 Å for 284 of Cα-atoms) 
(unpublished). In addition, other enzymes share a similar fold, such as thiaminase I 
from Bacillus thiaminolyticus (PDB_code 2THI; Z score 24.5; r.m.s.d. ≈ 3.4 Å for 
283 of Cα-atoms) [144]. 
Taken together, these structural similarities indicated that AgaE is most likely a 
solute binding protein. Therefore, The sequences of the protein that formed the top 
hits with AgaE in the Dali search were aligned with that of AgaE based on the 
structural similarity of these proteins (Figure 5.7). Each of these proteins contains 
approximately 420 residues, yet only 20 are strongly conserved across the family. 
These residues were plotted on the structure of AgaE (Figure 5.8), where it can be 
seen they are dispersed across the structure and indicate that these residues probably 
play a structural role in defining the fold of the protein family.  
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Table 5.3 Results of Dali search using the model of the putative sugar binding protein 
Mseg_0515 (AgaE).  The first 15 hits are listed based on the highest Z-score, RMSD score 
and sequence identity respectively. Although the AgaE structure shares similar structure to 
these proteins, the sequence identity is very low.  
  
 
 
 
 
 
 
   
Protein  PDB Z-
Score 
RMSD Seq. 
identity  % 
Substrate Organism 
MalE 3uor 42.6 2.1 21 Maltose Xanthomonas citri 
GacH 3k01 39.8 1.9 27 Acarbose & 
Maltose 
Streptomyces 
glaucescens 
TvuCMBP 2ZYO 39.8 3.0 21 Cyclo & 
maltodextrin 
Thermoactinomyces 
vulgaris 
TMBP 1EU8 39.2 2.9 23 Trehalose Thermococcus 
litoralis 
MalE 4HW8 39.1 2.6 23 PEG Staphylococcus 
aureus 
MalE 2GHB 38.6 2.8 22 Maltose Thermotoga 
maritima 
MalE 3PUY 36.0 2.5 20 Maltose  Escherichia coli K-
12 
MalX 2XD2 36.0 2.4 20 Maltopentaose 
 
Streptococcus 
pneumoniae 
GL-BP 2Z8F 31.9 3.3 18 Galacto-N-
biose-/lacto-N-
biose. 
Bacillus subtilis 
ttGBP 2B3B 29.1 4.2 16 Glucose  Bacillus subtilis 
MalE 3MBP 33.0 2.3 21 Maltose and 
maltotriose 
Escherichia coli K-
12 
MalE 3KJT 35.9 2.4 21 Maltose  Escherichia coli K-
12 
MalE 1URS 33.6 3.5 25 Maltose  Alicyclobacillus 
acidocaldarius 
PotD 4EQB 24.2 3.1 12 Spermidine & 
Putrescine. 
Streptococcus 
pneumoniae 
Thiaminase 2THI 24.9 3.4 12 2,5-Dimethyl-
pyrimidin-4-
ylamine 
Bacillus 
thiaminolyticus 
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AgaE          1  MI----RRWLCLAVVTAVACLLTACGGGSS---------SSGPVEIAVWHGYQDTEGEAFKGLIDQYNKE   57 
GacH          1  MR----RGIAATALFAAVAMTASACGGGDNGGSGTDAGGTELSGTVTFWDTSNEAEKATYQALAEGFEKE   66 
MalE          1  MKIKTGARILALS--ALTTMMFSASALA-----------KIEEGKLVIWING-DKGYNGLAEVGKKFEKD   56 
RafE          1  MEWYKKIGLLATT--GLALFGLGACSNYGK--------SADGTVTIEYFNQK-KEMTKTLEEITRDFEKE   59 
EcoUgpB       1  MKPL---HYTASA----LALGLALMGN------------AQAVTTIPFWHSMEGELGKEVDSLAQRFNAE   51 
MtbUgp        1  MDPLNRRQFLALA--AAAAGVTAGCAGMGGGGS-----VKSGSGPIDFWSSHPGQSSAAERELIGRFQDR   63 
Consensus_aa:    Mc......hhAht..shhhh.htttts.............p.ssplshWps...p...shp.lhppFpc- 
Consensus_ss:         hhhhhhhh  hhhhhhhhh                  eeeeeeee   hhhhhhhhhhhhhhhhh 
 
AgaE        58  HPDVHVTDLYSS--NDLVLQKVLTAVRG-GSAPDVAYMF--GSWSPNIAKIPQVVDMSDVVSQSDW--NW  120 
GacH        67  HPKVDVKYVNVP--FGEANAKFKNAAGGNSGAPDVMRTE--VAWVADFASIGYLAPLDGTPALD----DG  128 
MalE        57  T-GIKVTVEHPD----KLEEKFPQVAAT-GDGPDIIFWA--HDRFGGYAQSGLLAEITPDKAF------Q  112 
RafE        60  NPKIKVKVVNVP----NAGEVLKTRVLA-GDVPDVVNIYPQSIELQEWAKAGVFEDLSNKDY-------L  117 
EcoUgpB     52  NPDYKIVPTYKG-NYEQNLSAGIAAFRT-GNAPAILQVY--EVGTATMMASKAIKPVYDVFKEAGIQFDE  117 
MtbUgpB     64  FPTLSVKLIDAGKDYDEVAQKFNAALIG-TDVPDVVLLD--DRWWFHFALSGVLTALDDLFGQVGV--DT  128 
Consensus_aa:   pPplcVp.h.ss....ph.p.h.shh.s.tshPDlh.h......h.phA..shl.slss...b....... 
Consensus_ss:       eeeeee    hhhhhhhhhhhhh      eeeee    hhhhhhhh   ee   hhhhh      h 
 
AgaE       121  DDFYPAEREAAT--VGDKIVGIPALVDNLAIVYNKKLFADAGIAPPTADWTWDDFRAAAAKLTDPAKGQY  188 
GacH       129  SDHLPQAAASTR--YEGKTYAVPQVIDTLALFYNKELLTKAGVE---VPGSVAELKTAAAEITEKTG-AT  192 
MalE       113  DKLYPFTWDAVR--YNGKLIAYPIAVEALSLIYNKDLLPN-------PPKTWEEIPALDKELKAKGK--S  171 
RafE       118  KRVKNGYAEKYA--VNEKVYNVPFTANAYGIYYNKDKFEELGLK---VPETWDEFEQLVKDIVAKGQ--T  180 
EcoUgpB    118  SQFVPTVSGYYSDSKTGHLLSQPFNSSTPVLYYNKDAFKKAGLDPEQPPKTWQDLADYAAKLKASGM-KC  186 
MtbUgpB    129  TDYVDSLLADYE--FNGRHYAVPYARSTPLFYYNKAAWQQAGLP-DRGPQSWSEFDEWGPELQRVVG-AG  194 
Consensus_aa:   schhs.h...hp..hss+hhthPhh.shslhYNKchh.phGl....sPboWp-h..hs.clp..s...s 
Consensus_ss:   hh  hhhhhh       eeeeeeeeeeeeeeeeehhhhhh           hhhhhhhhhhhhh       
 
 
AgaE       189  GWLIPADGSE-DTVWHYVPMLWEAGGDI------LTPD------NEKAAFNSEAGVTALTMLQDMAVTDK  245 
GacH       193  GLYLRGD-----DPYWFLPYLYGEGGDL------VDEK------NKTVTVDDEAGVRAYRVIKDLVDSKA  245 
MalE       172  ALMFNLQ-----EPYFTWPLIAADGGYA------FKYENGK-YDIKDVGVDNAGAKAGLTFLVDLIKNKH  229 
RafE       181  PFGIAGADAWTLNGYNQLAFATATGGGKEANQYLRYSQ------PNAIKLSDPIMKDDIKVMDILRINGS  244 
EcoUgpB    187  GYASGWQ-----GWIQLENFSAWNGLPF------ASKNNGFDGTDAVLEFNKPEQVKHIAMLEEMNKKGD  245 
MtbUgpB    195  RSAHGWANAD-LISWTFQGPNWAFGGAY------SD--------KWTLTLTEPATIAAGNFYRNSIHGKG  249 
Consensus_aa:   shhhs........s@.hbsh.h..GGsh.......p.p........sl.hsp.....shphhpph..s.. 
Consensus_ss:   eeee         hhhhhhhhhhh                            hhhhhhhhhhhhhhh    
 
 
AgaE       246  SLY--LDTTNENGPKLMNSGKVGMLITGPWDLSQLSDID-----YGVQVMPTFAGSS---GAHQTISGPD  305 
GacH       246  AIT-DASDGWNNMQNAFKSGKVAMMVNGPWAIEDVKAGARFKDAGNLGVAPVPAGSA---GQGS-PQG-G  309 
MalE       230  MNA---DTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK-----VNYGVTVLPTFKG---QPSKPFVG-V  287 
RafE       245  KQKNWEGAGYTDVIGAFARGDVLMTPNGSWAITAINEQKP---NFKIGTFMIPGKEK---GQSLTVGAGD  308 
EcoUgpB    246  FSY---VGRKDESTEKFYNGDCAMTTASSGSLANIREYAK----FNYGVGMMPYDADAKDAPQNAIIG-G  307 
MtbUgpB    250  YA-----AVANDIANEFATGILASAVASTGSLAGITASAR----FDFGAAPLPTGPD---AAPACPTG-G  306 
Consensus_aa:   ......sss.sp....F.pGchtMhhsts.tlsslp........hshGhh.hPh..s...t...s..G.s 
Consensus_ss:            hhhhhhhhh   eeeeee hhhhhhhhh         eeeeee            eee    
 
 
 
AgaE       306  NWVVFDNG--DKRKQASIDFVKWLTAPEQVKAFSLQTGDLPTRSSVGDDQAVRDQLDQKLPGSSVFVENL  373 
GacH       310  WNLSVYAG--SKNLDASYAFVKYMSSAKVQQQTTEKLSLLPTRTSVYEVPSV-----ADNEMVKFFKPAV  372 
MalE       288  LSAGINAA--SPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEEL-----AKDPRIAATMENA  350 
RafE       309  LAWSISAT--TKHPKEANAFVEYMTRPEVMQKYYDVDGSPTAIEGVKQA--------GEDSPLAGMTEYA  368 
EcoUgpB    308  ASLWVMQGKDKETYTGVAKFLDFLAKPENAAEWHQKTGYLPITKAAYDLTREQGFY-EKNPGADTATRQM  376 
MtbUgpB    307  AGLAIPAKLSEERKVNALKFIAFVTNPTNTAYFSQQTGYLPVRKSAVDDASERHYL-ADNPRARVALDQL  375 
Consensus_aa:   hshsl.ss..pcpbp.t..Flc@hh.sc...bh.ppst.Lsh.pth.p..p.......css.h.hhhc.h 
Consensus_ss:   eeeeee       hhhhhhhhhhhh hhhhhhhhhh       hhhh  hhh hhh h  hhhhhhhhhh 
 
  
AgaE        374  NNAKKARPA-----VEQYPAISEALGQAIVAVMLGKEQPAAALNSAAEAADSALAGK---------  425 
GacH        373  DKAVE-RPW-----IAEGNALFEPIRLQMANVLSGETSPDEAAANTGDAYRKLLKDYK--------  424 
MalE        351  QKGEI-MPN-----IPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITK--------------  396 
RafE        369  FTDRH-LVW-----LQQYWTSEADFHTLTMNYVLTG-DKQGMVNDLNAFFNPMKADVD--------  419 
EcoUgpB     377  LNKPP-LPFTKGLRLGNMPQIRVIVDEELESVWTGKKTPQQALDTAVERGNQLLRRFEKSTKS---  438 
MtbUgpB     376  PHTRTQDYA-----RVFLPGGDRIISAGLESIGLRGADVTKTFTNIQKRLQVILDRQIMRKLAGHG  436 
Consensus_aa:   .ps....sh.....l.phss....lp..h.shh.s.pssp.hhssh.p.hp.hb.c.......... 
Consensus_ss:    hh               hhhhhhhhhhhhhhhh     hhhhhhhhhhhhhhhhhh           
 
 
 
Figure 5.7 Structure - based alignment of AgaE and other ABC binding proteins with 
different bound substrates. Proteins were selected based on their substrate specificity and 
structure similarity with AgaE as following; maltose binding proteins GacH from 
S.glaucescens in complex with maltotetroase and acarbose, the MalE from E.coli in complex 
with maltooligosaccharides and acarbose, Raffinose binding protein (RafE) from 
S.pneumoniae and glycerol 3-phosphate binding proteins (UgpB) from E.coli and 
M.tuberculosis with bound G3P and glycerophosphocholine (GPC), respectively. The β-
strands and α-helices are represented as blue and red residues, respectively. Conserved 
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residues are highlighted and boxed. Consensus residues (aa) represents the highly conserved 
amino acid residues, which are shown as bold and uppercase letters as following; aliphatic 
residues (I, V, L): l, aromatic residues (Y, H, W, F): @, hydrophobic residues (W, F, Y, 
M, L, I, V, A, C, T, H): h, alcohol residues (S, T): o, polar residues (D, E, H, K, N, Q, R, 
S, T): p, tiny residues (A, G, C, S): t, small residues (A, G, C, S, V, N, D, T, P): s, bulky 
residues (E, F, I, K, L, M, Q, R, W, Y): b, and charged (D, E, K, R, H): c. Consensus 
secondary structure prediction (ss) are shown underneath the alignment as alpha-helix: h 
and beta-strand: e. This figure was created using PROMALS3D [145]. 
 
!
Figure 5.8 Highly conserved residues of different solute binding transporter mapped 
onto AgaE. b) The back view of (a) with a vertical rotation of Y=180° between the two 
views. The highly Conserved residues were identified from sequence alignment of different 
ABC transporter shown in figure 5.7, which were boxed and shaded. The structure is colored 
blue and highly conserved residues are in raspberry color.   
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5.3.2 Structure classification of solute binding proteins 
 The structure of AgaE shares overall structural similarity with other solute binding 
proteins. Each domain of this family contains a five stranded β-sheet surrounded by 
α-helices. Both domains are linked to each other by a hinge region, composed of two 
loops and an α-helix from both domains that controls the movement of the two 
domains, upon substrate binding in the cleft between them. The structures of Solute 
Binding Proteins have been classified into two groups [146]. The classification is 
based on the variation on the number of linkages (hinge) between the two domains, 
and the β-sheet topology of both domains.  The first class includes structures that 
have the β-sheet topology of β2β1β3β4β5, with the hinge region formed by three 
loops connecting both domains together. This class includes structures that bind 
monosaccharides, such as the Escherichia coli glucose/ galactose binding protein 
[146, 147]. The second class includes structures that have the β-sheet topology 
β2β1β3βnβ4 and the hinge region between the two domains is formed by two loops 
only. The beta strand βn of the second class corresponds to the interdigitating strand 
that occurs after the other domain has folded [148]. This class includes structures that 
bind di and oligosaccharides, such as the maltose binding protein of Escherichia coli 
[124, 149].  An additional domain was identified as class three of a solute binding 
protein, and in this class, the domains are joined by only one connecting linker, of an 
α-helix between both domains, such as the staphyloferrin binding protein (HtsA) 
from Staphylococcus aureus [146, 150]. 
 Solute binding proteins have also been classified into six groups (A-F) based on 
structural alignments of all crystal structures submitted into the protein data bank 
(PDB) and their substrate specificities [148]. The group A SBPs are ABC 
transporters belonging to class III of the Fukami-Kobayashi classification and are 
specific for metal binding, while group B members belong to class I SBPs and 
mainly bind carbohydrates. However, this group has also been found to bind other 
molecules such as amino acids [146]. The group C, D and F are all class II SBPs and 
bind different types of substrate, such as carbohydrates, iron and thiamine, however, 
both C and D groups have an extra domain and they are larger in size (class C > 55 
kDa and class D > 40 kDa) [148]. Also, the lengths of the hinge regions between the 
two domains are shorter in group D (4-5 amino acids) than in group F SBPs (8-10 
amino acids). Furthermore, group D SBPs was also subdivided into further three 
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subgroups based on the substrate binding specificity; subgroup I SBPs are 
carbohydrate specific, such as MBP from E.coli; subgroup II are thiamine and 
polyamine specific binding proteins, subgroup III are SBPs that bind phosphate, 
sulfate and oxyanion molecules and finally, subgroup IV includes those SBPs that 
are specific for ferric iron binding [148]. The last group of the SBPs classification is 
group E, which belongs to the TRAP transporters protein family.  
As the overall structure of AgaE resembles that of maltose binding protein structure 
from E.coli, which was categorized as a class II SBP belonging to group D-1 in the 
substrate specificity based classification, it can be suggested that AgaE is a 
carbohydrate binding protein belonging to class II substrate binding protein. 
 
Figure 5.9 structural alignment of AgaE structure and other sugar binding proteins. 
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5.3.3 Binding site of carbohydrate binding proteins 
In order to investigate the possible binding site of AgaE, the binding sites of the 
solute binding proteins were compared to identify any similar features that were also 
present in the AgaE structure. The binding pocket of a typical solute binding protein 
is located in the cleft in the interface between the two globular domains, that are 
linked to each other by the three-hinge regions, forming a bilobate structure [151]. 
Comparing the AgaE structure with other solute binding proteins, such as the 
maltose and acarbose binding protein from S.glaucescens (GacH) and the maltose 
binding protein (MalE) from E.coli revealed that all solute binding proteins interact 
with their different substrates with a similar mode of action. In all the protein / sugar 
complexes determined, the sugar moiety binds in the cleft between the two domains. 
Upon binding the sugar, the two domains move closer together, by up to 6.0 Å, to 
exclude bulk water and to allow residues from both sides of the cleft to interact with 
the sugar. The molecular surfaces of this family of proteins all exhibit a bilobal 
structure (Figure 5.10), however the electrostatic surface of the cleft varies between 
them, reflecting the variety of substrates bound (Figure 5.10). 
The binding sites of a number of different members of the solute binding proteins 
family were compared, and a number of similarities were seen across the family. 
These include residues that make direct and water mediated hydrogen bonds to the 
various ligands as well as other residues involved in van der Waals contacts [151].  
The number and type of these interactions depends upon the size of the solute bound. 
The protein with the closest structural similarity to AgaE is the solute binding protein 
(GacH) from S.glaucescens, which is the receptor of the putative oligosaccharide 
ATP binding cassette transporter (GacFG). GacH is an acarbose / maltose binding 
protein [141], and its structure in complex with maltotetroase (4 rings of α-D-
Glucopyranosyl sugar) and acarbose (a maltose bound to an acarviosin moiety) and 
5C (acarviosyl-1,4-maltose-1,4-glucose-1,4-glucose) have been determined by 
Vahedi-Faridi, Licht et al. 2010). As GacH binds four ring solutes, its structure forms 
a good template to identify possible sugar binding regions of AgaE. The overall 
structure of the open form GacH binding protein is superimposed very well with 
AgaE structure with a root-mean-square deviation (RMSD) of Cα position of 1.9Å 
despite the low sequence identity of 25% (Figure 5.11). Although both structures 
share the same fold, their secondary structures have slight variations in the number 
and length of α-helices and β-strands. For example, additional small α-helices are 
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found within the GacH binding protein structure corresponded to loops in AgaE 
structure, such as the loop that is located in between α12 and β10 [141]. Also, the 
two antiparallel β-strands present in the C-domain in AgaE are not conserved in all 
MBP structures and replaced by short α-helices in maltopentose binding protein 
(MalX) from S.pneumoniae (PDB_code 2XD2) [152]. Furthermore, the hinge region 
that connects the two domains of GacH consists of three loops and link two β-strands 
are longer than those found in AgaE hinge regions (7-10 and 4-5 residues long, 
respectively) and α-helix [141]. The structure of GacH in complex with acarbose is 
shown in figure 5.11. The binding is constructed form residues from the N-domain, 
the C-domain and the loops that joins the two domains. The residues from the N-
domain and the joining loop mainly form hydrogen bonds to the hydroxyls of the 
solute, wheras, those from the C-domain construct a hydrophobic surface that 
interacts with the sugar rings. 
 
 
   
 
GacH-open 
 
GacH-closed 
 
PfuMBP-closed 
 
MalE-open 
 
MalE-closed 
 
ttMtBP-closed 
 
 
MalX-open 
 
MalX-closed 
 
tlMBP-closed 
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RafE-open 
 
RafE-closed 
 
                                  
TvuCMBP-closed 
 
AgcH 
 
AgcH 
 
 
tlMBP-closed 
 
AgaE-open 
 
 
 
 
 
not available 
 
 
 
AgaE-closed 
 
                
tGBP-closed 
 
Figure 5.10 Surface electrostatic representation of the carbohydrate binding protein 
structures with different sugar bound. The surface electrostatic was calculated for both 
open and closed forms based on the structure available in the protein database. Positive 
charged residues are colored blue and negative charged residues are colored red, 
respectively. The putative Binding site is shown between the two domains. The figure was 
produced using Pymol [98]. !
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(a)
 
(b) 
 
Figure 5.11 Structural alignment of GacH sugar binding protein structure and AgaE 
structure. a) The overall structure of GacH binding protein (orange) is superimposed very 
well with AgaE structure (raspberry) with a root-mean-square deviation (RMSD) of Cα 
position of 1.9Å. The bound acarbose of GacH is shown in between the two domains as 
purple stick and binding residues from each structure as sticks. b) Stereo view of a. 
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5.3.3.1 Hydrophobic surface 
The C-domain residues Y182, W183, W243, W254 and F368 form a hydrophobic 
surface on one side of the cleft in GacH (Figure 5.12). The equivalent residues in 
AgaE (W202, H203, W273, Y386 AND P387, table 5.3), are also hydropobic and 
aromatic and form a surface with similar properties (Figure 5.12). 
 
 
 
(a) 
  
(b) 
Figure 5.12 Superposition of AgaE (raspberry) and GacH (orange) binding sites. a) The 
C-domain binding residues alignment of AgaE and GacH. b) Stereo representation of a. the 
bound sugar (acarbose) of GacH is shown as purple stick. 
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5.3.3.2 Hydrogen bond interaction  
In GacH, residues from the N-domain provide side chains that form hydrogen bonds 
with the hydroxyl substituents of the four rings acarbose solute. Residues E32 and 
R81 form hydrogen bonds to the 2-OH of the second ring, with the carboxyl of E83 
frming hydrogen bonds to both the 2-OH of the third ring. R358  interacts with the 2-
OH of the third ring and the Nε of W385 interacts with both the 2-OH and the 3-OH 
of the fourth ring. Both D133 and R358 are found on the loops that join the two 
domains.  
In the AgaE structure there are residues with equivalent position and functional 
groups to all of these acarbose hydrogen-bonding residues in the GacH structure 
(Table 5.4). In the AgaE structure the bound PEG molecule partially occupies the 
position of rings three and four of the acarbose in the GacH / acarbose complex, with 
S95 forming a hydrogen bond to the PEG. As both the hydrophobic surface and the 
hydrogen bonding residues are conserved in the AgaE structure and PEG binds in a 
similar position, it seems likely that a carbohydrate type solute may bind to AgaE. 
 
 
 
 
 
 
 
                                       
                a) Hydrogen binding residues         b) Hydrophobic binding residues 
 
Tables 5.4 Residues involved in the sugar binding of the GacH and MalE binding 
proteins and their equivalents in AgaE protein structure. A) Hydrogen binding residues. 
B) Hydrophobic binding residues 
       
 
 
 
 
 
 
GacH MalE AgaE 
E32-O1 D14-O2 E43 
R81-NH1 K15-N Y91 
E83-O1 & O2 D65-O1 & 
O2 
S95 
W86-NE1 R66-NE 
& NH2 
W96 
D133-O2 E111-O1 D145 
W290-N1 - D305 
R358-NH1 & 
NH2 
M330 R380 
GacH MalE AgaE 
Y182 Y155 W202 
W183 F156 H203 
W234 Y210 - 
W254 W230 W273 
F368 W340 Y386 
- Y341 P387 
- - - 
- - - 
- - - 
- - - 
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        (a)    
 
Figure 5.13 Superposition of AgaE (raspberry) and GacH (orange) binding sites. a) N-
domain (left) and C-domain (right) binding residues alignment of AgaE and GacH are shown 
as stick. b) Stereo of (a). Acarbose is shown as purple stick in between the two domains. 
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5.3.4 Sugar binding site in other proteins 
The analysis described above was extended to the protein typical solute binding 
protein MalE from E.coli. This protein binds maltose and maltodextrin and its 
structure has been determined in complex with acarbose [143] (PDB_code 3JYR). 
However, when this structure is superimposed on that of the GacH / acarbose 
complex, the acarbose moieties do not fully superimpose. Rings 2, 3, and 4 of the 
acarbose in GacH occupy the same space as rings 1, 2 and 3 of the acarbose in the 
MalE / acarbose complex, showing how this family of proteins could bind sugars 
with more rings than acarbose (Figures 5.14 and 5.15). In the MalE structure, D14 
and K15 occupy the equivalent space as the first ring of the acarbose in the GacH 
structure. The carboxyl of D14 in MalE coordinate the 1-OH of the first ring of 
acarbose and the amine of K15 hydrogen bonds to the 2-OH of the same ring. These 
residues do not have equivalents in GacH. Furthermore, the loop between helix (α1) 
in GacH where these residues occur is longer than that in MalE, providing more 
space for the acarbose to bind. However, in AgaE D41 lies in an equivalent position 
to D14 of MalE, and upon domain closure in AgaE, may well occupy a similar 
position. The hydrophobic surface described for GacH and AgaE is also present in 
MalE, being formed by residues Y155, F156, Y210, W230, W340 and Y341 
(Figures 5.14 and 5.15). Also, in MalE, a similar set of residues provide hydrogen 
bonding to the acarbose, as seen in GacH, but as the acarbose moiety is displaced by 
one ring, the precise interactions are different. Residues involved are D14, K15, R66, 
E44 and E111. There is no direct equivalent to R358 in GacH, with MET 330 
occupying this position in MalE (Table 5.4). 
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(a) 
 
(b) 
 
Figure 5.14 Superposition of AgaE (raspberry) and MalE (cyan) binding sites. a) N-
domain (left) and C-domain (right) binding residues alignment of AgaE and GacH are shown 
as stick. b) Stereo of (a). Acarbose is shown as brown stick in between the two domains. 
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(a) MalE 
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(b) GacH 
Figure 5.15 Ligplot diagram representation of the binding site interaction of GacH and 
MalE with the bound acarbose. Residues in both sites are invoved in direct and waters 
mediated  hydrogen bonds and hydrophobic interaction. Figures were created using LigPlot 
[153]. !!!
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5.4 Sugar binding proteins specificity 
This analysis extended to mono-di and oligosaccharides binding proteins that have a 
similar structure to AgaE. These include five different types of solute binding 
proteins, malto-oligosaccharide binding proteins including GacH, MalE, ttMtBP, 
PfuMBP, TvuCMBP and MalX, Trehalose binding protein (tlMBP), raffinose binding 
protein (RafE), glycerol 3 phosphate binding proteins (UgpB) and monosaccharide 
binding proteins ttGBP and AgcH. The aligned sequences for these proteins are 
shown in figure 5.16, with the residues that bind the carbohydrate boxed. In all these 
structures, the residues that form the binding site come from three areas, site I (N-
domain residues), site II (C-domain residues) and site III (loops between the 
domains). When these structures are compared to that of GacH and MalE, some 
indications about substrate specificity of this family can be made (Figures 5.17, 5.18 
and 5.19). The hydrophobic surface is conserved throughout proteins that bind 
maltooligosaccharides, but not those that bind other substrates. These residues are 
lying on α9, α11, α12 and α18 (Site III). Similarly, the residues that form hydrogen 
bonds are lying on β1, β3 and β10 and helices α1, α2 and α3 (site I) and have similar 
properties. For ttGBP and AgcH, which bind monosaccharide, the loop between α17 
and α18 (L3, site III) is longer and takes a different path to GacH. This occlude the 
rings two and three of acarbose, indicating that AgaE could bind oligosaccharides. 
For MtbUgpB and EcoUgpB, which both bind G3P, R377 from site II, would occlude 
the position of rings three and four of acarbose in GacH (Figure 5.18). The 
equivalent residues are on α18 in AgaE S390 and in GacH F368 but R380 from loop 
3 in AgaE occupies the same space as R377 of the G3P binding proteins, perhaps 
indicating that AgaE could bind G3P (Figure 5.13). In the raffinose (trisaccharides) 
binding protein (RafE), the first ring of the ligand occupies the space of F67 on α2 
(site I) in GacH; in addition, the loop between β2 and α2 is shorter in RafE, to 
provide space for the raffinose substrate. AgaE has a structure similar to GacH in this 
area, and therefore probably does not bind raffinose. In disaccharides trehalose 
binding protein tlMBP, R363 on L3 occupies the space of ring three of the acarbose 
in GacH. However, the equivalent residue in GacH and AgaE is also arginine, but 
this residue occupies a different position in the complex, and thus no definitive 
argument can be made for the specificity of AgaE for trehalose. Taken together, 
these analyses suggest that AgaE may well bind G3P or malto-oligosaccharides like 
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acarbose, however, due to the low sequence similarity between all the structures, this 
is far from certain.  
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!β1 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!α1 
AgaE    1 M---IRRWLCLAVVTAVACLLTACGGGS---SSSGPVEIAVWHGYQ--DTEGEAFKGLIDQYNKEHP-   59 
GacH    1 M----RRGIAATALFAAVAT---------GLSGTVTFWDTSNE------AEKATYQALAEGFEKEHP-   48 
3MBP    1 -------------------------------KIEEGKLVIWING----DKGYNGLAEVGKKFEKDT-    31 
ttmtBP  1 -----------------------------------MKITVWTHFG--GPELEWLKEQARTFERTS--    28 
TvuCMBP 1 -----------------CGPKRDPYAKAGKSEGKPDKLVVWENADD--GVQLNNTKKWAGEFTKKT--   47 
MAlX    1 MGSSHHHHHHSS-GLVPRGSHMASDKPADSGSSEVKELTVYVDE-----GYKSYIEEVAKAYEKEA--   60 
tlMBP   1 ---------------------------------IEEGKIVFAVGGA--PNEIEYWKGVIAEFEKKYP--  32 
RafE    1 MH---HHHHHLEV---------LFQ-------GPSSTVTIEYFNQK---KEMTKTLEEITRDFEKENP-  46  
EcoUgpB 1 -------------------------------GSHMVTTIPFWHSME---GELGKEVDSLAQRFNAENP-  34 
MtbUgpB 1 MDPLNRRQFLALAAAAAGVTAGCAGMGGGGSVKSGSGPIDFWSSHP---GQSSAAERELIGRFQDRFP-  65 
ttGBP   1 ----------------------------------MKLEIFSWWA----GDEGPALEALIRLYKQKYP----29 
AgcH    1 MGSSHHHHHHSS------GLVPRGSHMS---VSDGNGPITFGSNYSDEAPKAAFASLMQQATTST------56 
Consensus_ss:                                  eeeeee     hhhhhhhhhhhhhhhhh   
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!β2 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!α2 !!!!!!!!!!!!!!!!!!!!!!!β3        α3 !!!!!!!!!!!!!!!!!!!!!!!!!!!!α4     
AgaE    60 DVHVTDLYSS-NDLVLQKVLTAVRGG-SAPDVAYMF---GSWSPNIAKIPQVVDMSDVVSQSDWNWD   121 
GacH    49 KVDVKYVNVP-FGEANAKFKNAAGGNSGAPDVMRTE---VAWVADFASIGYLAPLDGTPALD----DGS 109 
MalE    32 GIKVTVEHPD-KLEEKFPQVAATG--DGPDIIFWA----HDRFGGYAQSGLLAEITPDKA----FQD    87 
ttmtBP  29 GTKVEVVEVP-FAEIKQKFILGAPQG-QAADLVVTVP--HDWVGEMAQAGVLEPVGKYVTQA--YLA    89 
TvuCMBP 48 GIQVEVVPVA-LLKQQEKLTLDGPAG-KGADLVTWP---HDRLGEAVTKGLLQPIQVDNS----VKN   105 
MalX    61 GVKVTLKTGD-ALGGLDKLSLDNQNG-NVPDVMMAP---YDRVGSLGSDGQLSEVKLSDGAK-----   117 
tlMBP   33 GVTVELKRQA-TDTEQRRLDL3VNALRGKSSDPDVFLMDVAWLGQFIASGWLEPLDDYVQKDNYDLSV  98 
RafE    47 KIKVKVVNVP-NAGEVLKTRVLAG--DVPDVVNIYPQSIELQEWAKAGVFEDLSNKDY-------LK   103 
EcoYgpB 35 DYKIVPTYKGNYEQNLSAGIAAFRTG-NAPAILQVY-EVGTATMMASKAIKPVYDVFKEAGIQFDES    99 
MtbUgpB 66 TLSVKLIDAGKDYDEVAQKFNAALIGTDVPDVVLLD-DRWWFHFALSGVLTALDDLFGQVG--VDTT   129 
ttGBP   30 GVEVINATVTGGAGVNARAVLKTRMLGG-DPPDTFQVHAGMELIGTWVVANRMEDLSALFRQEG-WLQ   95 
AgcH    57 TVPVTVNTTD-HNTFQNNISNYLQ-G-TPDSLATWFA-GYRLQFFAAQGLLTPIDDVWDKI----GGT  116 
 Consensus_ss:eeeeee   hhhhhhhhhhhhh      eeeee    hhhhhhhhh        hhhh     hh 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!α5 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!β4 !!!!!!!L1 !!!!!!!!!!β5 !!!!!α6 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!α7   !α8 
AgaE    122  DFYPAEREAAT--VGDKIVGIPALVD-NLAIVYNKKLFADAGIAPPTADWTWDDFRAAAAKLTDPAK  185 
GacH    110  DHLPQAAASTR--YEGKTYAVPQVID-TLALFYNKELLTKAGV---EVPGSVAELKTAAAEITEKTG  170 
MalE     88  KLYPFTWDAVR--YNGKLIAYPIAVE-ALSLIYNKDLLPN-------PPKTWEEIPALDKELKAKGK  144 
ttmtBP   90  DLQGVAVEAFT--FGGRLMGLPAFAE-SVALIYNKKYVKE-------PPRTWEEFLALAQKLTTGAT  146 
TvuCMBP 106  QFDDVAMKALT--YGGKLYGLPKAIE-SVALIYNKKLMGQ-------VPATYDELFQYAKANNKPDE  162 
MalX    118  TDDTTKSLVTA--ANGKVYGAPAVIE-SLVMYYNKDLVKD----APKTFADLENLAKDSKYAFAGED  177 
tlMBP    99  FFQSVINLADK--QGGKLYALPVYID-AGLLYYRKDLLEKYGYSKPPETWQELVEMAQKIQSGERETN 163 
RafE    104  RVKNGYAEKYA--VNEKVYNVPFTAN-AYGIYYNKDKFEELGL---KVPETWDEFEQLVKDIVAKGQ  164 
EcoUgpB 100  QFVPTVSGYYSDSKTGHLLSQPFNSS-TPVLYYNKDAFKKAGLDPEQPPKTWQDLADYAAKLKASGM  165 
MtbUgpB 130  DYVDSLLADYE--FNGRHYAVPYARS-TPLFYYNKAAWQQAGLP-DRGPQSWSEFDEWGPELQRVVG  192 
ttGBP    96  AFPKGLIDLIS--YKGGIWSVPVNIHRSNVMWYLPAKLKGWGV---NPPRTWDKFLATCQTLKQKG-  157 
AgcH    117  FNDAAKSLSKG--LDGHYYLVPLYNY-PWVVFYNKSVFQSKGY---EVPASWEAFIALARKMQSDGL  177 
Consensus_ss:  hhhhhh       eeeeeeeeee   eeeeeee hhhhhh           hhhhhhhhhhhhh       
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!β6 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!α9 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!α10 
AgaE    186 GQYGWLIPADGSED-TVWHYVPMLWEAGGDILTP----DNEKAAFNSEAGVTALTMLQDMAVTDKS  246 
GacH    171 ATGLYLRGD-----DPYWFLPYLYGEGGDLVDE-----KNKTVTVDDEAGVRAYRVIKDLVDSKAA  226 
MalE    145 SALMFNLQ------EPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHM  204 
ttmtB   147 FGFLYNIG-----DPYFNFGFFKAFGAENVFAKDAKGNLDPTKLLIGGEVGEKALQFIKDLRFKYNL 208 
TvuCMBP 163 QKYGVLFEAN----NFYYTYFLFAAKGAAVFKEQDGTLDPNEIGLNSPEAVQGMNEVQKWFTEARL  224 
MalX    178 GKTTAFLADWT---NFYYTYGLLAGNGAYVFGQ-NGKDAKDIGLANDGSIVGINYAKSWYEKWPK   238 
tlMBP   164 PNFWGFVWQGKQYEG-LVCDFVEYVYSNGGSLGEFK-DGKWVPTLNKPENVEALQFMVDLIHKYKI  227 
RafE    165 -TPFGIAGADAWTLNGYNQLAFATATGGGKEANQYLRYSQPNAIKLSDPIMKDDIKVMDILRINGSK 230 
EcoUgpB 166 ----KCGYASGWQ---GWIQLENFSAWNGLPFASKNNGFDGTDAVLEFNKPEQKHIAMLEEMNKKGDF226 
MtbUgpB 193 -AGRSAHGWANADLISWTFQGPNWAFGGAYS-------DKWTLTLTEPATIAAGNFYRNSIHGKGY  250 
ttGBP   158-EAPLALGE--NWT-QQHLWESVALAVLGPDDWNN---LWNGKLKFTDPKAVRAWEVFGRVLDCANK  217 
AgcH    178 -VPLAFADKDGWP-ALGTFDILNLRINGYDYHIK---LMKHEVPWTDPGVTKVFDQWRELAAYQQK  238 
Consensus_ss: eeee         hhhhhhhhhhh                       hhhhhhhhhhhhhhh     
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                                                  α11                    β7             α12                             β8               L2             β9 
AgaE     247  LY-LDTTNENGPKLMNSGKVGMLITGPWDLSQLSDID-----YGVQVMPTFAGSSG--AHQTISGP 305 
GacH     227  ITDASDGWNNMQNAFKSGKVAMMVNGPWAIEDVKAGARFKDAGNLGVAPVPAGSAG---QGSP-QG 288 
MalE     205  N--ADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSK-----VNYGVTVLPTFKGQ---PSKPFVG 261 
ttmtBP   209  VP-EGVDYGVADGAFKDGALAMILNGPWALGDYKKAK----VDFGIAPFPVPPGA-KNPWGPFLG  268 
TvuCMB   225  P--QSLKADTVNGLFKSGKVAAVINGPWAIKDYQAAG----INVGVAPLPKIDGK---DAQTFIG  281 
MalX     239 GMQDTEGAGNLIQTQFQEGKTAAIIDGPWKAQAFKDAK----VNYGVATIPTLPNG--KEYAAFGG  299 
tlMBP    228 SPPNTYTEMTEEPVRLMFQQGNAAFERNWPYAWGLHNADDSPVKGKVGVAPLPHFPGH-KSAATLG  293 
RafE     231 QKNWEGAGYTDVIGAFARGDVLMTPNGSWAITAINEQKP- -NFKIGTFMIPGKEKG--QSLTVGAG 293 
EcoUgpB  227  SY----VGRKDESTEKFYNGDCAMTTASSGSLANIREYA--KFNYGVGMMPYDADAKDAPQNAIIG 287 
MtbUgpB  251  ------AAVANDIANEFATGILASAVASTGSLAGITASA--RFDFGAAPLPTGPDA--APAC-PTG 306 
ttGBP    218  DA-AGLSWQQAVDRVVQGKAAFNIMGDWAAGYMTTTLKLKPGTDFAWAPSPGTQG------VFMML 277 
AgcH     239  GANGRTWQDAAKALENKQAGMMFQGSNQVAANYSAKN---LPDLDFFVFPAINPQ-YGTDYMDAP  300 
Consensus_ss:         hhhhhhhhh   eeeeee hhhhhhhhh         eeeee              eeee 
 
 
 
  
                               β10                    α13                 α14                              α15           α16               α17 
AgaE    306 DNWVVFDNGDKRKQASIDFVK-WLTAPEQVKAFSLQTGDLPTRSSVGDDQAVRDQLDQKLPGSSVFVEN 372 
GACH    289 GWNLSVYAGSKNLDASYAFVK-YMSSAKVQQQTTEKLSLLPTRTSVYEVPSV----ADNEMVKFFKPA  351 
MalE    262 VLSAGINAASPNKELAKEFLE-NYLLTDEGLEAVNKDKPLGAVALKSYEEEL----AKDPRIAATMEN  323 
ttmtBP  269 VQGVVVNAYSKNKTQAVNFAK-TLVTGRNLVAFNQAGGRIPVSKSAVKQL-----EKDPVVAGFSKV   328 
TvuCMBP 282 VKGWYLSAYSKYPKYATELMQ-FLTSKEALASRFKETGEIPPQKELLNDPMIK----NNPVVNGFAKQ  343 
MalX    300 GKAWVIPQAVKNLEASQKFVD-FLVATEQQKVLYDKTNEIPANTEARSYAEG----KNDELTTAVIKQ  361 
tlMBP   294 GWHIGISKYSDNKALAWEFVKFVESYSVQKGFAMNLGWNPGRVDVYDDPAVV----SKSPHLKELRAV  356 
RafE    294 DLAWSISATTKHPKEANAFVE-YMTRPEVMQKYYDVDGSPTAIEGVKQA-------GEDSPLAGMTEY  352 
EcoUgpB 288 GASLWVMQGKDKETYTGVAKFLDFLAKPENAAEWHQKTGYLPITKAAYDLTREQGFYEKNPGADTATRQ 355 
MtbUgpB 307 GAGLAIPAKLSEERKVNALKFIAFVTNPTNTAYFSQQTGYLPVRKSAVDDASERHYLADNPRARVALDQ 374 
ttGBP   278 SDSFGLPKG—AKNRQNAINWLR---LVGSKEGQDTSNPLKGSIAARLDSDPS-KYNAYGQSAMRD     336 
AgcH    301 TDGFILPKKGKNAAAAKKVLQ--YIGTAEAEAAFLKTDHWDVGLANGLIAP----TYNDIQKKSVAE   360 
Consensus_ss: eeeeee       hhhhhhhhh hhh hhhhhhhhhh    hhhh  hhh     h  hhhhhhhhh 
 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!L3!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!α18 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!α19 
AgaE    373 LNNAKKARPA-VEQ----YPAISEALGQAIVAVMLGKE--QPAAALNSAAEAADSA-LAGK-------  425 
GacH    352 VDKAVE-RPW-IAE----GNALFEPIRLQMANVLSGET--SPDEAAANTGDAYRKL-LKDYK------  405 
MalE    324 AQKGEI-MPN-IPQ----MSAFWYAVRTAVINAASGRQ--TVDEALKDAQTRITK-------------  370 
ttmtBP  329  FPLGAP-MPN-IPE---MGKVWGPWGNAISLAIQRPD-SNVKKIVEDMVAEIKKA-IGRHHH---HH  385 
TvuCMBP 344  ASKGVP-MPS-IPE---MGVVWEPINNAHTFVAQGKQ--TPEQALNDAVKIMKEK-IQTMKQ-----  397 
MalX    362 FKNTQP-LPN-ISQ----MSAVWDPAKNMLFDAVSGQK--DAKTAANDAVTLIKET-LKQKFGE----  416 
tlMBP   357 FENAVP-RPI-VPY----YPQLSEIIQKYVNSALAGKI--SPQEALDKAQKEAEEL-VKQYS------  409 
RafE    353 AFTDRH-LVW-LQQ----YWTSEADFHTLTMNYVLTG---DKQGMVNDLNAFFNPM-----KM-----  401 
EcoUgpB 356 MLNKPP-LPFTKGLRLGNMPQIRVIVDEELESVWTGKK-TPQQALDTAVERGNQL-LRRFEKSTKS--  418 
MtbUgpB 375 LPHTRT-QDY-ARVF--LPGGDRIISAGLESIGLRGA--DVTKTFTNIQKRLQVI-LDRQIMRK-LAG  434 
ttGBP   337 WRSNRI-VGS-LVHGAVAPESFMSQFGTVMEIFLQTR--NPQAAANAAQAIADQVGLGRLGQHH-HHH  399 
AgcH    361 IGKCKS-VSQ-FMERD-TVPDMANAMIKLIQQFIDQPTPETIATVQKSAEDQAKTI-FR---------  415 
Consensus_ss:hh                hhhhhhhhhhhhhhhh       hhhhhhhhhhhhhhh hhhh          
 
 
 
Figure 5.16 Sequence alignments of AgaE and other carbohydrate binding proteins.  
Residues that are involved in sugar binding are green highlighted; malto-oligosaccharide 
binding proteins are GacH, MalE, ttmtBP, TvuCMBP and MalX, trehalose binding protein 
(tlMBP), raffinose binding protein (RafE), glycerol 3-phosphate (UgpB) and 
monosaccharide binding protein (ttGBP and AgcH). This figure was created using 
PROMALS3D [145]. 
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Figure 5.17 Superposition of AgaE and TvuCMBP binding sites. a) An overview picture 
of the binding residues of AgaE  (raspberry) and TvuCMBP (gray) alignment. b) The 
binding site of M.smegmatis AgaE (left) and Thermoactinomyces vulgaris TvuCMBP (right) 
shown in the same orientation. !!!!!!
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(a) 
 
 (b) 
Figure 5.18 Superposition of AgaE and EcoUgpB binding sites. a) An overview picture 
of the binding residues of AgaE  (raspberry) and UgpB closed form (brown). b) The binding 
site of M.smegmatis AgaE (left) and E.coli UgpB (right) shown in the same orientation. 
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Figure 5.19 Superposition of AgaE and ttMtBP binding sites. a) An overview picture of 
the binding residues of AgaE  (raspberry) and ttMtBP closed form (green). b) The binding 
site of M.smegmatis AgaE (left) and Thermus thermophilus ttMtBP (right) shown in the 
same orientation. 
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Chapter 6 
 
AgaE – sugar complex  
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6.1 Introduction 
As the structural analysis described in chapter five suggested that AgaE may well 
bind a mono or oligosaccharide substrate, a number of different experimental 
techniques were used to try and discover the substrate of AgaE. These included 
tryptophan florescence, circular dichroism (CD) assays and co-crystallization. For 
each of these experiments a large variety of different possible ligands were 
investigated, as the structural analysis were by no means certain in identifying 
possible substrates.  
6.2 Binding Assays 
6.2.1 Tryptophan Fluorescence Spectroscopy  
In order to gain a clear idea of the potential rational substrate that binds to AgaE 
active site, tryptophan fluorescence was performed using 16 different sugars. This 
assay will help to detect any interaction that might occur between AgaE and any 
sugar, by measuring the alteration in the intrinsic fluorescence of the AgaE 
tryptophan residues, which produce a high signal when excited at a wavelength of 
280 nm - 295 nm excitation.  The tryptophan emission fluorescence depends on the 
surrounding solvent. For example, a decrease in the polarity in the solvent 
surrounding the tryptophan will result in a lower wavelength and an increase in the 
intensity of the fluorescence emission spectrum. Other aromatic residues also can 
produce fluorescence signals, such as tyrosine and phenylalanine. However, the 
emissions of these two residues are measured at lower wavelength 274 nm and 257 
nm, respectively.  
 
6.2.2 Methodology  
The Cary Eclipse fluorimeter (Varian Ltd, UK) was used to measure the change in 
UV fluorescence of the intrinsic AgaE tryptophan residues. As binding of a sugar in 
the family of proteins usually results in the two domains moving closer together, it 
was hoped that this movement may give rise to a change in tryptophan fluorescence. 
The AgaE protein sequence contains 12 tryptophan and 11 tyrosine residues, 
respectively. The UV fluorescence of AgaE was measured using a spectrophotometer 
cuvette containing 0.2 µM protein in 3 volumes of a solution of 10 mM Tris-HCl 
buffer pH 7.4 at 30°C. The AgaE excitation was measured at 280nm with a cut of 5 
nm width and an emission wavelength of 300-400nm with a slit width of 20 nm. 
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AgaE had a maximum emission at about 370 nm with a 280 nm excitation. Then, 2 µM and 6 µM of each ligand, respectively, was added to the 3-volume solution 
containing 0.2 µM protein in similar buffer and the titration was measured with a 5 
nm and 20 nm window for excitation and emission, respectively.  
 
6.2.3!Results!!
The binding affinity for each sugar was tested separately. The sugars tested are 
shown in table 6.1. However, there was no indication of any ligand-protein 
interaction with all components that have been examined, as there was no change in 
the fluorescence emission of any of them. !!
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Figure 6.1 Traces of tryptophan fluorescent assay.!A the 0.2mM AgaE in Tris –HCL pH 
8.0 buffer, was excited at 280 nm, however, no emission was obtained upon sugar added. 
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6.3 Circular dichroism (CD) 
An alternative method was thus employed, to try to measure ligand binding. The 
alteration in the secondary structure of a protein can be measured using Circular 
dichroism (CD), which is produced by the interaction between protein molecules and 
UV circularly polarized light. As proteins are chiral molecules they absorb left and 
right circularly polarized light differently [154]. Furthermore, the presence of 
secondary structure (α-helices, β-sheets, turns) in the protein will produce a distinct 
CD signal [154]. Therefore, the alteration of the circular polarized light between left 
and right hands upon ligand binding are measured and this can result in a different 
CD signal as the protein structure changes on ligand binding.  The CD spectrum of a 
protein is usually determined at a wavelength and ellipticity length scales appropriate 
to measure the new signal form the complex. 
6.3.1 Methodology 
The CD spectrophotometer (Jasco 715 model) was used to test the binding affinity of 
AgaE with several mono, di and oligosaccharides. The CD machine is provided with 
temperature cooler, nitrogen gas cylinder and sample changer. The output data was 
processed using an attached computer. The protein sample was prepared in a 
solution, which had no intrinsic CD signal at the wavelength used (250-190 nm). The 
protein and buffer concentrations were adjusted in order to produce a good signal. 
Therefore, 2UM of AgaE protein was prepared in 4ml of 2mM Tris-HCL buffer pH 
8.0 only. For each cycle of protein-sugar binding affinity experiment, data were 
collected in the presence and absence of a single sugar at different concentrations. 
Thus, 190Ul of AgaE solution was added to a 1.0 mm cuvette and incubated for 30s 
before data collection. Then, a sugar of different concentrations (0.03, 1.0, 5.0 and 50 
mM) was added into the protein solution and data was collected again. The CD 
signal was measured between 210 nm and 222 nm and at a temperature of 20+/-
0.5˚C, CD speed time 50 nm/min with one spectrum accumulation.  
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6.3.2 CD Data analysis 
Circular dichroism spectroscopy has been used to obtain information on the protein-
ligand interaction by measuring the change in the environment of protein structure 
upon adding sugar in the solution. Firstly, the results revealed no significant 
indication upon adding 5 mM sugar concentration of the monosaccharide, such as 
glucose, galactose, xylose, and rhamnose, which suggest that AgaE is not a 
monosaccharide binding protein (Figure 6.3). Therefore they were not included in 
the lower concentration CD measurements. Secondly, binding of AgaE with tri or 
oligosaccharides, such as stachyose, verbascose, lactose, raffinose, and 
maltooligosaccharides, such as maltotriose, maltotetroase and maltohexoase, also 
show no significant change in the CD spectrum. However, raffinose does show some 
interaction with AgaE in only high concentration of sugar (50mM) (Figure 6.3).  
Furthermore, disaccharide sugars, such as maltose, trehalose, cellobiose and 
mellibiose, have been also attempted to measure their binding affinity to AgaE 
structure, and results revealed that AgaE structure conformation has been highly 
changed due to the addition of maltose more than other disaccharides. As the highest 
peak was indicated for maltose in 5mM sugar concentration followed by the CD 
signal peaks for glycerol 3-phosphate and acarbose, respectively, within the same 
concentration. To sum up, the results of CD experiment were performed first in 5mM 
sugar and the suspected binding sugar were attempted again in lower concentration 
(0.03mM) for higher affinity sugars, however, the CD signals from lower 
concentration sugar added were not significant as the 5 mM concentration, which 
caused a significant change in the structure occurred by adding 5mM maltose and 5 
mM glycerol 3-phosphate (Figure 6.2).  
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Figures 6.2 The CD spectrum of AgaE only and in complex with 5mM maltose, 
acarbose and glycerol 3-phosphate. None of these sugars showed any indication of binding 
to the protein. 
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Figure 6.3 The CD spectrum representation of the AgaE in complex with different 
sugar concentrations 0.3 mM, 1mM, 5mM and 50 mM at 222 nm intensity. Alteration in 
the spectrums was observed with two sugars glycerol 3 phosphate and maltose of 5 mM 
concentration. 
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6.4 AgaE – sugar complex 
6.4.1 Co-crystallization of AgaE with sugar  
The structural comparison of AgaE with other solute binding proteins revealed that 
AgaE is likely to be a carbohydrate binding protein of the ABC transporter family. 
Therefore, attempts to co-crystallize AgaE with the most likely sugars were 
performed in order to determine the structure of AgaE with its bound sugar. AgaE 
protein was expressed and purified as described in section 4.3. A total protein 
concentration of 10 mg/ml was prepared in 10 mM of Tris-HCL buffer, pH 8.0 for 
co-crystallization experiment as described in section 4.4. The Hydra II robot with 
commercial crystallization screens (PACT, JCSG, PEG, Ammonium sulfate and 
Classic) was used to crystallize AgaE in presence of 50 mM and 300mM 
concentrations of various sugars. All plates were incubated at 17˚C.  
 
6.4.2 Crystallization results 
The identification of successful hits was carried out by viewing each drop under a 
microscope. The crystallization plates were viewed after 24 hours, 3 days and 7 days 
of crystal growth. After 3 days of incubation, the AgaE protein started to form 
crystals under a number of different conditions in all screens. The trays were then 
left to equilibrate further, and the crystals grew bigger. (Tables 6.1 and 6.2) 
6.4.3 Data collection and processing of co-crystallized AgaE 
For each different potential AgaE complex, a single crystal was briefly washed in a 
cryoprotectant consisting of 25% ethylene glycol in the crystallization buffer and 5 
mM added sugar, flash cooled to 100 K and stored in liquid nitrogen prior to data 
collection on the Diamond synchrotron light source. Crystals grown from the AgaE –
G3P complex, were washed in 50% of glycerol instead of ethylene glycol. 
Data were collected at the Diamond light source in Oxford (I03 beam line) as 
described in section 4.4.5 (Table 6.3). All datasets were processed using the Xia2 
software at diamond and structures were determined using the molecular replacement 
method. The wild type AgaE model was used as a search model in the Phaser 
program [83].  
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6.4.4 Structure determination and analysis 
All structures were rebuilt with several rounds of refinement cycles, after adding 
water molecules, ethylene glycol and PEG molecules to the related electron density 
in the map of each structure using Coot and Refmac5 [134]. However, there was no 
indication for any sugar bound in the cleft of the protein as no electron density for a 
potential ligand could be observed in this region. In addition, all structures had the 
same cell dimensions as the apo AgaE structure, and were all in a similar 
conformation. 
AgaE sugar 
complex 
Crystal  Crystallization condition Resolution (Å) 
AgaE-glucose 
 
JCSG-D12 (0.04 M Potassium 
phosphate, 16% PEG 8000, 20% 
Glycerol)/ JCSG-H8 (0.2 M Na 
chloride, 0.1 M bis-Tris pH 5.5, 25 % 
PEG 3350 
1.24/2.2 
AgaE-galactose 
 
JCSG-B9 (0.1 M citric acid pH 5, 
20% PEG 6000 
1.54 
AgaE-fructose 
 
JCSG-B9 (0.1 M citric acid pH 5, 
20% PEG 6000 
1.41 
AgaE-fucose 
  
JCSG-B9 (0.1 M citric acid pH 5, 
20% PEG 6000 
1.37 
AgaE-Ribose 
 
JCSG-H8 (0.2 M Na chloride, 0.1 M 
bis-Tris pH 5.5, 25 % PEG 3350 
1.44 
AgaE- maltose 
 
JCSG-D12 (0.04 M Potassium 
phosphate, 16% PEG 8000, 20% 
Glycerol 
1.38 
AgaE-maltotriose  
 
 
 
   
 
JCSG-D12 (0.04 M Potassium 
phosphate, 16% PEG 8000, 20% 
Glycerol 
1.37 
AgaE-maltotetroase 
       
JCSG-D12 (0.04 M Potassium 
phosphate, 16% PEG 8000, 20% 
Glycerol 
1.63 
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AgaE-maltohexoase 
 
JCSG-D12 (0.04 M Potassium 
phosphate, 16% PEG 8000, 20% 
Glycerol 
1.34 
AgaE-maltodextrin 
 
 
JCSG-D12 (0.04 M Potassium 
phosphate, 16% PEG 8000, 20% 
Glycerol 
1.21 
AgaE-Cyclodextrin 
 
JCSG-B9 (0.1 M citric acid pH 5, 
20% PEG 6000 
1.45 
AgaE-maltopentose 
 
PACT-A1 (0.1M SPG buffer pH 4, 
25% PEG 1500) 
1.57 
AgaE-Acarbose  PACT-A1 (0.1M SPG buffer pH 4, 
25% PEG 1500) 
1.52  
AgaE-trehalose  
 
JCSG-D12 (0.04 M Potassium 
phosphate, 16% PEG 8000, 20% 
Glycerol 
1.33 
AgaE-Raffinose 
 
JCSG-D12 (0.2 M Na chloride, 0.1 M 
Phosphate-citrate pH 4.2, 20% PEG 
8000) 
1.64 
AgaE-mellibiose  JCSG-D12 (0.04 M Potassium 
phosphate, 16% PEG 8000, 20% 
Glycerol)/ 
PACT-A1 (0.1M SPG buffer pH 4, 
25% PEG 1500) 
1.34/1.28 
AgaE-cellobiose 
 
JCSG-B9 (0.1 M citric acid pH 5, 
20% PEG 6000)/ PACT-A1 (0.1M 
SPG buffer pH 4, 25% PEG 1500) 
1.7/1.89 
AgaE-G3P 
 
JCSG-B9 (0.1 M citric acid pH 5, 
20% PEG 6000 
1.85 
 
Tables 6.1 Photographs of the AgaE-sugar complex crystals. The tables represent crystals 
that were sent to Diamond for data collection with their crystallization conditions and data 
resolution.  
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DATA SET AgaE-
Glucose 
AgaE-
Galactose 
AgaE- 
Fructose 
AgaE- 
Fucose 
AgaE- 
Ribose 
Wavelength 
(Å) 
Energy 
(KeV) 
0.9763 
12.7 
0.9763 
12.7 
0.97620 
12.7 
0.9763 
12.7 
0.9763 
12.7 
Space group P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
Unit cell              
parameters                      
a (Å)                              
b (Å)                               
c (Å) 
                                      
α = β = γ (˚) = 
                                                        
                             
64.12                 
69.43                         
101.27                  
90.0 
                           
                      
64.10                 
69.31                   
101.9 
 
90.0 
                       
                       
64.05                 
69.24                    
101.1 
 
90.0 
                       
                        
64.14                
69.30                    
101.1 
  
90.0 
                       
                       
63.0                  
69.11                    
101.8 
  
90.0 
Resolution 
range (Å) 
30.6-1.24                
(1.27-1.24) 
69.31-1.54                  
(1.58-1.54) 
34.6-1.41                  
(1.45-1.41) 
50.6-1.37               
(1.41-1.37) 
53.5-1.44                  
(1.48-1.44) 
Unique 
observation 
126739                  
(8369) 
66423  
(4229) 
87206                
(6361) 
583196                
(6733) 
80845                
(5893) 
Rmerge 0.030               
(0.425) 
0.041              
(0.495) 
0.037              
(0.66) 
0.040               
(0.509) 
0.043                 
(0.60) 
Rpim 0.015                  
(0.340) 
0.020               
(0.298) 
0.17               
(0.30) 
0.019                  
(0.336) 
0.022                  
(0.290) 
Completeness 
(%) 
99.0                    
(90.1) 
98.6                 
(96.5) 
99.9                 
(100) 
99.7                  
(97.0) 
99.9                  
(99.9) 
Anomalous 
completeness 
(%) 
95.8                     
(70.8) 
97.2                 
(78.6) 
99.1                 
(99.8) 
98.1                 
(87.9) 
99.3                 
(98.6) 
Multiplicity 5.8                         
(2.7) 
6.2                   
(4.1) 
6.5                     
(6.7) 
6.1                     
(3.6) 
6.4                     
(5.6) 
Anomalous 
multiplicity 
2.3                        
(2.3) 
3.2                     
(2.0) 
3.3                     
(3.3) 
3.0                     
(1.7) 
3.3                     
(2.7) 
Mean (I)/σ(I) 23.8                      
(2.3) 
20.9                    
(2.4) 
21.1                    
(3.0) 
18.8                    
(2.3) 
18.6                    
(2.8) !!!!!!!!!!
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DATA SET AgaE-
Maltose 
AgaE-
Maltotriose 
AgaE- 
Maltotetroase 
AgaE- 
Maltopentose 
AgaE- 
Maltodextri
n 
AgaE-
Cellibiose 
Wavelength 
(Å) 
Energy 
(KeV) 
0.9763 
12.7 
0.9763 
12.7 
0.9763 
12.7 
0.9763 
12.7 
0.9763 
12.7 
0.96861 
12.7 
Space group P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
Unit cell              
parameters                      
a (Å)                              
b (Å)                               
c (Å) 
                                      
α = β = γ (˚) = 
                                                    
                         
63.83                 
69.18                         
101.65                  
90.0 
                           
                      
64.00                 
69.13                   
101.5 
 
90.0 
                        
                        
64.27                 
69.35                    
101.4 
 
90.0 
                           
                            
64.35                 
69.46                    
101.51 
 
90.0 
                        
                         
63.05                  
69.37                    
101.23 
  
90.0 
                                                        
                       
63.77                 
69.26                         
101.49                  
 
90.0 
Resolution 
range (Å) 
31.92-1.38                
(1.42-1.38) 
24.17-1.37                  
(1.41-1.37) 
57.24-1.63                  
(1.68-1.63) 
30.56-1.57                  
(2.50 -1.57) 
18.57-1.21                  
(1.24-1.21) 
23.58-1.7                
(1.74-1.7) 
Unique 
observation 
91282                  
(5890) 
94948     
(6928) 
56719                
(4134) 
60995        
(4229) 
137346                
(9795) 
49655                  
(74362638) 
Rmerge 0.038               
(0.545) 
0.039              
(0.64) 
0.082              
(0.91) 
0.041              
(0.495) 
0.03                 
(0.53) 
0.1               
(0.668) 
Rpim 0.018                  
(0.301) 
0.019               
(0.298) 
0.040               
(0.41) 
0.020               
(0.298) 
0.015                  
(0.341) 
0.053                  
(0.327) 
Completeness 
(%) 
98.9                    
(87.8) 
99.8                 
(99.9) 
99.8                 
(100) 
98.6                 
(96.5) 
99.7                  
(97.6) 
99.0                    
(98.7) 
Anomalous 
completeness 
(%) 
97.6                     
(80.6) 
98.7                 
(99.7) 
96.6                 
(99.1) 
97.2                 
(78.6) 
98.4                 
(89.4) 
93.5                     
(97.2) 
Multiplicity 6.2                         
(4.3) 
6.4                   
(6.3) 
6.2                     
(6.6) 
6.2                    
(4.1) 
6.2                     
(3.8) 
5.8                         
(6.1) 
Anomalous 
multiplicity 
3.2                        
(2.1) 
3.3                     
(3.2) 
3.1                     
(3.3) 
3.2                     
(2.0) 
3.1                     
(1.8) 
2.9                        
(3.0) 
Mean (I)/σ(I) 20.2                      
(2.5) 
19.6                    
(2.9) 
15.4                   
(2.6) 
20.9                    
(2.4) 
23.2                    
(2.3) 
9.7                      
(2.0) !!!!!!!!!!!!
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DATA SET AgaE-
Maltohexoa
se 
AgaE-
Cyclodextre
in 
AgaE- 
Trehalose 
AgaE- 
Acarbose 
AgaE- 
Raffinose 
AgaE-
Mellibiose 
Wavelength 
(Å) 
Energy (KeV) 
0.9763 
12.7 
0.9763 
12.7 
0.9763 
12.7 
0.9763 
12.7 
0.96861 
12.7 
0. 96861 
12.7 
Space group P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
P 21 21 21 
 
Unit cell              
parameters                      
a (Å)                              
b (Å)                               
c (Å) 
                                      
α = β = γ (˚) = 
                                                      
                           
63.93                
69.28                       
101.26                  
90.0 
                           
                      
64.22                 
69.34                   
101.14  
 
90.0 
                       
                       
64.07                 
69.2                    
101.26 
 
90.0 
                       
                       
64.2                  
69.2                    
101.0 
 
90.0 
                       
                        
64.31                  
69.37                    
101.56 
  
90.0 
                                                        
                             
64.42                 
69.39                         
100.86                  
 
90.0 
Resolution 
range (Å) 
28.61.34                
(1.37-1.34) 
64.22-1.45                  
(1.49-1.45) 
27.94-1.33                  
(1.37-1.33) 
34.59-1.52                  
(1.56 -1.52) 
27.50-1.64                  
(1.68-1.64) 
30.26-1.34                
(1.37-1.34) 
Unique 
observation 
101503                  
(7438) 
79539                
(5656) 
101723                
(6537) 
69102   
(4998) 
56357                
(4087) 
101930                  
(7479) 
Rmerge 0.035               
(0.615) 
0.047              
(0.611) 
0.027              
(0.401) 
0.04              
(0.6) 
0.077                 
(0.675) 
0.037               
(0.675) 
Rpim 0.016                  
(0.29) 
0.022               
(0.31) 
0.013               
(0.31) 
0.022               
(0.34) 
0.037                  
(0.313) 
0.017                  
(0.314) 
Completeness 
(%) 
100.0                    
(100.0) 
98.7                 
(96.1) 
98.6                 
(87.5) 
99.1                 
(98.6) 
99.9                  
(99.9) 
99.9                  
(99.9) 
Anomalous 
completeness 
(%) 
99.3                     
(3.2) 
97.7                 
(95.4) 
95.5                 
(71.8) 
94.9                 
(94.1) 
98.5                 
(99.3) 
98.7                     
(98.5) 
Multiplicity 6.5                         
(6.5) 
6.5                   
(6.1) 
5.9                     
(3.1) 
4.4                    
(4.5) 
6.3                     
(6.5) 
6.4                         
(6.3) 
Anomalous 
multiplicity 
3.2                        
(3.2) 
3.3                     
(3.1) 
3.0                     
(1.4) 
2.2                     
(2.2) 
3.2                     
(3.2) 
3.2                        
(3.1) 
Mean (I)/σ (I) 22.0                      
(3.0) 
17.9                    
(2.9) 
26.8                   
(2.4) 
19.9                    
(2.6) 
13.0                    
(2.5) 
22.7                      
(2.7) !
Tables 6.2 Data collection statistics for all AgaE-sugar complex crystals, values in 
parentheses refer to the high resolution shell. 
!!!!!!!!!!!
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6.5 Determination of more crystal structures of AgaE potential complex 
The CD spectra assay suggested that AgaE has some affinity for maltose, glycerol-3-
phosphate and acarbose, and for these sugars, crystals were grown in a number of 
different conditions. Therefore, more crystals of AgaE grown in the presence of these 
three sugars, and in different crystallization conditions, were sent to Diamond for 
data collection, in case the different conditions favoured complex formation. 
Surprisingly, data were collected in different P 212121 derivative space group and 
different cell dimensions (Table 6.3). For the AgaE in complex with maltose, the 
crystal grew in PACT-b1condition and data were collected to 2.85 Å and in space 
group P 212 21 and cell dimensions a=64.5, b=107.0 and c=113.4. For the AgaE in 
complex with acarbose, two data were collected from crystals obtained with different 
crystallization condition. The first crystals grew in the same crystallization 
conditions as the AgaE - maltose complex crystal, and data were collected to 2.34 Å 
and in different space groups P 21212 and different cell dimensions a= 64.7, b =112.5 
and c= 53.3Å. The second crystal grew in similar crystallization condition of the apo 
AgaE and data were collected to 1.22 Å and similar space group P 212121 and cell 
dimensions a= 62.3, b = 68.3 and c= 100.4Å. Data statistics for these three datasets 
are shown in table 6.3. Thus, structures were determined using the molecular 
replacement Phaser using the apo AgaE structure with water molecules deleted as a 
search model and refined using refmac5 (table 6.4), as mentioned in section 6.1.3. 
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Table 6.3 Data collection statistics for all data sets of AgaE crystals in complex with 
acarbose and maltose, values in parentheses refer to the high resolution shell. 
 
 
 
 
 
 
 
 
 
 
 
 
DATA SET AgaE-Maltose AgaE-Acarbose AgaE-Acarbose 
Crystallization 
condition 
PACT-b1 
(0.1M MIB 
buffer pH 4, 
25% PEG 
1500) 
PACT-b1 (0.1M 
MIB buffer pH 
4, 25% PEG 
1500) 
JCSG -A9 (0.2 
M Ammonium 
chloride pH 6.3, 
20% PEG 3350) 
Wavelength (Å) 
Energy (KeV) 
0.9763 
12.7 
0.9763 
12.7 
0.9763 
12.7 
Space group P 212 21 
 
P 21212 
 
P 212121 
 
Unit cell              
parameters                      
a (Å)                              
b (Å)                               
c (Å) 
α = β = γ (˚) = 
 
64.5                 
107.0                         
113.4 
 
90.000 
 
64.7                 
112.5                         
53.3 
 
90.000 
 
62.3 
68.3 
100.4                  
 
90.000 
Resolution 
range (Å) 
56.7-2.85                
(2.92-2.85) 
24.9-2.34                
(2.40-2.34) 
53.0-1.22                  
(1.25-1.22) 
Unique 
observation 
18948                  
(1362) 
16958                  
(1243) 
120904                
(6801) 
Rmerge 0.23               
(0.8) 
0.081               
(0.54) 
0.041              
(0.6) 
Rpim 0.012                  
(0.351) 
0.04                  
(0.25) 
0.02               
(0.3) 
Completeness 
(%) 
99.0                    
(99.0) 
100                    
(100) 
95.0                 
(74.0) 
Anomalous 
completeness 
(%) 
98.5                     
(94.4) 
98.0                     
(98.6) 
93.2                 
(66.5) 
Multiplicity 6.2                         
(6.4) 
6.3                         
(6.2) 
6.4                    
(5.5) 
Anomalous 
multiplicity 
3.2                        
(3.2) 
3.3                        
(3.2) 
3.3                     
(2.6) 
Mean (I)/σ (I) 6.6                      
(2.1) 
15.1                      
(3.1) 
19.4                    
(2.6) 
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Model Crystal I Crystal II Crystal III 
Resolution (Å) 2.85 Å 1.34 Å 1.22 Å 
Number of reflections 17932 25635 27836 
Protein molecules per 
asymmetric unit 
2 1 1 
Number of atoms 6946 3220 3111 
Number of waters 393 140 113 
Number of PEG 1 1 1 
Ramachandran favored 
(%) 
98.4 98.1 97.3 
Ramachandran outliers 
(%) 
0 0.3 0 
Poor rotamers (%) 1.9 0.6 1.0 
RMSD bond (Å) 0.006 0.007 0.011 
RMSD angle (O) 1.06 1.08 1.34 
Average B-factors (A2)    
Main chain (A2) 20.7 38 14.4 
Side chain (A2) 22 55 16.6 
PEG 31.35 33 - 
R-factor 0.15 0.22 0.19 
R-Free 0.21 0.29 0.25 
Molprobity score 0.93 
100th percentile 
 
0.71      
100th percentile 
 
0.99         
   100th percentile 
 
 
 
Table 6.4 The refinement statistics for three-crystal structures with potential 
sugar bound. 
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6.6 Structures analysis 
 
6.6.1 AgaE structure with potential binding of acarbose  
Two data sets were collected for AgaE in complex with acarbose, from different 
crystallization conditions JCSG-a9 and PACT-b1. The second data (b1) has been 
collected in different space group (Table 6.3) and both are in different cell 
dimensions than the native crystal. Crystal structures were determined using phaser 
and refined through several cycles using Refmac5. Both structures superimpose well 
with the apo structure and with each other with r.m.s.d value of about 0.4Å (Figure 
6.4). This indicated that no significant movement of the molecule was made upon 
alteration of the cell dimensions and different packing in the crystal. However, the 
binding site of the potential AgaE and acarbose complex structure has revealed some 
poor density for only one ring of the acarbose compound. This density was refined as 
the acarvision ring of acarbose as attempts failed to fit a glucose ring (Figures 6.5, 
6.6). However, structure comparison of AgaE in complex with acarbose with other 
acarbose binding proteins, such as MalE from E.coli and GacH from S.glaucescens, 
revealed that acarbose binds to MalE and GacH via the maltose moiety of the 
protein, and in both structures the reducing rings of maltose are bound to the inner 
moieties of maltose, however, in AgaE binding site, the acarvision ring of acarbose 
showed to be bound tightly to the internal maltose moiety instead of the glucose ring 
of its maltose. This might be due to the presence of PEG molecule that is bound 
tightly, which prevents the acarbose from binding in the same way it does in solution 
(Figures 6.7 and 6.8). 
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Figure 6.4 The 3D structure of AgaE (green) in complex with acarbose (wheat) and 
PEG molecule with electron densities.   
 
 
!
!
!
!
Figure 6.5 The binding site of AgaE with the acarbose bound. Residues that coordinate 
the acarviosin ring of acarbose are shown as stick. PEG molecule is shown as yellow stick.  
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!
!
!
Figure 6.6 Acarbose structure with electron density contoured to 0.6 σ. 
!
!
!
!
!
!
!
!
!
!
!
!
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(a)!
!
!
!
(b)!
!
Figure 6.7 Superposition of 3D structures of AgaE (green), GacH (cyan) and MalE 
(pink) in complex with acarbose. B) The binding site of the superimposed structures AgaE 
(green) and GacH (cyan) in complexes with acarbose. Acarbose and PEG molecule in AgaE 
are shown as wheat stick and coordinated residues as green stick. 
 
!
!
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!
!
!
!
!
!
!
Figure 6.8 Superposition of bound acarbose from the binding sites of AgaE (wheat), 
GacH (cyan) and MalE (slate). The PEG molecule that occupied the acarbose binding site 
is shown as yellow stick. !
!
!
!
!
!
!
!
!
!
!
!
!
!
!
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6.6.2!AgaE!Structures!with!potential!binding!of!G3P!and!maltose!
The binding site of AgaE structure in complex with G3P revealed no density for 
G3P, which indicates that G3P did not bind to AgaE. This might be due to the 
binding of ethylene glycol molecule in the one of the possible glycerol binding site. 
To test this, AgaE was co crystallized in ammonium sulfate precipitant screen, 
however, single crystals grew from the trials and washed with 50% of glycerol and 
stored in liquid nitrogen for data collection experiment. Unfortunately, data have not 
been collected due to the poor diffraction from the crystal. 
!
Moreover, the binding site of AgaE in complex with maltose has not revealed any 
clear density for maltose, despite the movement in the side chains that are thought to 
be involved in the maltose binding. 
!
!
6.7 Final discussion !
The nutritional resource that M.tuberculosis needs for its growth was first to be 
studied intensively since its discovery [28]. Examples of these molecules are fatty 
acids, amino acids, carbohydrates and alcohol. Since the emergence of molecular 
biology the use of one of these small molecules were examined by testing the 
measurements of oxygen used by the cell [155]. Moreover, this necessary nutrition is 
believed to be transported into the cells of mycobacterium by proteins that attached 
to the cell membrane. These proteins are called transporters. The vast majority of 
these transporter lipoproteins are still unknown; even with the progress of genetic 
analysis methods [156, 157], especially in M.tuberculosis and M.smegmatis. Also, it 
has been shown that mycobacterium utilize the glyoxylate cycle to survive [158]. 
These findings indicated that the pathogenic mycobacterium uses lipids as the carbon 
supply throughout the infection. In addition, proteins that are responsible for the 
transport of disaccharides have been shown to be encoded by genes that are essential 
for the growth of mycobacterium[75]. This observation suggests that mycobacterium 
might use lipids instead of carbohydrates during host attack.  
The non- pathogenic M.smegmatis is used as a fast growing model organism for the 
pathogenic M.tuberculosis to understand their physiological and pathogenesis 
aspects. Several studies have emerged in order to shed light on the transport system 
of both M.tuberculosis and M.smegmatis. There has also been some focus on the 
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nutrients transported and used for the carbon source. Most studies made to date have 
centered around the identification and characterization of some solute and amino 
acid transporters, based on homology with other bacterial transporters. Examples of 
these transporters are the phosphate and sulphate uptake proteins from M.smegmatis 
[159]. The composition of the mycobacterium cell wall has an effect on the solute 
transport in and out of the cell, which in turn has an effect on the life of 
mycobacterium and its pathogenicity. Thus the project described in this thesis has 
focused on different targets of lipid-anchored protein with different putative 
functions in M.smegmatis. The 3D structure of one target (Msmeg_0515) has been 
successfully determined out of 8 target proteins studied.  
Structural and biochemical analysis of Msmeg_0515 (AgaE) suggested that it is most 
likely to be a maltose binding protein of the ABC transport system. Previous 
bioinformatics study on the sugar transporters of M.smegmatis suggested that AgaE 
is a α-galactoside sugar binding protein [3], however, attempts to test the binding 
affinity of such α-galactosides sugars, such as raffinose, mellibiose, stachyose and 
verbascose, using two different assays have failed to indicate any significant 
interaction with AgaE. Also, a co-crystallization of AgaE in the presence of these 
four sugars revealed an open form structure with no indication for electron density of 
any bound sugar. These findings suggest that AgaE is not a α-galactoside sugar 
binding protein. Furthermore, ABC solute binding proteins usually have a high 
affinity of > 1 UM to its natural substrate, and the 1mM sugar concentration used in 
the co-crystallization experiment, should be sufficient for binding. In the case of 
AgaE a > 50 mM concentration of sugar was used, however, all crystal structures 
that have been determined were in an open form with no sugar bound in the binding 
site. Although, the initial CD spectrum showed the highest binding affinity for 5mM 
maltose, G3P and acarbose to AgaE, more data is required to support these results, 
such as an ITC experiment.   
The AgaE structure is most similar to other malto - oligosaccharide structures, and a 
sequence based structural alignment shows that the binding residues Y182 and W254 
of GacH, that protrude from the C-domain (site II) and form hydrophobic contacts 
with the ligand, are conserved in all other malto-oligosaccharide structures. These 
two residues corresponded to the W202 and W273 residues in AgaE; W172 and 
S250 in E.coli UgpB  (G3P binding protein) and C182 and W257 in Thermococcus 
litoralis MBP (trehalose binding protein). These two residues are suggested to be 
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critical for substrate specificity in these structures and thus mutagenesis experiments 
could be attempted on these two residues in AgaE to test its role for binding malto- 
oligosaccharide. !!!!!!!!!!!!!!!!!!!!!!!!!!
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Chapter 7 !
Structural studies on phosphoglucose isomerase (PGI) 
protein mutants from Pyrococcus furiosus. 
  !!!
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7.1 Introduction 
In parallel with the studies on proteins from M.smegmatis reported in this thesis, the 
effect of mutating residues in the model enzyme of phosphoglucose isomerase (PGI) 
from Pyrococcus furiosus was investigated. 
Although mutagenesis has long been used as a technique for studying the active site 
of enzymes, attempts to rationally design enzymes with improved activity, have not 
been very successful, despite obvious biotechnological applications [160, 161]. 
There are some examples where random mutagenesis has increased the activity of 
enzymes, but again these are limited [162-164]. More success has been seen in 
altering the substrate specificity of enzymes, [162] but in many cases these mutant 
enzymes show lower activity than the wild type.  
An alternative method to identify possible candidate residues for mutation has been 
proposed [165]. The correlation between sequences in proteins belonging to the same 
enzyme family is mapped [162]. Residues that show a high correlation of a similarity 
can be identified, and then subjected to mutagenesis to see if the activity of the 
enzyme can change. 
To test this correlated mutagenesis theory, the sequences of the cupin superfamily 
enzymes (of which Pyrococcus furiosus phosphoglucose isomerase (PfPGI) is a 
member) were aligned and a number of sites identified in the sequences, where the 
type of residue present at one position was correlated with the type of residue at 
another position (John Raedts and Jasper Akerboom, Wageningen University). Using 
this procedure, a number of correlated key residues were identified in PfPGI as a 
target for mutagenesis experiments to investigate their role in enzyme function, 
through activity measurements. The correlated positions identified were P132 and 
Y133 in the PfPGI sequence. All possible mutants were made at these two positions 
and, surprisingly, two of these mutant PGIs showed increased levels of activity 
compared to the wild type (Figure 7.2).  The aim of this study was therefore, to 
determine the 3D structures of these PGI mutants and two control mutants, to 
investigate the alteration in enzyme activity in terms of the protein structure. 
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7.2 P.furiosus Phosphoglucose isomerase (PGI) structure  
Phosphoglucose isomerase (PGI) is a catalytic enzyme found in several organisms 
including P.furiosus, which is a hyperthermophilic organism of archaea [166, 167]. 
PGI functions as reversible sugar catalytic enzyme, that converts fructose 6 
phosphate (F6P) to Glucose 6 phosphate (G6P) [168, 169]. The structures of PfPGI 
in complex with its substrate (F6P) and inhibitor (5PAA) were determined to 2.0 Å 
[170, 171] (Figure 7.1).  PfuPGI structure composed of two monomers of 21.5 kDa 
with 189 amino acids each and function as homodimer by gel filtration [172]. 
Although, PfuPGI shares similar structure of other organisms PGIs, its primary 
sequence shows no homology [173, 174]. Crystal structure analysis of PfuPGI 
revealed that, its fold belongs to the cupin superfamily that is formed of two separate 
β-sheets; each contains three β-strands and six β-strands respectively [175]. Cupin 
superfamily is a widespread family involved in different functions, such as 
oxidoreductases and isomerases. 
 
 
 
Figure 7.1 Cartoon representation of the dimer (white and green subunits) of the wild 
type PfPGI Mn+2/5PAA 3D-structure (PDB code: 1X7N). The correlated amino acid pair 
“PY” is indicated in red. Shown in yellow are those residues involved in metal ion (purple 
sphere) binding, including a water molecule (red sphere). The inhibitor 5-phospho-D-
arabinonate (5PAA) is shown as a stick model (green). 
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7.3 Active site and function of PfuPGI 
The main function of PfuPGI is to catalyze the reverse conversion of fructose 6 
phosphate and glucose 6 phosphate [168, 169], this mainly occurs through two 
processes, either by hydride shift directly or via a process called cis-enediol 
intermediate [171]. The first process, was based on a hydrogen atom that transfers 
between the C1 and C2 of fructose, however, this process was not observed in NMR 
experiment [171]. The second process where the hydrogen transfer occurs by process 
called cis-enediol intermediate. In this process a proton is transferred between the 
two carbons via a negative charged amino acid (E197) through chemical interaction 
with the solvent. 
The active site of PfuPGI is located in the core of β-barrel fold with three rings of 
histidine (H88, H90 and H136) atoms and glutamate (E97) in contact with bound 
metal ion (12,13). 
 
7.4 The identification of possible PGI mutants 
A PfPGI library has been generated based on predictions made using the Comulator 
CMA algorithm, as previously described [162]. The refined structure-based multiple 
sequence alignment of the cupin super-family, containing a total of 1711 sequences 
was used. The amino acids with the highest pair-wise correlated mutation score were 
Pro132 and Tyr133 in the PfPGI. These two residues are placed in a conserved 
structural loop across the family [162] (Figure 7.2). These two residues have been 
mutated into three different double mutants,  (P132A, Y133G), (P132R, Y133G),  
(P132A, Y133D), and one with single mutation (P132V). Functional activity for 
these four mutants PfPGI has been performed by Raedts, J et al,  (Wageningen 
University) and revealed increasing in the activity of PfPGI in the case of AG and 
RG, and less activity for the PFPGI with single mutation VY [162] (Figure 7.2). As 
these two mutated residues are not in contact with the active site residues, the 
changing in the activity of PfPGI mutants is not clear, thus, attempts to crystallize 
PfPGI mutants to determine their 3D structures were carried out in order to 
investigate these mutants and their effect on the activity at the atomic level.  
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Figure 7.2 Specific activity of wild type PfPGI (PY) compared to selected high 
occurrence/activity mutants RG and AG, and low occurrence/activity mutants AD and 
VY. Manganese was used as co-factor and added via titration (not published). 
 
 
7.5 Overexpression of PfuPGI mutants 
 
The gene that encoded PfPGI mutants was cloned into pET24d by Raedts, John et al,  
(Wageningen University), as described previously [169]. Glycerol stocks for each 
PfPGI mutant was provided and used to inoculate primary cultures in LB medium 
supplemented with 50 µg ml-1 kanamycin in a 37°C shaker. The overnight culture 
was used to inoculate (0.2% v/v) sterile glass tubes containing 10 milliliter LB/Km 
medium. When the optical density of the culture reached A600 = 0.5, gene 
expression was induced by addition of 0.1 mM isopropyl-1-thio-β-D-
galactopyranoside (IPTG). Growth was continued overnight at 37°C, after which the 
cells were harvested by centrifugation (4,600 x g for 15 min). Pelleted E.coli cells 
were resuspended in 20 mM Tris- HCl buffer (pH 8.0) and disrupted by sonication.  
Cell debris was removed by centrifugation (16,000 x g for15min). E.coli proteins 
were denatured by heating the cell free extract at 65°C for 30 min, and removed by 
centrifugation (16,000 x g for 15 min). The result was a heat-treated cell free extract 
containing mainly PfPGI. Its purity was checked by SDS-PAGE. Protein 
concentrations were determined by Coomassie Brilliant Blue G250, using bovine 
serum albumin as reference and analysis by SDS-PAGE (Quantity One®, Bio-Rad). 
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7.6 Purification of PfuPGI mutants 
The cell extract of 3g cell pellets was loaded into a 10 ml of DEAE sepharose fast 
flow column (Amersham Pharmacia Biotech). The column was equilibrated with 50 
mM Tris-HCl (pH 8.0). PGI activity eluted at 180 mM of NaCl during a linear 
gradient of 0 to 1 M NaCl. The fraction with the highest activity was loaded on a pre-
equilibrated Superdex 200 GL gel filtration column (GE Healthcare) and eluted in 20 
mM Tris-HCl (pH 7.0) containing 100 mM NaCl. Protein purification progress was 
checked using SDS PAGE. 
 
 
 
 
 
 
 
Figure 7.3 SDS-PAGE gel analysis of the purification of PfPGI. SDS represents samples 
taken through the purification process of PfPGI (AG) mutant. Lane 1: Mark12; lane 2: 
cell extracted (supernatant); lane 3: heat-treated fraction; lane 4: fraction of DEAE column; 
lane 5: combined fractions before gel filtration; lane 6: fraction of gel filtration column. 
Similar Purification processes were carried out for all PfPGI mutants and all resulted in 
equivalent yield protein with similar behavior. 
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7.7 Crystallization of PfuPGI mutants 
 
For crystallization, PfPGI was overexpressed and purified as described previously. 
For each mutant, protein was concentrated to 11.5 mg ml-1 in a solution of 10 mM 
Tris-HCl, pH 8.0, and 50 mM F6P and 5 mM MnCl2 (Figure 7.4). Mutants RG and 
AG crystallized from hanging drops by mixing equal volumes of protein solution 
with a reservoir solution containing 0.35 M MgCl2, 0.1 M sodium acetate pH 5.5 and 
10-35% PEG4000. For mutants AD and VY, crystals were grown using a Hydra plus 
One robot, and commercial screens. AD crystallized from a solution of 0.2 M 
calcium acetate, 0.1 M sodium acetate pH 6.5, 40% PEG300, whereas VY 
crystallized from solutions of 0.2 M sodium nitrate, 0.1 M Bis Tris Propane pH 6.5, 
20% PEG4000. 50 mM F6P was added to the AD and VY crystals, before mounting. 
For each different mutant, a single crystal was briefly washed in a cryoprotectant 
consisting of 25% ethylene glycol in the crystallization buffer, flash cooled to 100 K 
and stored in liquid nitrogen prior to data collection on the Diamond synchrotron 
light source. Data were processed using the Xia2 software and structures determined 
by molecular replacement using the wild type PfPGI coordinates as a search model 
(PDB_code 1X82) [176] and the program Phaser [81]. Rounds of building using 
Coot [86] and refinement in Refmac5 [134] gave acceptable models, verified using 
Molprobity [135]. For each structure, electron density was present for all the 
polypeptide chain and the models had no missing residues. However, density was 
weak for the side chains of Lys21, Lys188, Lys189 (AG); Arg25, Glu114, Asp116, 
Lys118, Lys188 and Lys189 (RG chain A); Glu114, Lys188 and Lys189 (RG chain 
B) and Lys188 and Lys189 (AD and VY, chains A and B). Data collection and 
refinement statistics are given in Tables 7.1 and 7.2. The four mutant structures were 
compared to the wild type Mn/5PAA Structure (IX7N) by superposition of all the 
protein atoms of the residues that coordinate the Mn2+ (His88, His90, Glu97 and 
His136) (Table 7.3). 
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Hanging drop Methods Robot hit screen 
RG  
 
0.35M Mgcl2, 0.1M Na acetate PH5.5 
19% PEG 4000 
5mM Mn + 50 mM F6P 
 
VY  
 
0.2 M Na nitrate, 0.1M Bis Tris Propane PH6.0  
20% PEG 4000 
5mM Mn + 50 mM F6P 
 
AG  AD  
0.35 M Mgcl2, 0.1M Na acetate PH5.5 
17% PEG 4000 
5mM Mn + 50 mM F6P 
 
0.2 M Ca Acetate, 0.1M Na acetate PH6.5 
40% PEG 300 
5mM Mn + 50 mM F6P 
 
 
Figure 7.4 Photographs of PfPGI mutants crystal. 
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MODEL AG 
 
RG AD 
 
VY 
 
Space group C2 P212121 P212121 P1 
Unit cell 
parameters (Å) 
a                            
b                             
c                              
α                            
β                              
γ 
 
                               
87.85                     
43.28                     
58.45                   
90.0°                    
122.0°                     
90.0° 
 
                      
72.95                   
74.47                   
75.90              
90.0°                    
90.0°                     
90.0° 
 
                                                 
41.3                                                  
60.03                    
146.7                      
90.0°                    
90.0°                        
90.0° 
 
            
44.9  
45.0                      
48.7                   
87.8°                
89.8°                     
75.5° 
Molecules per 
ASU 
1 2 2 2 
Resolution (Å) 28.92-1.41 
(1.44-1.41) 
26.58-2.04 
(2.09 -2.04) 
25.58-1.89 
(1.94 -1.89) 
 
18.49-1.79 
(1.84-1.79) 
Wavelength Å 0.97630 0.97630 0.97630 0.97630 
Unique  
observations 
32797       
(1460) 
26994  
(1969) 
29381          
(2144) 
33074              
(2386) 
Rpim  0.036       
(0.349) 
0.074  
(0.219) 
0.028         
(0.352) 
0.086               
(0.349) 
Rmerge 0.038    
(0.364) 
0.154    
(0.475) 
0.037         
(0.529) 
0.109              
(0.459) 
Completeness 91.2          
(55.4) 
99.6        
(99.9) 
98.5            
(99.2) 
95.7                  
(94.0) 
Multiplicity 3.1               
(2.4) 
6.3             
(6.4) 
3.5                
(3.5) 
1.8                    
(1.8) 
Mean((I)/sd(I)) 13.0             
(2.1) 
7.0             
(3.7) 
15.9                
(2.4) 
4.3                      
(2.2) 
Anomalous 
completeness 
79.6            
(42.6) 
98.1         
(99.2) 
86.2              
(91.5) 
63.8                  
(60.7) 
Anomalous 
multiplicity 
1.6               
(1.3) 
3.3             
(3.3) 
1.9                  
(1.9) 
1.0                      
(1.0) 
Table 7.1 Data collection statistics of PfPGI mutants crystals. 
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Model AG RG AD VY 
Resolution (Å) 1.4 2.0 1.9 1.8 
Number of reflections 31134 25635 27836 
 
31398 
Protein molecules per asymmetric 
unit 
1 2 2 2 
Number of atoms 1739 3221 3142 3308 
Number of waters 197 141 112 218 
Number of Mn ions 1 2 2 2 
Number of F6P 0 0 0 2 
Number of 5PAA 1 2 0 0 
Ramachandran favoured (%) 98.4 87.1 97.3 97.9 
Ramachandran outliers (%) 0 0.3 0.3 0 
Poor rotamers 1.3 1.6 0.6 0.3 
RMSD bond (Å) 0.006 0.007 0.011 0.009 
RMSD angle () 1.06 1.08 1.34 1.26 
Average B-factors (Å)     
Main chain 21 35 31 24 
Side chain 31 24 34 27 
Waters 37 36 33 26 
Mn 13 27 31 21 
5PAA/F6P 15 33 - 26 
R-factor 0.14 0.22 0.19 0.17 
R-FREE 0.20 0.29 0.25 0.22 
Molprobity score 0.80 
100th 
percentile 
 
0.94 
100th 
percentile 
 
0.99 
100th 
percentile 
 
1.03 
100th 
percentile 
 
 
Table 7.2 Final refinement Statistics. 
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Mutant HIS88-N2 HIS90-N2 HIS136-N2 GLU97-O1 
PY WT 
(1X81) 
2.45 2.25 2.29 2.26- O2 
RG 2.20 2.30 2.29 2.17-O1 
AG 2.32 2.25 2.23 2.33-O1 
AD 2.24 2.21 2.35 1.98-O1 
VY 2.31 2.31 2.28 2.09-O1 
 
Table 7.3 Mn2+ ligands and coordination distances (Å). 
 
7.8 Structure analysis of the mutation-carrying loop 
To further examine possible conformational changes, for instance in the active site 
structure and metal coordination, crystallization trials were initiated for the four 
PfPGI mutants. First crystallization attempts were set up with manganese as 
incorporated cofactor and F6P as substrate. These co-crystallization trials 
successfully yielded well-diffracting crystals for both the mutants RG and AG (Table 
7.1). The AG mutant structure is the highest resolution (1.4 Å) for any PfPGI variant, 
and interestingly, the electron density map for this structure (and also for the RG 
structure) clearly showed that 5-phosphoarabinonic acid (5PAA) (Figure 7.5), rather 
than F6P (as added to the crystallization mixture) was bound in the active site 
(Figure. 7.8). Thus an unexpected conversion had occurred: during the experiment 
F6P had been, at least partially, oxidized to 5PAA, resulting in preferential binding 
for 5PAA in the active site of both mutant structures. To confirm that 5PAA had 
indeed been produced, a solution of the same composition as the crystallization 
solution was analyzed by mass spectrometry after being left at room temperature for 
one week. The spectra contained a small peak of m/e ratio 259, (F6P), but also many 
other peaks with m/e ratios less than F6P, including a large peak with m/e ratio of 
245 corresponding to 5PAA, clearly indicating that a breakdown of the sugar had 
taken place (Figure 7.6). The oxidation of F6P to 5PAA in the presence of 
permanganate has been observed before [177] and thus we presume a similar 
reaction occurs in the crystallization solution. For the other two mutants (VY and 
AD), no ternary complex structures were obtained by co-crystallization, and thus 
protein crystals were grown in the presence of MgCl2, and subsequently soaked in a 
solution of F6P for two hours prior to X-ray data collection. This approach was 
successful for mutant VY, resulting in a structure with F6P in the active site. For 
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mutant AD, the only structure that could be obtained contained solely Mn2+ in the 
active site (Figure 7.7). 
The crystal structures of the four mutants reveal that in each structure clear electron 
density remains remarkably consistent, with only minor changes in the position of 
the main chain atoms. However, the changes in the side chains of Pro132 and Tyr133 
have more marked effects on the positions of residues 92-94 of the 90-96 loop, and 
also on the position of the N-terminal 5 residues from the adjacent subunit of the 
dimer. There are also some small consequential changes in the positions of second 
shell residues packing against these two loops (Figure 7.9).  
 
 
 
Figure 7.5 A stereo representation of the mFO – DFC electron density (grey mesh), 
contoured at 1.5σ, for the AG mutant PfPGI structure, showing the manganese (purple 
sphere), coordinating water (red sphere), bound 5PAA and metal coordinating residues 
(sticks). 
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Figure 7.6 Mass spectrometry experiment result of the crystallization buffers of AG 
and RG mutants crystals. The results confirmed the conversion of the F6P to 5PAA. The 
spectra contained a small peak of m/e ratio 259, (F6P), but also many other peaks with m/e 
ratios less than F6P, including a large peak with m/e ratio of 245 corresponding to 5PAA, 
clearly indicating that a breakdown of the sugar had taken place. 
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Figure 7.7 Mn+2 coordination in the mutant PfPGI structures. For all mutant structures, 
the Mn+2 ion (purple sphere) is coordinated in an octahedral arrangement: mutant AD (blue), 
mutant VY (pink), mutant AG (yellow) and mutant RG (wheat). Ligands to the metal are 
highlighted in stick representation, water molecules are shown as red spheres. 
 
 
 
 
 
 
 
 
 
 
 
 
                           
 
235!
 
 
 
 
 
 
Figure 7.8 Electron densities of substrate and inhibitor of PfPGI mutants. The F6P 
(pink) bounds to VY, 5PAA (yellow) and 5PAA (wheat) bound to AG and RG mutants, 
respectively. 
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Figure 7.9 Comparison of the structure of the loops adjacent to the mutation position in 
the four mutant structures. In each panel the wild type structure (1X7N) is shown in white, 
with relevant residues highlighted in stick representation and labeled. Y3’ and K4’ refer to 
the N- terminal strand from the adjacent subunit in the dimer. (a) Mutant AD (blue), (b) 
mutant VY (pink), (c) mutant AG (yellow) and (d) mutant RG (wheat). 
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For the P132R-Y133G mutant, the loss of the tyrosine side chain at position 133, is 
somewhat alleviated by the side chain of R132 occupying approximately the same 
position in the structure. There are movements of up to 0.5Å in the positions of both 
the Leu93-Asp94 and Tyr3-Lys4 loops, compared to the wild-type structure. In the 
P132A-Y133G mutant, the changes to the position of Leu93 and Asp94 are more 
marked, with movements of 1.8Å and 1.6Å for the alpha carbons of Leu93 and 
Asp94 compared to the wild type structure. Given that both mutations in this AG 
structure are to smaller residues than those in the wild type, these fairly large 
movements are, somewhat counter-intuitively, away from the 132-133, presumably 
making the packing worse. In the P132V single mutant (VY), the change of the 
proline side chain to valine pushes the Leu93-Asp94 loop away, in order to 
accommodate the larger bifurcated side chain of valine. Movements of 0.4Å and 
0.7Å are seen between the Cαs of Leu93 and Asp94, respectively. In mutant AD, the 
movement of the alpha carbons of Leu93 and Asp94 away from 132-133 is 0.7Å and 
0.9Å, respectively. In this mutant AD, the change from tyrosine to the negatively 
charged aspartic acid has had little effect on the position of the side chain of Tyr3 
from the adjacent subunit. 
 
As might be expected, the small (2-fold increase) in activity seen for the AG and RG 
mutants did not result in major differences in the structure of the enzyme. Indeed, 
understanding the precise role of individual residues in the activity of enzymes is 
fraught with difficulty, as small changes in position of residues far from the active 
site can marginally influence the binding of the substrate and/or the stabilization of 
the transition state, thus altering the activity. In addition, a two-fold increase in 
enzyme activity is not usually regarded as significant, as this degree of change can be 
within the error of the experiment. Nevertheless, in a biotechnological environment, 
a two-fold increase in activity and therefore productivity could be a very worthwhile 
result. Thus the method of correlated mutagenesis could therefore be a very valuable 
technique in producing optimized enzymes for biotechnological processes, and 
requires moiré testing to evaluate. 
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Appendix 
 
Symbols and abbreviations 
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Abbreviation  
Symbols Definition  
Crystallographic  
ASU  Asymmetric unit. 
A, b, c, α, β & γ     Dimensions and angles of the real space unit cells in the crystal. 
Å        Angstrom (10-10m). 
dhkl           Inter-planar spacing in the reciprocal lattice 
MAD Multiple-wavelength anomalous dispersion 
SAD Single-wavelength anomalous dispersion 
R R-factor 
Rfree Free R-factor 
Rmerge Merging R-factor. 
Rpim Precision-indicating merging R-factor 
F  Structure factor 
F’ Structure factor from the atomic dispersive scattering.  
F” Structure factor from the atomic anomalous scattering.  
F0 Structure factor from the normal atomic scattering. 
Fhkl Structure factor for a single reflection with indices hkl. 
FA Structure factor of the anomalous contribution of all atoms. 
FH Structure factor of the atoms in a heavy metal substructure. 
FP Structure factor of the atoms in a protein structure. 
FPH Structure factor of a protein structure containing heavy atoms.  
FT Structure factor of the total contribution of all atoms. 
|Fhkl| Structure factor amplitude for the reflection with indices hkl. 
|Fcalcs| Calculated structure factor amplitude. 
|Fobs| Observed structure factor amplitude. 
lhkl Intensity of a reflection with indices hkl. 
I / σI Signal to noise ratio. 
ƒ’ Dispersive atomic scattering factor.  
ƒ” Anomalous atomic scattering factor. 
ƒanomalous  Atomic scattering from an anomalously scattering atom 
hkl Miller indices. 
X,y,z Real space coordination. 
Vm Mathew’s coefficient number. 
Z Number of equivalent positions in the unit cell 
λ Wavelength of X-ray 
P(u, v, w) Patterson space coordinates. 
α Phase angle. 
αA Calculated phase. 
ρ Electron density. 
 
Chemicals & 
Biological 
 
DNA Deoxyribonucleic acid. 
DNTP  Deoxyribonucleotide deoxyribonucleic acid. 
EDTA Ethylene diaminetetraacetic acid. 
SDS Sodium dodecyl sulfate. 
TRIS Tris (hydroxymethyl) aminomethane. 
ATP Adenosine triphosphate 
Nad(P)H Nicotinamide adenine dinucleotidew (phosphate). 
IPTG Isopropyl-D-1-thiogalactopyranoside 
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EDTA Ethylenediaminetetraacetic acid 
PEG Polyethylene glycol 
  
Miscellaneous  
bp Nucleic acid base pair.  
PCR Polymerase chain reaction. 
LB media Lysogeny broth media: 1 % (w/v) tryptone, 0.5 % (w/v) yeast 
extract, 1 % (w/v) NaCl. 
AU Absorbance unit. 
pI Isoelectric point. 
OD  Optical density. 
PAGE Polyacrylamide gel electrophoresis. 
RMSD Root mean square deviation. 
PDB Protein data bank. 
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"
Abstract)26"
To!enable!rational!approaches!in!protein!engineering,!various!bioinformatics!tools!are!being!27"
developed.!In!this!work!we!used!structure9based!multiple!sequence!alignments!(MSAs)!and!a!28"
correlated! mutation! analysis! (CMA)! tool! to! identify! target! amino! acid! residues! for!29"
mutagenesis! enabling! ‘smart! library! design’.! CMA! analysis! of! the! cupin! super9family!30"
revealed! a! set! of! correlated! amino! acids.! Using! the! phosphoglucose! isomerase! from!31"
Pyrococcus! furiosus! (PfPGI)! as!model! enzyme,!we! varied! the! strongly! correlated! residues!32"
Pro132!and!Tyr133!by!saturation!mutagenesis.!Although!this!amino!acid!pair!is!located!in!a!33"
loop!relatively!distant! from!the!active!site,! their!predicted!relevance!could!be!confirmed!by!34"
activity! measurements! of! the! PfPGI! substitution! mutants.! Screening! of! the! generated!35"
substitution! library! revealed! a! positive! correlation! between! the! prevalence! of! correlating!36"
amino! acid! pairs! in! the! superfamily! and! the! specific! activity! of! the! corresponding! PfPGI!37"
mutants.!All!tested!mutants!retained!protein!stability!like!wild!type!PfPGI.!Crystal!structures!38"
of!a!selection!of!the!mutants!were!determined!to!increase!our!understanding!of!the!molecular!39"
basis!of! the!observed!differences!in!activity.! Interestingly,! the!obtained!crystal!structures!of!40"
the!four!selected!PfPGI!variants!did!not!reveal!major!changes!in!substrate!and!metal!binding.!41"
This!could!be!confirmed!by!electron!paramagnetic!resonance!(EPR).!This!study!suggests!that!42"
CMA!can!play!an!important!role!in!predicting!non9obvious!mutations!that!could!lead!to!subtle!43"
optimization! of! protein!performance! however!without! necessarily! introduction! of! structural!44"
changes.!45"
)46"
Keywords:*47"
protein! engineering,! Comulator,! cupin! superfamily,! phosphoglucose! isomerase,! protein!48"
structure!49"
!50"
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Abbreviations*used:*51"
5PAA,! 59phosphoarabinonic! acidc! CMA,! correlated! mutation! analysis! toolc! EPR,! electron!52"
paramagnetic!resonancec!F6P,!D9fructose!69phosphatec!MSA,!multiple!sequence!alignmentsc!53"
PfPGI!Pyrococcus!furiosus!phosphoglucose!isomerasec!PGI,!phosphoglucose!isomerase!54"
!55"
Introduction!56"
The!variety!of!enzymes!to!be!found!in!nature!is!enormous,!thereby!providing!a!rich!source!of!57"
potential! biocatalysts! for! industrial! purposes.! However,! in! the! course! of! natural! evolution!58"
these!enzymes!have!been!optimized!to!function!optimally!in!in!vivo!environments,!which!may!59"
differ! substantially! from! in! vitro! industrial! conditions.! Therefore,! often! there! is! a! need! for!60"
optimization! of! proteins! for! their! applicability! in! an! industrial! setting.! Generally! this! is!61"
achieved! by! the! generation! of! large! libraries! of! protein! variants,! from!which!mutants!with!62"
improved! features! are! selected.!As! screening! of! large! libraries! typically! is! costly! and! time!63"
inefficient,!reductions!in!library9size!by!“smart!library!design”!is!an!appreciable!step!forward!64"
1,2.!The!use!of!smart!library!design!of!a!small!set!of!promising!candidates!might!be!as!equally!65"
effective!to!improve!enzyme!activity,!as!a!complete!(random)!library.!66"
Smart! library!design!requires!identification!of!key!residues.!Such!amino!acids!either!67"
can! be! identified! through! experimental! analyses,! or! via! functional! predictions! using!68"
bioinformatics.!Comulator,!a!stand9alone!extension!of! the!3DM!software!suite,! is!a!recently!69"
developed!bioinformatics! tool! that! uses! a! correlated!mutation! analysis! (CMA)!algorithm! to!70"
identify!co9evolved!residues!in!large!structure!based!multiple!sequence!alignments!(MSAs)3971"
7.!Two!very!distinct! roles!have!been! linked! to!CMA9based! residues!prediction.!On! the!one!72"
hand,!correlated!residues!are!proven!to!represent!contact!positions!in!the!protein!structure!and!73"
as!such!these!residues!can!be!used!for!the!prediction!of!amino!acid!side9chain!interactions!of!74"
the!correlated!residues!8910.!However,!many!of!these!correlated!residues!do!not!contact!each!75"
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4"
"
other,!and!are"therefore!not!directly!involved!in!packing!within!the!protein!structure11.!On!the!76"
other!hand,!instead!of!physical!contacts!in!the!tertiary!structure,!correlated!residues!can!also!77"
play!a!role!in!the!protein!function6,11,12.!The!functional!relevance!of!correlated!residues!makes!78"
CMA!also!suited!for!the!identification!of!functionally!relevant!residues.!79"
The! subject! of! this! study! is! the! cupin! super9family,! a! large! group! of! structurally!80"
related!proteins!present!in!all!three!domains!of!life!13.!Members!of!this!super9family!cover!a!81"
wide! range! of! functions,! including! isomerases,! dioxygenases,! oxidoreductases! and! storage!82"
proteins.! The! name! cupin! has! been! derived! from! the! latin! word! “cupa”! (small! barrel),!83"
reflecting!the!conserved!beta9barrel!structure.!High!resolution!structures!have!been!obtained!84"
for!many!members!of!the!cupin!superfamily!14.!One!of!the!best!characterized!members!is!the!85"
phosphoglucose!isomerase!of! the!archaeon!Pyrococcus!furiosus! (PfPGIc!EC!5.3.1.9).!PfPGI!86"
is!a!glycolytic!enzyme!that!catalyses!the!reversible!isomerization!of!glucose969phosphate!to!87"
fructose969phosphate! (F6P)! 15,16.! Several! crystal! structures! of! this! homodimer! (monomeric!88"
subunit! is!21.5!kDa)!have!been!solved,! the!coordination!of! the!catalytic!metal! ion!has!been!89"
elucidated! using! electron! paramagnetic! resonance! (EPR)! analysis,! and! ample! insight! in! the!90"
catalytic!mechanism!of!the!enzyme!has!been!gained!17919.!Moreover,!several!practical!features!91"
make!PfPGI!an!ideal!candidate!for!our!engineering!analysis:!very!efficient!expression!in!E.!92"
coli,!straightforward!purification!and!activity!assay,!and!last!but!not!least,!the!native!enzyme!93"
is!very!stable.!!94"
In! this! study! we! describe! the! generation! of! a! small! library! in! which! we! randomly!95"
substituted! two! correlated! amino! acids! at! a! previously! identified! “hot! spot”! in! our! model!96"
enzyme!PfPGI!(Fig.1).!The!predicted!relevance!of!the!correlated!residues!was!validated!by!a!97"
detailed! analysis! of! selected! mutants,! in! which! specific! activity,! metal! coordination,! and!98"
overall!3D!structure!were!compared.!This!study!shows!that!CMA!may!be!useful!as!a!guide!to!99"
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5"
"
functionally! relevant!sites! in! the!periphery!of!a!protein!structure,!and!as!such! that! it!can!be!100"
used!as!a!tool!to!identify!non9obvious!“hot!spots”!for!mutagenesis.!!101"
!102"
Materials)and)Methods)103"
Yeast!glucose969phosphate!dehydrogenase!was!purchased!from!MP!biomedicals.!Chemicals!104"
were! purchased! from!Sigma9Aldrich! and!Roche.!The!PfPGI!mutant! library!was! created! by!105"
BaseClear!(The!Netherlands),!the!genes!were!cloned!in!expression!vector!pET24d!(Novagen).!106"
!107"
PfPGI*mutant*library*108"
The!cloning!of!the!gene!pgiA!has!been!described!previously!16.!A!site!saturation!library!was!109"
designed!and!created!based!on!CMA!using!the!Comulator!software.!The!constructed!library!110"
consisted!of!pgiA!variants!that!had!alterations!in!two!strongly!correlated!amino!acidsc!proline!111"
132!and! tyrosine!133.!The!corresponding!numbering! in! the!3DM!alignment!was!Pro27!and!112"
Tyr28!(Fig.1).!The!created!pgiA!variants!were!cloned!in!expression!vector!pET24d!and!used!113"
to!transform!E.!coli.!114"
!115"
PfPGI*expression*and*purification*116"
Starter! cultures! of! the! PfPGI!mutants!were! inoculated! from! a! glycerol! stock! and! grown! in!117"
+("(*%"$"+$)+''#$%*-"*!
5 $#91!kanamycin!(LB/Km)!in!a!37°C!shaker.!118"
The! overnight! culture! was! used! to! inoculate! (0.2%! v/v)! sterile! glass! tubes! containing! 10!119"
milliliter!LB/Km!medium.!When!the!optical!density!of!the!culture!reached!A600!=!0.5,!gene!120"
expression! was! induced! by! addition! of! 0.1! mM! isopropyl919thio949D9galactopyranoside!121"
(IPTG).!Growth!was! continued! overnight! at! 37°C,! after!which! the! cells!were! harvested! by!122"
centrifugation!(4,600!x!g!for!15!min).!Pelleted!E.!coli!cells!were!resuspended!in!20!mM!Tris9123"
HCl!buffer!(pH!8.0)!and!disrupted!by!sonication.!DNAse!was!added!to!degrade!the!DNA!in!124"
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6"
"
the!cell!lysate!to!reduce!viscosity.!Cell!debris!was!removed!by!centrifugation!(16,000!x!g!for!125"
15!min).!E.!coli!proteins!were!denatured!by!heating!the!cell!free!extract!at!70°C!for!30!min,!126"
and!removed!by!centrifugation!(16,000!x!g!for!15!min).!The!result!was!a!heat!treated!cell!free!127"
extract! containing! mainly! PfPGI.! Its! purity! was! checked! by! SDS9PAGE.! Protein!128"
concentrations!were! determined! by!Coomassie!Brilliant!Blue!G250! 20,! using! bovine! serum!129"
albumin!as!reference!and!analysis!by!SDS9PAGE!(Quantity!One®,!Bio9Rad).!130"
PfPGI! was! purified! to! homogeneity! using! an! FPLC! method! similar! as! described!131"
before! 6.! Heat! treated! cell! free! extract!was! diluted! to! lower! the! salt! concentration,! filtered!132"
*!(&+ !  	
 5$ "#*( % #& &%  9sepharose! fast! flow! column! (Amersham!133"
Pharmacia! Biotech).! The! column! was! equilibrated! with! 20! mM! Tris9HCl! (pH! 8.0).! PGI!134"
activity!eluted!at!180!mM!of!NaCl!during!a!linear!gradient!of!0!to!1!M!NaCl.!The!fraction!135"
with! the! highest! activity! was! loaded! on! a! pre9equilibrated! Superdex! 200! GL! column! and!136"
eluted! in! 20!mM!Tris9HCl! (pH! 7.0)! containing! 100!mM!NaCl.! Protein! concentrations! and!137"
purity!were!determined!after!which!the!purified!enzyme!fraction!was!used!for!activity!assays.!138"
)139"
PfPGI*activity*assay*140"
Any!divalent!metal!was!stripped!from!the!purified!PfPGI!using!50!mM!ETDA!by!incubated!141"
at!50°C!for!20!min!just!prior!to!the!activity!measurement.!PfPGI!activities!were!determined!142"
by!measuring!NADPH!formation!in!a!coupled!enzyme!assay!with!yeast!glucose969phosphate!143"
dehydrogenase.! This! yeast! enzyme! was! present! in! excess! to! ensure! that! the! detection! of!144"
)&(%*	%$2$91cm91)!corresponded!to!PfPGI!activity.!The!assay!145"
mixture! contained! 0.5! mM! NADP,! 5! mM! F6P! and! 0.35! units! of! D9glucose969phosphate!146"
dehydrogenase,!all! in!20!mM!Tris9HCl!buffer! (pH!7.0).!All!assays!were!performed!using!a!147"
Hitachi!U2001!spectrophotometer!with!a! temperature!controlled!cuvette!holder!set!at!50°C.!148"
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7"
"
The!optimal!activity!was!measured!after!careful!titration!with!MnCl2,!while!an!excess!of!this!149"
salt!resulted!in!enzyme!inhibition.!150"
)151"
PfPGI*crystallization*152"
For! crystallization,! PfPGI! was! overexpressed! and! purified! as! described! previously! 21.! For!153"
each!mutant,!protein!was!concentrated!to!11.5!mg!ml91!in!a!solution!of!10!mM!Tris9HCl,!pH!154"
8.0,!50!mM!F6P!and!5!mM!MnCl2.!Mutants!RG!and!AG!crystallized!from!hanging!drops!by!155"
mixing!equal!volumes!of!protein!solution!with!a!reservoir!solution!containing!0.35!M!MgCl2,!156"
0.1!M!sodium!acetate!pH!5.5!and!10935%!PEG4000.!For!mutants!AD!and!VY,!crystals!were!157"
grown! using! a! Hydra! plus! One! robot,! and! commercial! screens.! AD! crystallized! from! a!158"
solution!of!0.2!M!calcium!acetate,!0.1!M!sodium!acetate!pH!6.5,!40%!PEG300,!whereas!VY!159"
crystallized! from! solutions! of! 0.2!M! sodium! nitrate,! 0.1!M!Bis!Tris! Propane! pH! 6.5,! 20%!160"
PEG4000.! 50!mM!F6P!was! added! to! the!AD! and!VY! crystals,! before!mounting.! For! each!161"
different!mutant,! a! single!crystal!was!briefly!washed! in!a!cryoprotectant!consisting!of!25%!162"
ethylene! glycol! in! the! crystallization! buffer,! flash! cooled! to! 100! K! and! stored! in! liquid!163"
nitrogen! prior! to! data! collection! on! the! Diamond! synchrotron! light! source.! Data! were!164"
processed! using! the! Xia2! software! 22! and! structures! determined! by!molecular! replacement!165"
using!the!wild!type!PfPGI!coordinates!as!a!search!model!(pdb!code!1X82)17!!and!the!program!166"
Phaser! 23.! Rounds! of! building! using!Coot! 24! and! refinement! in! Refmac! 25! gave! acceptable!167"
models,!verified!using!Molprobity!26.!For!each!structure,!electron!density!was!present!for!all!168"
the!polypeptide!chain!and!the!models!had!no!missing!residues.!However,!density!was!weak!169"
for! the! side! chains! of! Lys21,! Lys188,! Lys189! (AG)c! Arg25,! Glu114,! Asp116,! Lys118,!170"
Lys188!and!Lys189!(RG!chain!A)c!Glu114,!Lys188!and!Lys189!(RG!chain!B)!and!Lys188!171"
and!Lys189!(AD!and!VY,!chains!A!and!B).!Data!collection!and!refinement!statistics!are!given!172"
in! Tables! 1! and! 2.! The! four! mutant! structures! were! compared! to! the! wildtype!Mn/5PAA!173"
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8"
"
structure!(IX7N)!by!superposition!of!all!the!protein!atoms!of!the!residues!that!coordinate!the!174"
Mn!(His88,!His90,!Glu97!and!His136).!!175"
*176"
EPR*spectroscopy*177"
Electron! paramagnetic! resonance! spectra! were! obtained! from! circa! 5! mg! ml91! samples! of!178"
PfPGI! mutants! in! 10! mM! Tris9HCl,! pH! 8.0,! to! which! 0.2! mM! of! MnCl2! was! added!179"
anaerobically.!Spectra!were!also!taken!for!the!PfPGI!ternary!complexes!produced!by!10!min!180"
incubation! with! 10! mM! F6P.! X9band! spectra! were! collected! on! a! Bruker! ECS9106!181"
spectrometer!using!a!microwave!frequency!of!9.45!GHz,!a!microwave!power!of!0.126!mW!or!182"
126!mW,!a!modulation! frequency!of!100!kHz,!a!modulation!amplitude!of!6.3!gauss,!and!a!183"
sample!temperature!of!13!K.)184"
!185"
Protein*Data*Bank*accession*codes*186"
The! structure! factors! and! coordinates! for! the! four! mutant! PfPGI! structures! have! been!187"
deposited! in! the! protein! data! bank!with! accession! 4LTA! (RG),! 4LUK! (AG),! 4LUL! (AD),!188"
4LUM!(VY).!189"
!190"
Results)and)Discussion)191"
A!PfPGI!library!has!been!generated!based!on!predictions!made!by!using!the!Comulator!CMA!192"
algorithm,! as! previously! described! 6.!We!used! a! refined! structure9based!MSA!of! the! cupin!193"
super9family,! containing!a! total! of!1711! sequences.!The! amino!acids!with! the!highest! pair9194"
wise!correlated!mutation!score!were!Pro132!and!Tyr133!in!PfPGI!(3DM9numbers!27!and!28)!195"
(Fig.1).!This!amino!acid!pair!is!located!in!a!structurally!conserved!surface!loop!6!that!can!be!196"
found! in! most! members! of! the! cupin! super9family! including! PfPGI! (Fig.2).! Previous!197"
experiments!have!shown!that!a!PfPGI!double!mutant!exhibited!elevated!PGI!activity9levels,!198"
Page 8 of 31
John Wiley & Sons, Inc.
PROTEINS: Structure, Function, and Bioinformatics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
9"
"
while! the! two! single! mutants! were! less! active! than! wild! type! PfPGI! 6.! This! result! is! not!199"
obvious!since!this!peripheral!surface!loop!is!not!in!close!proximity!to!the!catalytic!residues.!200"
)201"
PfPGI*mutant*activity*levels*202"
To!examine! the!effect!on! the!PGI! activity!of! the!correlated! residues!Pro132!and!Tyr133! in!203"
more!detail,!we!selected!fifteen!mutants! (out!of! the!400!possible)! that!correspond! to!amino!204"
acid! pairs! that! are! either! (highly)! abundant! or! (almost)! absent! within! the! refined! cupin!205"
superfamily! alignment! (Fig.1).! Cultures! of! these! mutants! could! be! grown! as! described!206"
previously6!and!PfPGI!expression!could!be!induced!successfully!for!any!of!the!mutants.!As!a!207"
control! we! included! E.! coli! harbouring! the! empty! vector! (plasmid! pET24d),! to! have! a!208"
correction! for! background! protein! concentrations! and! to! exclude! possible! background!209"
activity.!Most!E.!coli!proteins!could!be!removed!from!the!cell!lysate!by!a!heat!treatment!step!210"
and!subsequent!centrifugation.!PfPGI!was!stripped!with!EDTA!to!remove!any!bound!divalent!211"
cations! and! subsequently! titrated!with!Mn2+! as! cofactor,! as! this! cation! results! in! highest! in!212"
vitro! activity! 18.! The! resulting! heat! stable! cell! free! extract! was! used! for! PfPGI! activity!213"
measurements,!to!compare!activity!of!the!selected!mutants!with!wild!type!PfPGI!(Fig.3).!214"
We! could! detect! PGI! activity! in! the! lysates! of! all! the! fifteen!mutantsc! none! of! the!215"
PfPGI!mutants!completely!lost!activity.!The!negative!control!(strain!with!empty!vector)!was!216"
free! of! background! activity,! hence! the!measured! PGI! activity! originated! from!PfPGI! only.!217"
Significant! differences! were! detected! between! the! specific! activities! of! the! examined! PGI!218"
mutants.!Interestingly,!we!observed!elevated!activities!for!those!amino!acid!combinations!that!219"
based! on! the!CMA! are! abundant! in! the! protein! family! alignment! (for! pair! frequencies! see!220"
Figures!1!and!3).!For!those!combinations!of!amino!acids!that!are!absent!or!less!abundant!than!221"
wild!type!PfPGI!in!the!MSA,!typical!activity!levels!were!observed!that!were!comparable!or!222"
lower! than! wild! type! PfPGI! (amino! acid! pair! PY).! These! findings! suggest! a! positive!223"
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10"
"
correlation! between! the! natural! prevalence! of! an! amino! acid! pair,! and! the! activity! of! the!224"
corresponding!mutant.!225"
To!validate! these! values,!we! selected! the! two!mutants! that! had! highest! activity! and!226"
two!mutants!that!performed!similar!to,!or!less!than,!wild!type!PfPGI.!These!four!mutants!and!227"
the! wild! type! enzyme! were! purified! to! homogeneity,! to! enable! a! precise! analysis! of! their!228"
specific! activity.! A! total! of! five! large! batch! cultures! were! grownc! wild! type! PfPGI!229"
(P132/Y133)! and!mutants!P132A/Y133G! (AG),! P132R/Y133G! (RG),! P132A/Y133D! (AD)!230"
and! P132V! (VY).! Based! on! the! CMA,! the! first! two! mutants! contain! an! amino! acid!231"
combination! that! is! highly! abundant,!while! the! other! two!mutants! represent! an! amino! acid!232"
combination!that!is!not!found!in!the!MSA!(VY)!or!at!a!low!frequency!(AD)!compared!to!wild!233"
type.! The! five! PfPGI! variants! were! purified! to! homogeneity! by! heat! treatment! and! two!234"
subsequent! chromatography! steps.! The! resulting! pure! samples! were! used! to! determine! the!235"
specific!activity!of!each!of!the!PfPGI!variants!(Fig.4).!236"
Comparing! the! specific! activities!measured! for! the! purified!PfPGI! variants,! there! is!237"
good! agreement! with! the! values! as! described! above! (Fig.3),! although! the! relative! activity!238"
presented!there!was!slightly!overrated,!likely!due!to!difficulties!in!obtaining!accurate!protein!239"
concentrations!in!cell!lysate.!In!comparison!with!the!wild!type!PfPGI!(PY)!we!again!observed!240"
an!increased!activity!for!both!mutant!RG!and!mutant!AG,!while!both!mutant!VY!and!mutant!241"
AD!have!a!similar!or!decreased!specific!activity,!respectively,!compared!to!PY.!242"
The!intriguing!question!to!address!is! the!underlying!molecular!basis!of! the!observed!243"
differences!in!PGI!activity.!Obviously,!the!catalytic!site!should!be!examined.!In!addition,!the!244"
differences! in! activity!might! relate! to! the! PGI!metal! binding! site.!Removal! of! the! divalent!245"
metal!co9factor!results!in!complete!loss!of!PGI!activity,!which!can!be!restored!by!the!addition!246"
of!divalent!metals.!Despite!the!fact!that!the!surface!loop!carrying!the!correlated!mutations!is!247"
located! rather! distant! from! the! metal! binding! site! and! the! catalytic! site,! it! is! tempting! to!248"
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11"
"
speculate! that! the!mutations! in! this! loop! have! an! effect! on! the!metal! binding! site! and! the!249"
catalytic!site!and!hence!lead!to!the!observed!differences!in!activity.!250"
!251"
Structure*analysis*of*the*mutation*carrying*loop*252"
To!further!examine!possible!conformational!changes,!for!instance!in!the!active!site!structure!253"
and!metal!coordination,!crystallization!trials!were!initiated!for!the!four!PfPGI!mutants.!First!254"
crystallization! attempts! were! set! up! with! manganese! as! incorporated! cofactor! and! F6P! as!255"
substrate.!These!co9crystallization!trials!successfully!yielded!well9diffracting!crystals!for!both!256"
the!mutants!RG!and!AG!(Table!1).!The!AG!mutant!structure!is!the!highest!resolution!(1.4!Å)!257"
for!any!PfPGI!variant,!and!interestingly,!the!electron!density!map!for!this!structure!(and!also!258"
for!the!RG!structure)!clearly!showed!that!59phosphoarabinonic!acid!(5PAA),!rather!than!F6P!259"
(as! added! to! the! crystallization! mixture)! was! bound! in! the! active! site! (Fig.! 5).! Thus! an!260"
unexpected!conversion!had!occurred:!during!the!experiment!F6P!had!been,!at!least!partially,!261"
oxidized!to!5PAA,!resulting!in!preferential!binding!for!5PAA!in!the!active!site!of!both!mutant!262"
structures!(Table!2).!To!confirm!that!5PAA!had!ind ed!been!produced,!a!solution!of!the!same!263"
composition!as!the!crystallization!solution!was!analysed!by!mass!spectrometry!after!being!left!264"
at! room! temperature! for! one! week.! The! spectra! contained! a! small! peak! of! m/e! ratio! 259,!265"
(F6P),!but!also!many!other!peaks!with!m/e!ratios!less!than!F6P,!including!a!large!peak!with!266"
m/e!ratio!of!245!corresponding!to!5PAA,!clearly!indicating!that!a!breakdown!of!the!sugar!had!267"
taken! place.! The! oxidation! of! F6P! to! 5PAA! in! the! presence! of! permanganate! has! been!268"
observed! before! 27! and! thus! we! presume! a! similar! reaction! occurs! in! the! crystallization!269"
solution.!270"
For!the!other!two!mutants!(VY!and!AD),!no!ternary!complex!structures!were!obtained!by!co9271"
crystallization,! and! thus! protein! crystals! were! grown! in! the! presence! of! MgCl2,! and!272"
subsequently!soaked!in!a!solution!of!F6P!for! two!hours!prior! to!X9ray!data!collection.!This!273"
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12"
"
approach!was!successful!for!mutant!VY,!resulting!in!a!structure!with!F6P!in!the!active!site.!274"
For!mutant!AD,!the!only!structure!that!could!be!obtained!contained!solely!Mn2+!in!the!active!275"
site.!(Table!2).!276"
The!crystal!structures!of! the!four!mutants!reveal! that! in!each!structure!clear!electron!277"
density!was!present!for!the!1329133!loop!that!carries!the!substitutions.!This!demonstrates!that!278"
this! loop! is! not! disordered! in! any! of! the! structures,! and! that! the! native! fold! of! PfPGI! can!279"
accommodate!the!substitutions!within!its!structure,!as!predicted!by!the!Comulator!software.!280"
However,!as!might!be!expected,!a!number!of!differences!are!noted!when!comparing!the!loop!281"
structure!in!detail!(Fig.6).!In!the!wild!type!structure!(P132/Y133)!one!face!of!the!side!chain!of!282"
Pro132!packs!against!the!Arg95,!Ala96!peptide!and!the!(&%.#1%4&Asp94,!with!283"
the!carboxyl!of!Asp94!pointing!away!from!Pro132.!The!side!chain!of!Tyr133!packs!against!284"
the!main!chain!of!Leu93,!with!additional!interactions!forming!between!the!edge!of!the!phenyl!285"
moiety!and!the!side!chain!of!Leu93.!The!other!face!of!the!Pro1329Tyr133!loop!packs!against!286"
the!side!chains!of!residues!Tyr3!and!the!aliphatic!part!of!Lys4,!from!the!second!subunit!in!the!287"
PGI!dimer.! In! the!four!mutant!structures,! the!main!chain!conformation!of! the!1319134! loop!288"
remains! remarkably! consistent,!with! only!minor! changes! in! the! position! of! the!main! chain!289"
atoms.!However,! the! changes! in! the! side! chains! of! Pro132! and!Tyr133! have!more!marked!290"
effects!on!the!positions!of!residues!92994!of!the!90996!loop,!and!also!on!the!position!of!the!N9291"
terminal! 5! residues! from! the! adjacent! subunit! of! the! dimer.! There! are! also! some! small!292"
consequential! changes! in! the! positions! of! second! shell! residues! packing! against! these! two!293"
loops.!!294"
For!the!P132R9Y133G!mutant,! the!loss!of! the!tyrosine!side!chain!at!position!133,! is!295"
somewhat!alleviated!by!the!side!chain!of!R132!occupying!approximately!the!same!position!in!296"
the!structure.!There!are!movements!of!up!to!0.5Å!in!the!positions!of!both!the!Leu939Asp94!297"
and!Tyr39Lys4!loops,!compared!to!the!wild9type!structure.!In!the!P132A9Y133G!mutant,!the!298"
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13"
"
changes!to!the!position!of!Leu93!and!Asp94!are!more!marked,!with!movements!of!1.8Å!and!299"
1.6Å!for!the!alpha!carbons!of!Leu93!and!Asp94!compared!to!the!wild!type!structure.!Given!300"
that!both!mutations!in!this!AG!structure!are!to!smaller!residues!than!those!in!the!wild!type,!301"
these! fairly! large! movements! are,! somewhat! counter9intuitively,! away! from! the! 1329133,!302"
presumably!making!the!packing!worse.!In!the!P132V!single!mutant!(VY),!the!change!of!the!303"
proline!side!chain!to!valine,!pushes!the!Leu939Asp94!loop!away,!in!order!to!accommodate!the!304"
#( ("+(*)"!"%&,#"%&,$%*)&	/%/()%*-%*!1)305"
of! Leu93! and! Asp94,! respectively.! In! mutant! AD,! the! movement! of! the! alpha! carbons! of!306"
Leu93!and!Asp94!away!from!1329133!is!0.7Å!and!0.9Å,!respectively.!In!this!mutant!AD,!the!307"
change! from! tyrosine! to! the! negatively! charged! aspartic! acid! has! had! little! effect! on! the!308"
position!of!the!side!chain!of!Tyr3!from!the!adjacent!subunit.!309"
!310"
Structure*analysis*of*the*manganese*coordination*311"
In!all!four!PGI!mutant!structures,!the!manganese!is!69coordinated!in!an!octahedral!geometry!312"
(Fig.7).!Three!of!the!ligands!are!the!imidazole!nitrogens!of!residues!His88,!His90!and!His136.!313"
The! fourth! ligand! is! one! of! the! carboxyl! oxygens! of! Glu97.! The! 5th! and! 6th! ligands! are!314"
different! depending! on! the! substrate.! In! mutant! AD,! water! molecules! provide! these! two!315"
ligands.!In!the!two!structures!with!5PAA,!mutants!RG!and!AG,!the!5th!ligand!is!one!of!the!316"
carboxylate!oxygens!of!5PAA!and!the!6th!ligand!a!water!molecule.!In!the!F6P!soaked!crystal!317"
structure,!mutant!VY,!both!the!5th!and!6th!ligands!are!provided!by!the!F6P!substrate,!one!is!318"
the!C2!carbonyl!and!the!other!the!C1!hydroxyl.!In!this!short!F6P!soak!crystal!structure,!there!319"
is! no! indication! that! any! of! the! F6P! has! been! turned! over! to!G6P,! as! the! electron! density!320"
clearly! shows! the! C2! carbon! to! have! trigonal! (sp2)! geometry,! and! the! C1! carbonyl! to! be!321"
tetrahedral!(sp3),!indicating!the!presence!of!the!ketone!isomer!of!the!substrate.!322"
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14"
"
Despite! these!quite! large!changes! in! the!relative!positions!of! the!1329133!and!93994!323"
loops! between! the! different! mutants,! the! position! of! the! manganese! coordinating! residue!324"
His90,!which!lies!only!three!residues!away!from!the!moving!residue!Leu93,!is!very!similar!in!325"
all! the! structures! (Table! 3).! The! same! is! true! for! His88,! Glu97! and! His136.! Thus,! these!326"
mutations,!whilst!altering!the!structure!local!to!the!mutated!residues,!seem!to!have!little!effect!327"
on! the! coordination! of! the! manganese! or! the! general! architecture! of! the! active! site.! The!328"
changes!seen!in!the!activities!between!these!different!mutants!are!thus!presumably!due!to!the!329"
accumulative!effect!of!many!small!changes!between!the!structures.!330"
Based!on!the!obtained!crystal!structures!of! the!wild!type!PGI!and!the!4!variants,!we!331"
can!conclude!that!differences!in!manganese!coordination!are,!at!most,!very!subtle.!For!a!more!332"
sensitive! investigation! of! the! coordination! state! of! the! bound! manganese! during! catalysis,!333"
EPR! spectral! analyses! have! been! performed! of! the! four! PfPGI!mutants,! comparing! PfPGI!334"
without!substrate!as!well!as!in!complex!with!F6P!(Fig.8).!In!agreement!with!previous!results!335"
19,!we!find!that!the!addition!of!F6P!to!any!of!the!manganese9containing!PfPGI!mutants,!leads!336"
to! a! collapse!of! the!hexacoordinate!manganese! signal.!Additionally,! there! is! a! considerable!337"
change!of!the!signal!from!pentacoordinate!manganese,!leading!to!a!substantial!increase!in!the!338"
pentacoordinate!over!hexacoordinate!ratio.!All!this!indicates!that!the!manganese!coordination!339"
of!the!apo9enzyme!shifts!towards!pentacoordinate!upon!F6P!binding,!very!similar!to!what!has!340"
been! observed! and! reported! previously! for! the! wild! type! PfPGI! 19.! Therefore,! it! can! be!341"
concluded!that!the!metal!binding!site!is!not!significantly!changed!by!any!of!the!substitutions.!342"
*343"
Conclusion)344"
Rational!design9based!protein!engineering,!aiming!for!improved!enzyme!activity,!often!builds!345"
on!changes!in!(non9catalytic)!residues!located!in!close!proximity!to!the!catalytic!site!and/or!346"
substrate/cofactor! binding! residues,! as! these! residues! generally! are!more! easy! to! predict! 28.!347"
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15"
"
Although!multiple!examples!exist!where! this!has!been!proven!successful! 29932,! focussing!on!348"
only!these!residues!misses!additional!opportunities!for!protein!improvement.! In!our!specific!349"
case,!the!loop!containing!residues!132/133!is!not!an!obvious!pick!based!on!its!distance!to!the!350"
catalytic! site! and! cofactor! binding! site.! Nonetheless,! alterations! in! this! loop! do! have! the!351"
potential!to!improve!PGI!activity!levels.!352"
Comparing! the! mutant! PGI! activity! levels,! a! general! trend! could! be! observed.!353"
Although!the!differences!in!activity!are!rather!subtle,!it!could!be!shown!that!those!amino!acid!354"
correlations! that! have! a! high! occurrence! typically! result! in! a! variant!with! a! higher! activity!355"
than!wild!type,!whereas! those!amino!acid!correlations!that!have!a!low!occurrence!generally!356"
result!in!a!mutant!with!a!decreased!activity!compared!to!wild!type.!357"
Admitted,! the!mutations!we! introduced! did! only! result! in! a! rather! small! increase! in!358"
specific!activity.!However,!selection!of!a!mutant!with!a!multi9fold!increase!in!activity!was!not!359"
the!primary!goal.!Remarkably,!none!of!the!15!tested!PfPGI!mutants!completely!lost!activity.!360"
Moreover,! despite! changes! in! the! activity,! the! protein! structure! and! stability! seemed!361"
consistently!without!detectable!changes.!For! the!4!crystallized!mutants! there! is!no!evidence!362"
for! disorder! in! the! mutated! residues! or! for! the! adjacent! stretches! of! the! polypeptide.! This!363"
contrasts! favourably!with! other! studies!where! generally!many!mutations! of! this!magnitude!364"
result! in! (local)! disorder! in! the! mutated! residues,! or! for! the! adjacent! stretches! of! the!365"
polypeptide.!Site9directed!mutagenesis!of!residues!that!lead!to!improved!catalytic!properties!366"
often!affect!the!protein9structure!stability!33935.!Therefore,!additional!compensatory!mutations!367"
are!often!required! to!neutralize! this!destabilization!36,37.!Evaluating! the!data!presented!here,!368"
we!can!conclude!that!this!is!a!very!promising!result!for!Comulator9based!CMA!predictions,!369"
validating! the! Comulator! software! to! predict! stable! mutations! within! the! PGI! structural!370"
framework.!!371"
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16"
"
No! significant! differences! were! found! in! the! structures,! neither! in! the! substrate!372"
binding! pocket,! nor! in! the! coordination! of! the! catalytic! manganese.! However,! minor!373"
differences! in! the! conformation! and!packing!of! the! loops! surrounding! the!mutated! residues!374"
were! observed! between! the! different! PfPGI! variants.! These! subtle! differences! in! packing!375"
presumably!propagate!through!the!structure!to!result!in!small!differences!in!substrate!binding!376"
and/or!catalytic!efficiency,!resulting!in!the!differences!in!activity!seen!between!the!mutants.!377"
Another! explanation! for! the! changed! activity! may! be! that! the! substituted! loop! residues!378"
somehow! affect! (either! positively! or! negatively)! the! enzymes’! flexibilityc! something! that!379"
cannot!be!observed!in!a!static!condition!like!a!crystal!structure.!380"
To!conclude,!we! showed! that!CMA!based!predictions!have! the!potential! to! identify!381"
hotspots! that! are! possibly! interesting! target! residues! for! substitutions,! as! they!may! lead! to!382"
improved! protein! performance.! This! is! a! very! different! application! of!CMAs,! compared! to!383"
using!CMAs!for!predictions!of!residue!contact!points!in!a!protein!structure!8910,!and!as!such!as!384"
a!tool!for!the!ab!initio!prediction!of!protein!structures!38941.!We!think!that!caution!is!required!385"
in!the!selection!of!correlated!residues!for!such!structural!prediction!tools,!as!we!show!that!this!386"
specific,!strongly!correlated,!amino!acid!pair!in!the!cupin!superfamily!has!no!important!effect!387"
in! the!protein! structure,! thereby!providing! an!obvious! example!of! a!CMA9based!correlated!388"
residue!prediction!containing!functional!information!rather!than!structural!information.!All!in!389"
all,!the!presented!results!show!that!CMAs!also!have!the!potential!to!be!used!for!generation!of!390"
small!size,!“smart”!libraries!containing!beneficial!variants.!The!selected!mutations!are!based!391"
on!changes!in!highly!correlated!amino!acids.!As!these!residues!may!be!distantly!located!from!392"
the!enzyme’s!active!site,!and!as!such!have!no!obvious!relation!to!the!enzymes’!performance,!393"
they!may!easily!be!overlooked!in!other!rational!design!approaches.!394"
! )395"
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Figures!517"
Figure!1.!Residue!pair!frequency!table!of!amino!acid!couple!27!and!28!(3DM!numbering).!In!518"
wild! type!PfPGI! these! residues!are!Pro132!and!Tyr133.!The!occurrences!are! relative! to! the!519"
number!of!unique!sequences!in!the!super!family!alignment.!520"
!521"
Figure! 2.! Cartoon! representation! of! the! dimer! (white! and! green! subunits)! of! the!wild! type!522"
PfPGI!Mn2+/5PAA!3D9structure!(PDB!code:!1X7N).!The!correlated!amino!acid!pair!“PY”!is!523"
indicated! in! red.!Shown! in! yellow!are! those! residues! involved! in!metal! ion! (purple! sphere)!524"
binding,! including! a! water! molecule! (red! sphere).! The! inhibitor! 59phospho9D9arabinonate!525"
(5PAA)!is!shown!as!a!stick!model!(green).!526"
!527"
Figure! 3.! Graphical! representation! of! the! relative! activity! of! each! PfPGI! mutant! (Y9axis)!528"
compared!to!the!amino!acid!pair!occurrence!according!the!Comulator!based!CMA!predictions!529"
(X9axis).!All!PGI!activities!are!relative!to!wild!type!PfPGI!(PYc!in!bold).!530"
!531"
Figure! 4.! Specific! activity! of! wild! type! PfPGI! (PY)! compared! to! selected! high!532"
occurrence/activity!mutants!RG!and!AG,!and! low!occurrence/activity!mutants!AD!and!VY.!533"
Manganese!was!used!as!co9factor!and!added!via!titration.!534"
!535"
Figure!5.!A!stereo!representation!of!the!mFO!–!DFC!electron!density!(grey!mesh),!contoured!536"
* 
3 &( *!  $+*%*  )*(+*+( )!&-"%  *! $% %) '+('# )'!(537"
coordinating!water!(red!sphere),!bound!5PAA!and!metal!coordinating!residues!(sticks).!!538"
!539"
Figure!6.!Comparison!of! the! structure!of! the! loops! adjacent! to! the!mutation!position! in! the!540"
four!mutant!structures.!In!each!panel!the!wild!type!structure!(1X7N)!is!shown!in!white,!with!541"
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"
relevant!residues!highlighted!in!stick!representation!and!labelled.!Y3’!and!K4’!refer!to!the!N9542"
terminal!strand!from!the!adjacent!subunit!in!the!dimer.!(a)!Mutant!AD!(slate),!(b)!mutant!RG!543"
(wheat),!(c)!mutant!AG!(yellow)!and!(d)!mutant!VY!(pink).!544"
!545"
Figure! 7.!Mn2+! coordination! in! the!mutant! PfPGI! structures.! For! all!mutant! structures,! the!546"
Mn2+!ion!(purple!sphere)!is!coordinated!in!an!octahedral!arrangement:!(a)!mutant!AD!(blue),!547"
(b)!mutant!RG! (wheat),! (c)!mutant!AG! (yellow)! and! (d)!mutant!VY! (pink).!Ligands! to! the!548"
metal!are!highlighted!in!stick!representation,!water!molecules!are!shown!as!red!spheres.!549"
!550"
Figure!8.! Invariance!of!EPR!spectra! from! the!PfPGI!mutants.!The! red! traces!were! taken!at!551"
low!microwave!power!(0.126!mW)!for!a!full!record!of!the!six9line!pattern!around!3300!gauss!552"
typical!for!hexacoordinate!Mn2+.!The!black!traces!were!taken!at!high!microwave!power!(126!553"
mW)! to! emphasize! the! broad! features! over! the! whole! magnetic9field! range! from!554"
pentacoordinate!Mn2+.!The! left9hand! traces!are! in! the!absence!of! substrate,!while! the! right9555"
hand!traces!are!in!the!presence!of!10!mM!F6P.!556"
)557"
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Table&1&(&Data&collection&statistics&
Data$set$ AG$ RG$ AD$ VY$
Spacegroup& C2& P212121& P212121& P1&
Unit&cell&
parameters&(Å)&
& & & &
a& 87.9& 73.0& 46.2& 80.7&
b& 43.3& 74.5& 46.2& 42.6&
c& 58.5& 75.9& 186.2& 88.9&
& 90.0°& 90.0°& 90.0°& 90.0°&
& 122.0°& 90.0°& 90.0°& 104.9°&
& 90.0°& 90.0°& 120.0°& 90.0°&
Molecules&per&
ASU&
1& 2& 2& 2&
Resolution&(Å)1& 28.92(1.41&&
(1.44&(&1.41)&
26.58(2.04&
(2.09&(2.04)&
25.58(1.89&
(1.94&(1.89)&
18.49(1.79&
(1.84(1.79)&
Wavelength&(Å)& 0.97630& 0.97630& 0.97630& 0.97630&
& & & & &
Unique&
observations1&
32797&(1460)& 26994&(1969)& *********& 33074&(2386)&
Rpim1& 0.036&
(0.349)&
0.074&
(0.219)&
0.028&
(0.352)&
0.086&
(0.349)&
Completeness&
(%)1&
91.2&
(55.4)&
99.6&
(99.9)&
98.5&
(99.2)&
95.7&
(94.0)&
Multiplicity1& 3.1&
(2.4)&
6.3&
(6.4)&
3.5&
(3.5)&
1.8&
(1.8)&
Mean((I)/sd(I))& 13.0&
(&2.1)&
7.0&
(3.7)&
15.9&
(2.4)&
4.3&
(2.2)&
1&Numbers&in&parentheses&indicate&values&for&the&highest&resolution&shell&#
! !
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Table&2&(&Refinement&Statistics&
Model$ AG$ RG$ AD$ VY$
Resolution&(Å)& 1.4& 2.0& 1.9& 1.8&
Number&of&reflections& 31134& 25635& 27836& 31398&
Protein&molecules&per&
asymmetric&unit&
1& 2& 2& 2&
Number&of&atoms& 1739& 3221& 3142& 3308&
Number&of&waters& 197& 141& 112& 218&
Number&of&Mn2+&ions& 1& 2& 2& 2&
Number&of&F6P& 0& 0& 0& 2&
Number&of&5PAA& 1& 2& 0& 0&
Ramachandran&favoured&(%)& 98.4& 87.1& 97.3& 97.9&
Ramachandran&outliers&(%)& 0& 0.3& 0.3& 0&
Poor&rotamers&(%)& 1.3& 1.6& 0.6& 0.3&
RMSD&bond&(Å)& 0.006& 0.007& 0.011& 0.009&
RMSD&angle&(O)& 1.06& 1.08& 1.34& 1.26&
Average&B(factors&(Å)& & & & &
Main&chain& 21& 35& 31& 24&
Side&chain& 31& 24& 34& 27&
Waters& 37& 36& 33& 26&
Mn2+& 13& 27& 31& 21&
5PAA/F6P& 15& 33& (& 26&
R(factor& 0.14& 0.22& 0.19& 0.17&
R(Free& 0.20& 0.29& 0.25& 0.22&
MolProbity&score& 0.80&
100th&percentile&
0.94&
100th&percentile&
0.99&
100th&percentile*&
1.03&
100th&percentile&
&
&
$
$
$
Table&3&(&Mn2+&ligands&and&coordination&distances&(Å).&
Mutant$ His$885N2$ His$905N2$ His$1365N2$ Glu$975$
PY&WT&
(1X81)&
2.45& 2.25& 2.29& 2.26(&O2&
RG& 2.20& 2.30& 2.29& 2.17(O1&
AG& 2.32& 2.25& 2.23& 2.33(O1&
AD& 2.24& 2.21& 2.35& 1.98(O1&
VY& 2.31& 2.31& 2.28& 2.09(O1&
&
&
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